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ABSTRACf
Purine nucleobase and nucleoside transporters play an important role in the physiology
and biochemistry of protozoan parasites, because these parasites can not synthesize
purines de novo and depend upon salvaging the purines from their hosts. The
differences in purine metabolism between these parasites and their mammalian host
could be of great pharmacological importance to the rational design of new drugs. In
addition, purine transporters are interesting to the current pharmacology of these
important human pathogens, as they have been shown to mediate the uptake of purine
analogues such as allopurinol and several front-line non-purine drugs that are
selectively cytotoxic to the parasites. Selective delivery of drugs to parasites via plasma
membrane transporters offers an effective approach to specifically target pathogens.
Using biochemical techniques, we have identified and characterised a number of
purine nucleobase and nucleoside transporters in protozoan parasites such as
Leishmania major, Leishmania mexicana, Trypanosoma brucei and Toxoplasmagondii
In one study, the uptake of (3H]adenine, [3H]hypoxanthine, and [3H]allopurinol, an
antileishmanial hypoxanthine analogue, by Leishmania major promastigotes was
investigated. The results showed that these compounds were all taken up by a single
high-affinity transporter, LmajNBTI, with Km values of 4.6 ± 0.9,0.71 ± 0.07, and 54 ± 3
IlM and Vmax values of 3.2 ± 0.3, 2.8 ± 0.6, and 0.24 ± 0.06 pmol (107 cells):' S-I.
respectively. [3H]adenine transport was fully inhibited by the natural purines guanine
and xanthine, with Xi values of 2.8 ± 0.7 and 23 ± 8 IlM, respectively. Using purine
analogues. an extensive inhibitor profile for LmajNBTI was obtained. which allowed
the construction of a quantitative model for the interactions between the transporter
binding site and the permeant. The model predicts that hypoxanthine was bound
through hydrogen bonds to N(I)H. N3, N7. and N(9)H of the purine ring, with a total
Gibbs free energy of -39.5 kl/mol. The interactions with adenine were similar, except
for a weak hydrogen bond to NI (unprotonated in adenine). The predicted model of
substrate binding for LmajNBTl was almost identical to that for the Trypanosoma
III
brucei H2 (ThH2) transporter. It is proposed that the architecture of their respective
binding sites is very similar and that LmajNBTI can be named a functional homolog of
ThH2.
This thesis also reports the first identification and characterization of a purine
nucleobase transporter in Leishmania amastigotes. Uptake of PH]hypoxanthine by
Leishmania mexicana amastigotes was mediated by a single high-affinity transporter.
LmexNBTI. with Km and Vmaxvaluesof 1.6 ± 0.4 JlMand 0.092 ± 0.057 pmol (10' cells):'
S-I. respectively. with high affinity for adenine. guanine. and xanthine. with Rivalues of
4.2 ± 0.8. 1.7 ± 0.1, and 13 ± 2 flM. respectively. but low affinity for nucleosides and
pyrimidine nucleobases. Allopurinol was apparently taken up by the same transporter
(Km of 33.6 ± 6.0 flM). All evidence was compatible with a model of a single purine
nucleobase transporter being expressed in amastigotes. Using various purine nucleobase
analogues. a model for the interactions between hypoxanthine and the transporter's
permeant binding site was constructed and compared with previously obtained models
for substrate recognition by nucleobase transporters. and found to be very similar to
the models of the LmajNBTI and ThH2 transporters, but markedly different from the
human FNTI transporter.
The work with procyclic forms of Trypanosoma brucei has led to the identification and
characterization of a novel nucleobase transporter, designated H4, with Km and VmlX
values of 0.55 ± 0.07 flM and 0.27 ± 0.08 pmol (10' cells):' S-I, respectively. The kinetic
profile obtained from the characterization of H4 was identical to the one observed in a
parallel study in our laboratory from the yeast-expressed nucleobase transporter
ThNBTl. Moreover. introduction of tetracycline-inducible RNAi constructs in
procyclic trypanosomes reduced H4-activity by -90%. These findings confirmed that
the TbNBTl gene encodes the first high affinity nucleobase transporter from protozoa
to be identified at the molecular level and that H4 is likely to be the gene product of
TbNBTl.
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In the next chapter, we describe in great detail the functional characterisation of
Adenosine Transporter B (AT-B) [or Nucleoside Transporter 10 (NT10)] and Adenosine
Transporter D (AT-D) or [Nucleoside Transporter 9 (NT9)] expressed in yeast, and their
expression in different developmental stages in the life cycle of T. brucei. Our
observations confirm that NT10/AT-B is a PI-type transporter expressed specifically in
short-stumpy bloodstream forms. The uptake of [3H]adenosine and [3H]inosine in
Saccharomyces cerevisiae strain MG887-1 expressing AT-B, was rapid and saturable,
exhibiting an apparent Km values of 0.44 ± 0.02 and 0.52 ± 0.05 flM and Vmax values of
0.60 ± 0.05 and 0.25 ± 0.05 pmol(10' cellsrts+, respectively. We also report a full
characterisation of NT9/AT-D, which is also shown to be a PI-type transporter: it is
predominantly a purine nucleoside transporter with at best a secondary capacity to
transport nucleobases or pyrimidines. But NT9/AT-D displayed much higher affinity
for adenosine than any other nucleoside transporter yet reported, with Km values of 58
± 12 nM and 2.7 ± 0.70 flM and Vmax values of 0.011 ± 0.004 and 0.12 ± 0.039 pmol(10'
cellsj+s', for adenosine and inosine, respectively. This high affinity of NT9/AT-D
appeared to be a result of the transporter binding adenosine through interactions with
both the PI and P2 substrate recognition motifs.
Finally, purine transport in T. gondii has been investigated and novel nucleoside and
nucleobase transporters were identified. The hypoxanthine carrier TgNBT1 (L of 0.91
± 0.19 flM and Vmax of 0.0045 ± 0.0014 pmol(10' cellsr-s') is inhibited by guanine (Ki =
6.9 flM) and xanthine (Ki = 134 flM). It is the first high affinity nucleobase transporter
to be identified in an apicomplexan parasite. We have also identified a novel nucleoside
transporter, TgAT2, which is high affinity and inhibited by adenosine (L of 0.49 ±
0.12 flM and Vmax ofO.17 ± 0.04 pmol(lO' cellsr-s"), inosine (L ofO.77 ± 0.20 flM and
Vmax of 0.0048 ± 0.002 pmol(IO' cellsr-s-'), guanosine (X = 1.5 ± 0.3 flM), uridine (Ki =
1.5 ± 0.4 ~M) and thymidine (Ki = 1.3 ± 0.5 ~M) as well as cytidine (Ki = 32 ± 10 ~M).
TgAT2 also recognises several nucleoside analogues with therapeutic potential. We
have investigated the basis for the broad specificity of TgAT2 and found that hydrogen
v
bonds are formed with the 3' and 5' hydroxyl groups and that the base groups are
bound through H-bonds with either N3 of the purine ring or N(3)H of the pyrimidine
ring, and most probably 1t-stacking as well. The identification of these high affinity
purine nucleobase and nucleoside transporters reconciles for the first time the low
abundance of free nucleosides and nucleobases in the intracellular environment of the
parasite with the efficient purine salvage carried out by T.gondii
In summary, a survey of purine transport in many of the most important protozoan
pathogens has been undertaken, identifying numerous new transport activities and
characterising them in detail. At the same time, several putative purine transporters
from T. b. brucei were cloned and expressed in heterologous systems. This enabled us
to match these genes to specific transporter activities observed in live parasites and
study their expression patterns in the life cycle.
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GENERAL INTRODUCTION
CHAPTER 1GENERAL INTRODUCTION
1.1 Leishmaniasis
1.1.1 Disease
Leishmaniasis is a disease caused by the parasites of the genus Leishmania. The
Leishmania protozoan was first described in 1903 by Leishman and Donovan, working
separately (Herwaldt, 1999a). Since then, this organism has been found to be a complex
grouping of species, at least 20 of which cause infections in humans. The disease is the
cause of great suffering and death. There are 12 million people throughout the world
that suffer from leishmaniasis, and the leishmaniases and the suffering they cause
threaten 350 million men, women and children in 88 countries around the world, 72 of
which are developing countries (Figure 1.1). The leishmaniases are related to
environmental changes such as deforestation, building of dams, new irrigation
schemes, urbanization and migration of non-immune people to endemic areas. It
seriously hampers productivity and vitally needed socioeconomic progress and
epidemics have significantly delayed the implementation of numerous development
programmes. This is particularly true in Saudi Arabia, Morocco, the Amazon basin and
the tropical regions of the Andean countries. Infection by Leishmania gives rise to a
variety of clinical manifestations classically labelled as cutaneous, diffuse cutaneous,
mucocutaneous and visceral, depending on the species, geographic region and host
immune response (Pearson and Sousa, 1996; Pearson, et sl., 2001). The World Health
Organization has reported that 90% of all visceral leishmaniasis occur in Bangladesh,
Brazil, India and the Sudan, 90% of mucocutaneous leishmaniasis occur in Bolivia,
Brazil and Peru, and 90% of cutaneous leishmaniasis cases occur in Afghanistan, Brazil.
Iran, Peru, Saudi Arabia and Syria (World Health Organization 2002).
Visceral Leishmaniasis (VL) is known as Kala-azar and is the most serious form of the
disease and can be fatal if untreated. The etiological agents belong to the Leishmania
donovani complex, Ld donovani, L.d infantum and L.d archibaJdi in the old world and
2
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L.d chagasi in the new world. The old world species are transmitted by the sandfly
vector (Phlebotomus sp). Humans, wild animals and domestic animals are known to act
as reservoir hosts. Lutzomyia logipalpis is the only sand fly vector that has been
implicated in the transmission of the new world species of visceral leishmaniasis and
wild and domesticated dogs are known to serve as reservoir hosts (WHO expert
committee report, 1991;Shiddo, etal., 1995;Arias, etal., 1996).
FIGURE 1.1 Geographical distribution of Leishmaniasis. Map of the world showing the
endemic areas in 88 countries on 4 continents. Image was obtained from: WHO, TDR
Disease website. http:www.who.intltdr/diseases/leish!diseaseinfo.htm
The annual incidence of visceral leishmaniasis is estimated to be in the region of
500,000, 90% of which occurs in India, Nepal, Bangladesh, Sudan, and Brazil (Bora,
1999; Guerin, et al., 2002; Desjeux, 2004; Gramiccia and Gradoni, 2005). In Sudan, an
epidemic killed 100,000 people between 1984 and 1996 (Seaman, et al., 1996). In Brazil,
the disease is a common cause of admission to hospital (Costa, et al., 1990), and visceral
leishmaniasis cases were 1840 and 6000 in 1998 and 2002, respectively (Gramiccia and
Gradoni, 2005). In southern Europe co-infection with HIV, which has led to difficulties
with diagnosis and treatment, is changing the epidemiological pattern of the disease
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and may be introducing a new, human, reservoir of infection (Alvar, et al., 1997;
Capelli, et a1., 2004). In the Mediterranean basin 1.5-9% of AIDS patients develop
visceral leishmaniasis and 25-70% of the adult visceral leishmaniasis cases are related to
HIV infection. Many of the cases are in children. In India, 40% of patients are aged <13
years (Bora, 1999). In Sudan, 65% are aged <15 years (World Health Organization,
1998), and in Brazil, 60% of patients are aged <5 years (Desjeux, World Health
Organization, 1991). The new world and the old world forms of the disease display
similar symptoms and are often complicated by secondary infections (WHO www
website, 1997). It is a generalized infection of the reticuloendothelial system (RES)
involving the spleen, liver, bone marrow and lymph nodes. The disease is characterized
by fever, hepatomegaly, enlarged lymph nodes and tonsils. Patients often exhibit a
wasting syndrome despite good appetite as the disease progresses. Other possible
manifestations include oedema, anaemia, leucopaenia, monocytoses, lymphocytoses,
and thrombocytopaenia (Figure 1.2). Inadequate treatment can lead to cutaneous
disease known as post kala azar dermal leishmaniasis characterized by nodular lesions
similar to diffuse cutaneous leishmaniasis. In contrast to DCL, this post kala azar is
easily cured with treatment.
FIGURE1.2 Child with Visceral Leishmaniasis in Bangladesh. Image was obtained from
Guerin, et a1. (2002).
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Cutaneous leishmaniasis (CL) is the most common manifestation of the disease. These
are generally benign self-healing lesions that are painless and non-pruritic and take
weeks to months to heal. Quite often the lesions are ulcerated with a raised border and
without pus. However, the lesions can become secondarily infected with bacteria.
These simple cutaneous lesions can also be of a popular or nodular nature. The lesion
represents a localized infection at the site of the sandfly bite. Satellite lesions in the
vicinity of the original lesion are sometimes observed. In the Gulf War (1990 to 1991),
approximately 19 cases of cutaneous leishmaniasis were diagnosed in the U.S troops
(William, et el., 2004), and about 150 cases of leishmaniasis have reportedly been
diagnosed in U.S. soldiers serving in Iraq in 2003 (McNeil, 2003), Preliminary data on
22 cases of cutaneous leishmaniasis contracted by American troops in Afghanistan,
Kuwait, and Iraq and treated at Walter Reed Army Medical Center between August
2002 and September 2003 were recently released (Centers for Disease Control and
Prevention, CDC, 2003). The majority of these persons were infected with Leishmania
majorin urban areas of Iraq after a median period of deployment of 60 days.
More than 90% of the world's cases of cutaneous leishmaniasis are in Afghanistan,
Algeria, Brazil, Iran, Iraq, Peru, Saudi Arabia, and Syria (Murray, et al, 2005).
However, approximately 75% of the cases that are evaluated in the United States were
acquired in Latin America, where leishmaniasis occurs from northern Mexico (rarely in
rural southern Texas) to northern Argentina. In Brazil, cutaneous leishmaniasis cases
were 21,800 in 1998, while there were 40,000 in 2002 (Gramiccia and Gradoni, 2005).
Leishmaniasis is not found in Australia or the South Pacific. Kabul is the largest centre
of cutaneous leishmaniasis in the world, with an estimated 67,500 cases. The figure
accounts for a third of the 200,000 cases in all of Afghanistan, At the same time, the
influx of large numbers of displaced people threatens to increase the disease's already
epidemic levels. With little immunity to leishmaniasis, displaced people. or in this case,
people returning from neighbouring Pakistan, are typically more susceptible to the
disease. (World Health Organization, News, 2004). Cutaneous leishmaniasis occurs in
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the New World and the Old World. Old World disease is primarily caused by
Leishmania tropica in urban areas and Leishmania major in dry desert areas. The two
subgenera of interest in Latin America are Leishmania leishmania (e.g., Leishmania
mexicana, Leishmania amazonensis, and Leishmania chagasl) and Leishmania viannia
(e.g., Leishmania panamensis, Leishmania brasiliensis, and Leishmania guyanensis).
The incubation period is two to eight weeks, although longer periods have been noted.
The disease begins as an erythematous papule at the site of the sandfly bite on exposed
parts of the body. The papule increases in size and becomes a nodule. It eventually
ulcerates and crusts over. The border is usually raised and distinct. There may be
multiple lesions, especially when the patient has encountered a nest of sandflies. The
ulcer is typically large but painless unless there is secondary bacterial or fungal
infection (Markle and Makhoul, 2004).
Mucocutaneous leishmaniasis (MeL) is also called mucosal form and usually occurs
after an initial cutaneous infection. Ninety percent of cases of mucosal leishmaniasis are
found in the tropics of South America Brazil, Bolivia, and Peru, and they usually begin
in the nose or palate (WHO report, 2003). This manifestation is primarily due to
members of the L. braziliensis complex (Gramiccia and Gradoni, 2005). Mucocutaneous
disease begins as simple skin lesions that metastasize via the blood stream or
lymphatics, particularly to the mucosae of the nose and mouth, other symptoms
include fever, weight loss, and anemia. The expression of this form of the disease can
occur several years after the primary lesion. This disease will generally continue to
progress and can lead to severe pathology and even deformity if not treated. Although
some patients may simultaneously exhibit skin and mucosal lesions, it has been
observed that in the majority of cases (59%) from Amazonian Brazil the mucosal
disease has resulted from an old, prolonged, and untreated (self-healing) cutaneous
infection with L. (v.) braziliensis (Silveira, et sl., 1999). This parasite is recognized as
the most important etiologic agent of mucocutaneous leishmaniasis in the New World
(Lainson, 1983;Grimaldi, et al, 1987; Lainson and Shaw, 1998).
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Diffuse cutaneous leishmaniasis (DeL) and leishmaniasis recidivans are two rare
manifestations of cutaneous leishmaniasis. This disease is characterized by disseminated
nodular lesions that resemble lepromatous leprosy. These lesions tend to be scaly and
not ulcerated. Recivida is a chronic recurrence of nodular lesions or a rash
characterized by hypersensitivity. Neither diffuse cutaneous leishmaniasis nor recidiva
is easily cured. This type of disease occurs most often in Ethiopia. Brazil. Dominican
Republic. and Venezuela. The lesions of diffuse cutaneous leishmaniasis are very
similar to those of localized cutaneous leishmaniasis. except they are spread all over the
body. The patient's immune system apparently fails to battle the protozoa. which are
free to spread throughout the body. In the New World. diffuse cutaneous leishmaniasis
has been associated with Leishmania pifanoi (Schnur. et al. 1983). L. smszonensis, L.
mexicana (Simpson, et al, 1968; Grimaldi, et al., 1989; Gramiccia and Gradoni, 2005),
and L. venezuelensis (Bonfante-Garrido, et sl., 1992). In the Old World it has been
associated with L. aethiopica (Grevelink and Lerner, 1996), L. major (Morsy, et sl.,
1997), and L. tropica (Takahashi Sato, 1981).
1.1.2 Organisms and life cycle
Leishmaniasis is a disease complex caused by species of haemoflagellate protozoan
parasites belonging to the genus Leishmania, which belong to the order Kinetoplastida,
family Trypanosomatidae. Leishmania spp are divided into two subgenera: the Viannia
subgenus includes L. (Viannia) braziliensis and related species that develop in the
hindgut before migrating to the midgut and foregut. The other subgenus such as L.
(leishmania) donovani, occupy only the midgut and foregut (Lainson and Shaw. 1987).
Morphologically, leishmania is divided in to two forms. Amastigotes are spherical in
shape, only about 2-3 ~m in diameter, and they reside and multiply within
phagolysosomes in mammalian mononuclear phagocytes. There is a prominent nucleus
and kinetoplast, and the cytoplasm is vacuolated and contains lysosomes. The outer
7
CHAPTER 1GENERAL INTRODUCTION
membrane has a polysaccharide component but there is no surface coat (Lindsay, et al,
2002). Promastigotes are similar in structure, apart from the prominent flagella.
Leishmaniasis is transmitted through the bite of female phlebotomine sandflies in
Mediterranean Europe, North Africa, East Africa, India and China (Figure 1.3). In
South America, transmission is by the genus Lutzomyia (Rogers, et al., 2004; Murray,
et sl., 2005). Sandflies feed on plant juices but for the most part the females need a
blood-meal in order to develop eggs. Autogeny occurs in a few species. Blood is taken
from humans and animals such as dogs, farm livestock, wild rodents, snakes, lizards
and birds. Each sandfly species has specific preferences for its source of blood, but the
availability of hosts is an important factor. The saliva of sandflies can enhance the
virulence of inoculated Leishmania parasites (Titus and Ribeiro, 1988; Theodos, et al.,
1991). Sandfly species are only important as vectors of leishmaniasis if they feed
regularly on humans.
FIGURE 1.3 Phlebotomine sandflies. 1.3 - 3.5 mm in length, hairy appearance,
conspicuous black eyes, long, stilt-like leg. Obtained from: WHO documents 1997:
www.who.intlentity/water_sanitation_healthiresources/vectorOO7to28.pdf
The sandfly vector becomes infected when feeding on the blood of an infected
individual or an animal host. The Ieishmanis parasites live in the macrophages as
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round, non-motile amastigotes. The macrophages are ingested by the fly during the
blood- meal and the amastigotes are relesed into the vector midgut. These parasites
then differentiate into the motile, elongated (10-20 micrometers), flagellate metacyclic
promastigote form which takes 1-2 weeks. The mature metacyclic promastigotes then
migrate to the alimentary tract of the fly, where they live extracellularly and multiply
by binary fission (Schmidt and Roberts, 1989). Four to five days after feeding the
promastigotes move forward to the salivary glands of the insect. When the sandlfy next
feeds on a mammalian host, promastigote forms of the leishmanial parasite enter the
mammalian host via the proboscis (Figure 1.4). Once in the host the promastigotes are
taken up by the macrophages where they rapidly revert to the amastigote form within
the phagolysosome by losing its flagellum and becoming more spherical (Bates and
Rogers, 2004; Rogers, et al, 2004).
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FIGURE 1.4 Diagrammatic representation of the Leishmania life cycle. Obtained from:
Protozoa as Human Parasites website: http://www-micro.msb.le.ac.uk/
224/Parasitology.html.
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The Leishmania are able to resist the microbiocidal action of the acid hydrolases
releaseed into the lysozymes and so survive and multiply inside the macrophages,
eventually leading to the lysis of the macrophages. The released amastigotes are taken
up by additional macrophages and so the cycle continues. Ultimately all the organs
containing macrophages and phagocytes are infected. especially the spleen. liver and
bone marrow.
1.1.3 Therapy
The treatment of leishmaniasis depends on the infecting leishmania sp. and the clinical
syndrome (Pearson and Sousa. 1996; Berman. 1997). Pentavalent antimonial
compounds. either sodium stibogluconate (Pentostam) or meglumine antimoniate
(Glucantime). have remained the first choice of drug in the treatment of all forms of
leishmaniasis for many decades (Berman. 1997; Croft. et al. 2005). Many studies have
confirmed that pentavalent antimonials, in sufficient doses. are effective against several
types of leishmaniasis e.g. (Arana. et al.• 2001; Soto, et al.•2005). They are widely used
despite their toxicity. difficult administration. relatively high cost of treatment. and the
appearance of resistant parasite strains. These compounds induce many side effects
including headache. nausea. anorexia. arthralgias, phlebitis. and cardiotoxicity when
used in very high doses (Navin. et al. 1992; Olliaro and Bryceson, 1993). Other side
effects include cough. skin rash. fever. gastrointestinal irritation (Wyler and Marsden.
1984). malaise. myalgia. transient leucopenia. thrombocytopenia. hepatotoxicity
(Hepburn. et al. 1993). and pancreatitis. (Gasser. et al.• 1994; Mcbride, et al. 1995). In
addition. the drug can not be given during pregnancy and requires a close supervision
when administered to patients with cardiac problem. The limitations on the use of
these drugs have stimulated a widespread interest in evaluating alternative drugs.
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The polyene antibiotic amphotericin B is currently a second-line treatment for visceral
leishmaniasis (VL) and mucocutaneous leishmaniasis. The use of this drug is fraught
with well-known adverse effects including fever, malaise, nausea, vomiting,
nephrotoxicity, and phlebitis. In order to reduce this dose-limiting toxicity, different
commercial lipid-based formulations have been developed and used in the clinical
management of VL, AmBisome (Davidson, et sl., 1991; Berman, et al, 1998), Abelcet
(Sundar and Murray, 1996; Sundar, et al., 1998a),and Amphotec (Dietze, et sl., 1993).
These have also been used as alternative treatments for mucocutaneous leishmaniasis
(Zijlstra, et sl., 2003). In some developed countries, AmBisome is now indicated as the
first-line therapy against VL (Sundar, et sl., 2003; Croft, et sl, 2005). However, the
high prices of these formulations restrict their use in the regions most affected by these
tropical diseases (Lockwood, 1998; Guerin, et el., 2002). New lipid formulations of
amphotericin B exhibit much less toxicity, but are extraordinarily expensive by
developing world standards. Lipid-amphotericin B formulations with lower toxicity
than the parent drug that were developed for the treatment of systemic mycoses have
proved to be an effective treatment for VL, especially AmBisome. This drug is named a
"miracle drug" because it is simple to use (maximum of 10 days), revives patients within
hours of getting the first shot, and has virtually no side effects. The drawback is that
there is only one producer and it is astronomically expensive - the best current price
offer is US$I,500-2,400 per treatment, well beyond the reach of the average patient. In
vitro, free amphotericin B was three to six times more active than the liposomal
formulation AmBisome against both Leishmania major promastigotes in culture and
amastigotes in murine macrophages. It has been suggested that liposomal amphotericin
B may be useful in the treatment of cutaneous Leishmaniasis (Yardley and Croft, 1997).
In dogs naturally infected with L. infantum were treated with liposomal amphotericin
B (Oliva, et sl., 1995; Lamothe, 2001). Despite nephrotoxicity, amphotericin B is being
increasingly used both as the drug of choice for human visceral leishmaniosis in
patients with human immunodeficiency virus infection, and in cases where there is
pentavalent antimonial resistance (Walker, et sl., 1998).
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Pentamidine was tried for leishmania in an attempt to limit side-effects of systemic
antimony. The drug was highly effective and acceptably tolerated as an alternative to
antimony in the treatment of cutaneous Leishmaniasis in the New World (Ouellette, et
al, 2004), but was used in only one study in the Old World (Hellier, et el., 2000).
Pentamidine isethionate is associated with many adverse effects, such as headache,
hypotension, nausea, vomiting, and hypoglycemia followed by diabetes mellitus and
the development of drug resistance (Thakur, et el., 1995; [ha, et al., 1998; Sundar, et al.,
1998a, Sundar, 2001a).
Allopurinol is a drug in use for the treatment of gout. It is supposed to function as an
alternative substrate for the enzyme Hypoxanthine Guanine Phosphoribosyl
Transferase (HGPRTase), so allowing the formation of allopurinol riboside
monophosphate, and its incorporation into RNA, which leads to the inhibition of
protein synthesis in the parasite (Marr, et sl., 1982). It is also on trial for the treatment
of Chagas disease and the drug is now widely used for the treatment of leishmaniasis in
dogs. Allopurinol monotherapy has no effect on Colombian cutaneous disease primarily
caused by L. panamensis and therefore is unlikely to be effective against cutaneous
leishmaniasis in other endemic regions (Velez, et al., 1997). Allopurinol, a purine
analogue, has been used to treat leishmaniasis alone (Pfaller and Marr, 1974; Marsden,
et al., 1984), or combined with other drugs such as antimonial compounds (Chunge, et
al, 1985; Martinez and Marr, 1992; Momeni and Aminjavaheri, 1995; Martinez, et al.,
1997; Denerolle and Bourdoiseau, 1999; Momeni, et sl., 2002; Pasa, et al., 2005). A
novel combination uses ketoconazole and allopurinol, two drugs that have been
individually suggested as second line treatments for visceral leishmaniasis (Hueso, et al.
1999). Low cost. stability. safety, ease of administration (oral). and lack of toxicity make
allopurinol a particularly appealing drug for tropical and subtropical diseases.
Miltefosine is the most recent treatment to come to market. which has the advantage of
being orally active in contrast to almost all the other drugs (Sundar. et sl., 2002; Croft.
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et al, 2005). This anti-cancer drug was discovered to be effective against kala-azar in
mid-1990s, but has only been registered for use in India. However, extreme caution
must be observed when administering this drug to women of child-bearing potential,
and it is too expensive for most of the developing world. Orally administered
miltefosine appears to be an effective treatment for Indian visceral leishmaniasis (Jha, et
al, 1999) and a promising oral drug for cutaneous leishmaniasis (Arana, et al, 2001).
Despite the recent success with miltefosine as an antileishmanial drug (Herwaldt,
1999b; Soto, et al, 200I), its use is limited because of the risk of the rapid development
of resistance ifit is used alone (Bryceson, 2001).
Ketaconazole is a drug for fungal infections, but also inhibits sterol synthesis in
Leishmania and interferes with the growth and division intracellular amastigotes. It is
on trial for the use in dogs and in humans. Ketaconazole and itraconazole, have also
been tested for cutaneous leishmaniasis, but results obtained were not completely
satisfactory (Arana, et al, 2001; Storer and Wayte, 2005). Although the ketoconazole
tablet has been reported to be effective in the treatment of some cases of cutaneous
leishmaniasis, the low response rate in patients receiving ketoconazole cream indicates
that it cannot be used as the single agent in the treatment of cutaneous leishmaniasis
patients (Momeni, et al, 2003) or for visceral leishmaniasis when tested in L. infantum
as an experimental model (Gangneux, et al., 1999).
Paromomycin is a new potential drug for leishmaniasis, the effectiveness of this old
antibiotic against kala-azar and cutaneous Leishmaniasis (Croft, et al, 2005; [ha, et sl.,
2005) was discovered accidentally in the 1960s. But the drug got stuck in the research
pipeline, as it "would not make a lot of money". Moreover, its current formulation has
not yet been registered for use anywhere in the world. However, WHOlfDR and
Institute of One World Health (IOWH) are working to get the drug registered for use
in India. In addition, the Drugs for Neglected Diseases Initiative (DNDi) Foundation is
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launching clinical trials of the anti-leishmanial drug paromomycin for registration in
Africa, (DNDi Press Release, Geneva 2004).
1.1.4 Drug resistance
The recent emergence of widespread clinical resistance in leishmania parasites is a
major problem to their control. Drug resistance has great public health importance for
anthroponotic Leishmania donovani and Leishmania tropica. Most other forms of
leishmaniasis are zoonotic and so the spread of drug resistance is less likely (Croft and
Coombs, 2003). The lack of response to pentavalent antimonials in visceral
leishmaniasis has been a problem for many years and is increasing world wide,
occurring in about 5-70% of the patients in some endemic areas in some developing
nations (Ouellette and Papadopoulou, 1993; Guerin, et al.• 2002). In the state of Bihar
in north-western India, up to 70% of Leishmania cases are resistent to antimonials
(Sundar, 2001; Croft, et al., 2006). The HN epidemic is spreading from the towns into
the country villages and is likely to make the situation worse and drug resistance is the
priority. In Bangladesh, Brazil, resistance continues to grow (Seaman, et al, 1996), and
is spreading along the borders with Ethiopia (WHO Report, 2002). A relatively high
proportion of patients with visceral leishmaniasis fail to respond to pentamidine in
Kenya (Wijers, 1974), India (Thakur, et el., 1993; Giri, 1994; Sundar, 2001), and China
(Akhtar, and Humber, University of East London' website) due to increased resistance
(Dietze, et sl., 1995;Thakur, et el., 1995).
Resistance to paromomycin (aminosidine) has not yet been reported, but experience
with its antibacterial usage suggests that the potential is there if it were used widely on
its own (Bryceson, 2001). It has been reported that impairment in miltefosine (HePC)
uptake is likely to be the main mechanism of resistance in L. donovsni promastigotes
(Perez-Victoria, et al. 2003). In developed Mediterranean nations, drug-resistant
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leishmaniasis continues to spread as the number of patients co-infected with HIV
increases. Primary resistance to amphotericin B has not been reported and secondary
resistance only in HIV co-infected patients. Isolates from HIV co-infected adult
patients in France were increasingly resistant to amphotericin B following relapse after
treatment (Di Giorgio. et al. 1999). The mechanism of resistance to antimony in field
strains is unknown. However. some studies of the drug resistance in vitro have
suggested that there are many reasons. including reduced accumulation of the drug
(Dey. et el., 1994; Brochu. et el., 2003). It has been reported that the resistance to
paromomycin might be due to decreased drug uptake. A sensitive method to detect and
to quantify intracellular paromomycin was developed showing that the main
mechanism of resistance seems to be due to decreased drug uptake probably as a
consequence of altered membrane composition (Maarouf et el., 1998).
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1.2African Trypanosomiasis
1.2.1 Disease
African trypanosomiasis or sleeping sickness is a disease caused by infection with
protozoan parasites of the genus Trypanosoma, which enter the blood-stream via the
bite of bloodfeeding tsetse flies (Glossina spp.). Trypanosomiasis remains as much a
major public health hazard today as it did when studies first began more than 100 years
ago (Hide, 1999). The disease affects both people (Human African Trypanosomiasis,
HAT or sleeping sickness) and animals (Animal African Trypanosomiasis AAT, or
nagana) and occurs in 37 sub-Saharan countries covering more than 9 million kms, an
area which corresponds approximately to one-third of the Africa's total land area, 22 of
these countried are among the least developed countries in the world (Figure 1.5). The
infection threatens an estimated 60 million men, women and children (Molyneux,
1997), and about 50 million head of cattle. However, only 3 to 4 million of these people
are under surveillance and the 45.000 cases reported in 1999 do not reflect the reality
of the situation, but simply show the absence of case detection. The estimated number
of people thought to have the disease is between 300 000 and 500 000 (WHO report,
2001).
Human African trypanosomiasis (HAT) is a disease caused by two subspecies of
Trypanosoma brucei. Trypanosoma brucei gambiense, which causes Gambian or
chronic sleeping sickness, mainly in West and Central Africa. Trypanosoma brucei
rhodesiense causes Rhodesian or acute sleeping sickness in East and South-central
Africa (Balakrishnan and Zumla, 2001; Pepin and Meda, 2001). The parasites first
develop in the blood, lymph and peripheral organs, which is known as stage one
(Barrett, et sl., 2003), the main clinical signs of human trypanosomiasis are high fever,
weakness, headache, joint pains and pruritus (itching). Gradually, the immune defence
mechanisms and the patient's resistance are exhausted. As the parasite develops in the
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lymph and blood of the patient, the initial symptoms become more pronounced and
other manifestations such as anaemia, cardiovascular and endocrine disorders, and
abortion, oedema and kidney disorders appear.
•
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"
FIGURE 1.5 Map of the world showing the distribution of
trypanosomIasIs. Image was reproduced from: WHO,
http://www.who.intltdr/dw/tryp2004.htm.
human African
TDR disease.
In advanced stages of disease, the parasite invades the central nervous system (Chimelli
and Scaravilli, 1997; Enanga, et al., 2002). The patient's behaviour changes, they can no
longer concentrate and become indifferent to their environment. Sudden and
unpredictable mood changes become increasingly frequent, giving rise to lethargy with
bouts of aggressiveness. Patients are overcome by such extreme torpor that eating,
speaking, walking or even opening the eyes call for an unsurmountable effort. At night
they suffer insomnia and during the day are exhausted by periods of sleep-like
unconsciousness. Finally, patients fall into a deep coma and die, this occurs mainly in
east and southern Africa.
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African animal trypanosomiasis (AAT) is caused by genus Trypanosoma congolense
resides in the subgenus Nannomonas, a group of small trypanosomes with medium-
sized marginal kinetoplasts, no free flagella. and poorly developed undulating
membranes. In east Africa. T. congolense is considered to be the single most important
cause of AAT. This parasite is also a major cause of the disease in cattle in West Africa.
Sheep. goats. horses. and pigs may also be seriously affected. In domestic dogs. chronic
infection often results in subacute. acute. or chronic disease characterized by
intermittent fever, anemia. occasional diarrhea, and rapid loss of condition and often
terminates in death. In southern Africa the disease is widely known as nagana, which is
derived from a Zulu term meaning "to be in low or depressed spirits". T. brucei brucei
resides in the subgenus Trypanozoon. T. b. brucei is an extremely polymorphic
typanosome occurring as short. stumpy organisms without clear flagella. long slender
organisms with distinct flagella. and intermediate forms that are usually flagellated.
Horses, dogs, cats, camels and pigs are very susceptible to T. b. brucei infection
(Schmidt and Roberts. 1989). Infection of cattle. sheep, goats and sometimes pigs results
in mild or chronic infection. This last observation. although widely accepted. has been
called into question by Moulton and Sollod, who cite evidence that this organism is
widespread in east and west Africa and that it can cause serious disease and high
mortality in cattle. sheep. and goats (Moulton and Sollod, 1976). T. vivax is a member
of the subgenus Duttonelle, a group of trypanosomes with large terminal kinetoplasts,
distinct free flagella. and inconspicuous undulating membranes. T. vivax is a large (18-
26 Ilm long) monomorphic organism that is very active in wet-mount blood smears.
Cattle. sheep, and goats are primarily affected (Roeder. et sl., 1984). Although this
organism is considered to be less pathogenic for cattle than T. congolense, it is
nevertheless the most important cause of AAT in West African cattle. This
trypanosome readily persists in areas free of tsetse flies (for example. in Central and
South America and in the Caribbean). where it is transmitted mechanically by biting
flies or contaminated needles. syringes. and surgical instruments.
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A few species of Trypanosoma are also found in the New World. From the standpoint
of human health, the most important is Trypanosoma cruzi which causes American
trypanosomiasis or Chagas disease. Chagas disease is found throughout much of central
and northern South America, Central America, and Mexico. T. cruzi is found in a
number of animals other than humans, including dogs, cats and rodents, but it is not
known how often infections in these animals are transmitted to humans.
1.2.2 Organisms and life cycle
The parasite is an elongated cell with single nucleus which usually lies near the centre
of the cell. Each cell bears a single flagellum which appears to arise from a small
organelle of the kinetoplast. The kinetoplast is a specialised part of the mitochondria
and contains DNA. The length and position of the trypanosome's flagellum is variable.
In trypanosomes from the blood of a host the flagellum originates near the posterior
end of the cell and passes forward over the cell surface, its sheath is expanded and
forms a wavy flange called an undulating membrane (Figure 1.6).
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FIGURE 1.6 Diagram to show principal structures revealed by the electron microscope
in the epimastigote stage of Ttypsnosome, Reproduced from Mark F. Wiser, Tulane
University 1999. http://www.tulane.edu;-wiser/protozoology/noteslkinet.html#cycle
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African trypanosomes are transmitted by several speCIes of tsetse flies of genus
Glossina. The tsetse fly becomes infected with bloodstream trypomastigotes when
taking a blood meal on an infected mammalian host. The trypanosomes in the
vertebrate's blood migrate into the vector's midgut, where the short stumpy forms
complete the development of their mitochondrion and change their surface coat to
differentiate into the long, slender procyclic trypomastigotes. As the procyclic stages
have a fully developed mitochondrion and polysomes highly loaded with mRNA, they
exhibit significantly higher levels of metabolic activity and protein synthesis than do
the bloodsteam stages (Brecht and Parsons, 1998). They multiply by binary fission,
leave the midgut, and transform into epimastigotes. The epimastigotes reach the fly's
salivary glands and continue multiplication by binary fission. Eventually, some
epimastigotes undergo a final transformation stage into non-dividing metacyclic
trypomastigotes, which are short, stumpy, and highly motile. They lack free flagella,
and have a terminally located kinetoplast. The cycle in the fly takes approximately 3
weeks (Figure 1.7).
FIGURE 1.7 Diagram represents the life cycle of Typanosoma. SS: Short Stumpy
bloodstream forms, PT: Procyclic Trypomastigotes, E: Epimastigotes, MT: Metacyclic
Trypomastigotes, and LS: Long Slender bloodstream forms. Reproduced from Mark, F.
Wiser, Tulane University 1999: httpc//www.tulane.edu/Twiser Iprotozoology/noteslk
inet.html#cycle.
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During a blood meal on the mammalian host, an infected tsetse fly (genus Glossina)
injects metacyclic trypomastigotes into skin tissue. The parasites enter the lymphatic
system and develop into the long slender bloodstream forms. Inside the host, they
transform into bloodstream trypomastigotes, are carried to other sites throughout the
body, reach other blood fluids (e.g., lymph, cerebro-spinal fluid), and continue the
replication by binary fission until a threshold population is reached, whereupon a
switch occurs, resulting in a subpopulation of long slender bloodstream forms
transforming first into intermediate forms and then into short stumpy bloodstream
forms. This transition involves cell cycle arrest and a decrease in protein synthesis, as
evidenced by a reduction in ribosome loading (Brecht and Parsons, 1998). The SSforms
are morphologically and functionally very different from the long slender bloodstream
forms as they do not divide and have no free flagellum. It is likely that the short
stumpy bloodstream form is the infective stage for the tsetse, and the switch from a
predominance form of long slender bloodstream forms to short stumpy bloodstream
forms is therefore essential for the cycle to continue (Seed, 1998).
1.2.3 Therapy
The use of drugs for the prevention and treatment of trypanosomiasis has been
important for many decades. The drug regimen depends on the infecting species and
the stage of infection. Treatment has always been difficult, especially when the disease
has reached an advanced stage with central nervous system involvement, as few
effective drugs are available.
Diamidines, including pentamidine and berenil (diminazene aceturate), have been
first-line drugs for the treatment of early stage African trypanosomiasis for decades
(Pepin and Milord, 1994; Croft, et el., 2005). Pentamidine isethionate and suramin,
under an investigational New Drug Protocol from the Centers for Disease Control
(CDC) drug service, are used before the Central Nervous System (CNS) involvement,
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and are the drugs of choice to treat the hemolymphatic stage of West and East African
Trypanosomiasis (Croft, et el., 2005). However, Pentamidine is not effective against
late-stage disease and Suramin has to be administered intravenously and can have
adverse side-effects. Berenil is a veterinary drug that has also been used occasionally
without licence (Barrett, et sl., 2003). Melarsoprol, an arsenical drug developed over 50
years ago, is the drug of choice for late-stage disease with central nervous system
involvement, but often induces serious, sometimes fatal side effects.
A newer drug, eflornithine, originally developed as an anticancer agent, has shown to
be effective against the T. b. gambiense form. This polyamine synthesis inhibitor
difluoromethylornithine (DFMO) has emerged as an alternative therapy when the
outlook has hitherto been grim. This drug is used after the failure of the usual first-line
treatment Melarsoprol (Milord, et sl., 1992; Khonde, et el., 1997;Na-Bangchang, et sl.,
2004; Croft, et al, 2005), and because it is very expensive, a complete treatment costs
US$ 250, making its use as a first choice drug almost impossible in Africa (Aksoy, 2003).
Some of the older chemoprophylactic drugs such as the quinapyramine derivatives
Antrycide and Antrycide prosalt are still used and give effective protection against T. b.
brucei infection in horses, camels, and cattle for a short time. Quinapyramine
derivatives are the most commonly used trypanocidal drug in China. Drug resistance in
T. evansi isolates has been reported from Africa (Boid, et al., 1989; El Rayah, et sl.,
1999) and the far east of Asia (Dieleman, 1986).
The drug pyrithidium bromide (Prothidium and AD2801) is useful in the prophylaxis
of T. vivax and T. congolense infections in cattle, sheep, and goats and can give
protection for up to 6 months. The most widely used of the chemoprophylactic drugs is
isometamidium chloride which has been in use for over 20 years and sold under the
trade names Samorin and Trypamidium, is excellent for the prophylaxis of all three
African animal trypanosomes, and gives protection for 3-6 months. Homidium bromide
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has also been found to be an effective chemophrophylactic drug in Kenya, and both
homidium and isometamidium chloride are drugs in use against trypanosomiasis in
cattle in the African countries (Stevenson, et al.• 1995).
Pentamidine isethionate (Diamidine) Berenil (Diminazene aceturate)
NoO,Sn °n.~-~
N.o,S I SO,N.
H,N _ yF ~H
~
Suramine (Moranyl®)
Difluoromethylornithine, DFMO
(Eflomithine®)
Melarsoprol (Arsobal®)
,H,
Hh=D;YCH''- I ~H,C-N ==N)=Ii NH,
H,N
r{-n;-1-~-~~
NO,
Nifurtimox (Lampit®) Antrycide Benznidazole (Radinil®)
"i)
N==N
/
HH,N
Isometamidium chloride (Samorin ) Homidium bromide
FIGURE 1.8 Structural formulas of drugs used against Human African Trypanosomiasis
(HAT) and Animal African Trypanosomiasis (AAT).
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In addition, control relies mainly on systematic surveillance of at-risk populations,
coupled with treatment of infected people. Reduction of tsetse fly numbers plays a
significant role, especially against the rhodesiense form of the disease. In the past, this
has involved extensive clearance of bush to destroy tsetse fly breeding and resting sites,
and widespread application of insecticides. More recently, efficient traps and screens
have been developed that, usually with community participation, can keep tsetse
populations at low levels in a cost-effective manner (Kabayo, 2002; Torr, et al, 2005).
1.2.4 Drug resistance
Since there is no indication that new products against trypanosomaiasis will become
available in the near future, it is importance that measures are taken to avoid or delay
the development or spread of resistance, and to maintain the efficacy of the currently
available drugs. Resistance to one or more of the trypanocidal drugs used in human and
cattle has been reported in many countries in sub-Saharan Africa (Peregrine, 1994).
This is probably an underestimation of the true situation, because in several countries
surveys for resistance have not yet been carried out or cases of resistance have not been
published.
Over the past few years, reports of treatment failure in melarsoprol-treated patients are
on the increase, particularly in Sudan, Angola, Democratic Republic of the Congo and
Uganda. In Uganda, relapse rates of up to 30% have been reported (Legros, et al., 1999).
The development of resistance to isometamidium chloride has been reported in both
east and west Africa (Peregrine, 1994). The use of a double dose of diminazene only
slightly improved the therapeutic efficacy for resistant T. congo1ense (Silayo, et sl.,
1992). The weekly monitoring of cattle and treatment with diaminazine aceturate
failed to provide effective control and as a result, almost a quarter of the animals died
or removed from the trial in an extremely weak condition (Stevenson, et al., 1995). T.
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bruceiwas resistant to diminazene and isometamidium in Nigeria (Kalu, 1995), and in
Kenya resistance to melarsoprol has been reported in Trypanosoma brucei rhodesiense
(Bales, et al, 1989). In Uganda, Trypanosoma brucei rhodesiense were resistant to
melarsoprol (Ogada, 1974), and T. bruceito diminazene and isometamidium (Matovu,
et sl., 1997), and Trypanosoma brucei rhodesiense to DFMO (Iten, et sl., 1995).
Resistance has also been found in T. brucei against isometamidium in Zambia
(Chitambo and Arakawa, 1991), and, in D.R.Congo, Trypanosoma brucei gambiense
was resistant to melarsoprol (Pepin, et sl., 1987). Resistance to one drug may also occur
as a result of induction of parasite resistance to other related compounds (Mwambu,
and Mayende, 1971). Such cross-resistance to diminazene, isometamidium and
homidium, for example, is thought to develop as a result of resistance to quinapyramine
(Ndoutamia, et al, 1993)
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1.3 Toxoplasmosis
1.3.1 Disease
Toxoplasmosis is a disease caused by an intracellular protozoan parasite, Toxoplasma
gondii, and is widespread throughout the world (Iackson and Hutchison, 1989;
Bhopale, et el., 1997). Toxoplasma gondii has very low host specificity, and it will
probably infect almost any mammal. The disease is of major medical and veterinary
importance, being a cause of congenital disease and abortion in humans and in
domestic animals (Ioiner and, Dubremetz, 1993). Humans can be infected with T
gondii by ingestion or handling of undercooked or raw meat (mainly pork and lamb)
containing tissue cysts or water or food containing oocysts excreted in the faeces of
infected cats. In addition to being swallowed, Toxoplasma parasites can enter the body
through contaminated blood transfusions or through organ transplants taken from
infected donors. The United States Department of Agriculture (USDA) estimates that
50% of T. gondii infections in the United States are caused by ingestion of raw or
undercooked infected meat (Buzby and Roberts, 1996). This was confirned by a
community-based study in Maryland (Roghmann, et el., 1999). In 1999, Mead and
colleagues estimated deaths caused by toxoplasmosis at 750 each year, making
toxoplasmosis the third leading cause of foodborne deaths in the US (Mead, et al.,
1999). According to the U.S. Centers for Disease Control and Prevention (CDC), an
estimated 225,000 cases of toxoplasmosis occur every year in the United States, with
5,000 hospitalizations and 750 deaths. About 50% of all cases of toxoplasmosis are
related to food. In the United States, up to 4% of lamb products and 32% of pork
products are contaminated with toxoplasmosis. In some areas of Brazil, the serological
prevalence of T.gondii infection ranges from 50% to 80% of the adult population, with
the highest values found in some northern and southern states (Bahia-Oliveira, et al.,
2003). In northern Rio de Janeiro State, water has been identified as a source of T.
gondii infection (Benenson, et sl., 1982; Bowie, et sl., 1997).
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The disease is commonly asymptomatic when acquired by healthy persons. However, it
can cause significant morbidity and mortality in people whose immune defenses are
weakened because of AIDS, cancer or immunosuppressant medication. Under these
coditions, a new toxoplasmosis infection may spread out of control and become deadly,
or dormant Toxoplasma parasites from an old toxoplasmosis infection may suddenly
become active again and cause severe illness. This situation is especially dangerous for
people with AIDS. In these people, dormant toxoplasmosis can reactivate and cause a
severe brain infection (encephalitis), which can lead to seizures and other neurological
problems (Araujo and Remington, 1987; Luft and Remington, 1992; Jones, et al., 1999).
If left untreated, the death rate from encephalitis is very high.
Also, if a toxoplasmosis infection develops ina pregnant woman, there is a 50% chance
that the parasites will cross the placenta and cause toxoplasmosis in the infant,
resulting in a spontaneous abortion, a still born, or a child that is severely handicapped
mentally and/or physically. This is called congenital toxoplasmosis (Remington and
Desmont, 1973). In the United States, congenital toxoplasmosis occurs in 400 to 4,000
newborns each year (CDC. Report, 2000), and these newborns are at high risk of
toxoplasmosis-related eye problems and developmental disabilities (Jones, et al., 2001).
Toxoplasmosis is causing great financial loss in the agricultural industry (Schwartzman,
2001), being a major cause of abortion and stillbirth in sheep flocks in Britain, Australia
and New Zealand. Toxoplasmosis is the most frequently diagnosed cause of abortion in
sheep and accounts for approximately 80% of all sheep abortions in the UK. Abortions
are higher in colder areas, and while 30% of ewes in a flock aborting would be
considered at the higher end of the scale it is not unknown. Toxoplasmosis occurs in
isolated occurrences in Tasmania throughout the lambing season. While the economic
impact to the industry is small, high lambing loss percentages can have a devastating
financial impact on individual farm businesses in anyone season. Reports suggested
that some farm businesses no longer run ewes and lambs because of toxoplasmosis
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(Tasmanian Farmers & Graziers Association report TFGA. Report, 2004). In the U.S,
pigs are also infected with an estimated 3% of market pigs and 18% of breeding stock.
The parasitic infection persists in pigs despite good quality management procedures.
Among food animals, pigs are the major source of human infection. Domesticated pigs
can become infected by eating feed contaminated by cats, or by eating other infected
hosts such as dead rodents in hog pens (College of Agricultural, Food, and
Environmental Sciences. CAFES.Report, 2001). In the UK, about 0.5-1% of individuals
become infected each year.
The most common symptoms of the infection are confusion, headaches, fever,
paralysis, seizures, and difficulty seeing, speaking and walking. Untreated, the infection
can lead to progressive lethargy (lack of energy), coma and even death. The most
important factors in preventing the complications of toxoplasmosis are early
recognition of symptoms, prompt initiation of treatment, and lifelong suppressive
therapy to prevent the recurrence of brain abscesses.
1.3.2 Organisms and life cycle
Toxoplasma gondii is an obligate intracellular protozoan parasite that belongs to the
phylum Apicomplexa, class Sporozoa, subclass Coccidian, and suborder Eimeria
(Levine, et sl., 1980). It is therefore related to malaria and a number of coccidians that
generally infect birds and most mammals, including man (Joiner and Dubremetz,
1993). The parasite was discovered independently by the French parasitologists Charles
Nicolle and Louis Herbert Manceaux while looking for a reservoir host of Leishmania
in a North African rodent, the gundi Ctenodactylus gondii (Schwartzman, 2001). T.
gondii is a single-celled parasitic organism that can infect most animals and birds, but
because it reproduces sexually only in cats, wild and domestic felines are the parasite's
ultimate host (Figure 1.9).
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FIGURE1.9 Diagrammatic representation of the ultrastructure of a Toxoplasma gondii
tachyzoite. Reproduced from Ajioka, et al. (2001).
T gondii's complex life cycle begins when a cat eats infected prey, usually a mouse or
bird. Cats can also become infected if they are fed raw, contaminated meat or ingest
infected soil. Once ingested, T gondii burrows into the walls of the eat's small
intestine, forming early-stage cells called oocysts that the cat eliminates in its feces,
usually for a period of two to three weeks. Oocysts, which are shed in feces of recently
infected cats, are resistant to desiccation and heat (Dubey, 1995). A single stool may
contain millions of oocysts. Most healthy cats will not shed oocysts after this initial
acute stage. Within a few days, the oocysts develop into mature, highly-infectious cells
that under certain conditions can survive in the soil for a long time. When they are
ingested by another animal, they multiply rapidly inside the host, eventually forming
inactive eggs (cysts) that lodge mainly in the brain or muscles (Figure 1.10). The new
host animal usually remains symptom-free and will not excrete oocysts (Tenter, et al.,
2000).
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FIGURE 1.10 Diagrammatic representation of the life cycle of Toxoplasma gondii.
Obtained from: Protozoa as Human Parasites. http://www-micro.msb.le.ac.uk 1224 I
Parasitology .html.
In many respects, the pattern is similar in humans, after infection with T gondii, the
parasite forms cysts that can affect almost any organ but most often affects the brain,
skeletal and heart muscle. If the person is generally healthy, the immune system keeps
the parasites in the body in an inactive state for life. This provides immunity so that the
person can not become infected with the parasite again. However, if the resistance is
weakened by disease or certain medications, the infection can be reactivated, leading to
serious complications.
1.3.3 Therapy
Most healthy people do not require any treatment for toxoplasmosis, unless having
signs and symptoms of acute toxoplasmosis. The major drugs used for the therapy of
toxoplasmosis are targeted at the folate pathways of the parasite. The mainstay, and
currently most effective therapy for toxoplasmosis, is the combination of
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pyrimethamine (Daraprim) and sulfadiazine, which has been used for both adults and
children. Using pyrimethamine may prevent your body from absorbing the important
B vitamin folate (folic acid, vitamin B-9), especially when taking high doses over a long
period of time, it may recommend taking additional folic acid. Other potential side
effects of pyrimethamine include bone marrow suppression, leukopenia, anemia,
thrombocytopenia and liver toxicity (Schwartzman, 2001).
Sulfadiazine is the preferred sulfonamide, which is an antibiotic used in combination
with pyrimethamine to treat toxoplasmosis. Possible side effects include nausea,
vomiting and diarrhea. In pregnancy, spiramycin is usually given and it has not been
shown to be teratogenic, and appears to decrease the severity of disease (Hohlfeld, et
sl., 1989; Montoya and Liesenfeld, 2004). This drug has been extensively used in
Europe.
Clindamycin, a lincomycin, inhibits the parasite by unknown mechanism that involves
the parasite organelle called the apicoplast (Fichera and Roos, 1997). Clindamycin is
often substituted for sulfadiazine in patients with sulfa allergy (Gabriel Torres, 1991).
One retrospective study showed that 11 of 15 patients treated with clindamycin had
clinical improvement and resolution of brain lesions caused by toxoplasmosis
(Dannemann, et sl., 1988), however, the side effects of clindamycin often preclude its
use as a chronic therapy, and toxicities include diarrhea, skin rashes, and abdominal
pain. Clindamycin has also been associated with the development of colitis
(inflammation of the colon from an overgrowth of bacteria) and strong diarrhea.
Clarithromycin (Klacid) is a macrolide antibiotic which has been shown to inhibit the
growth of Toxoplasma gondii in vitro. In studies using the blood cells of mice,
clarithromycin eradicated infection in 42% of the cells with disseminated lethal
toxoplasmosis (Chang, et el., 1988). In a human trial, twelve patients received
clarithromycin and pyrimethamine, 75% of them showed total or partial resolution of
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brain lesions and a striking clinical response after six weeks of treatment. The high dose
of clarithromycin was well-tolerated except for mild hearing loss. Azithromycin is
another macrolide antibiotic which has been shown to have potent anti-toxoplasma
activity in mice (Araujo, 1988), the drug protected 80% of mice infected with
Toxoplasma.
Combination regimens are considered to be the first choices for the treatment of
different toxoplasmosis. Pyrimethamine, sulfadiazine and leucovorin (folinic acid) are
used for the documented fetal infection (after 12 or 18weeks of gestation), whereas the
same combination plus corticosteroids (prednisone) is effective against congenital
toxoplasma infection in the infant and toxoplasmic chorioretinitis in adults (Montoya
and Liesenfeld, 2004; Bonfioli and Orefice, 2005). The Standard regimens for
acute/primary treatment of toxoplasma encephalitis in patients with AIDS include
pyrimethamine, leucovorin and Sulfadiazine or Clindamycin. Possible alternative
regimens trimethoprim, pyrimethamine and leucovorin plus one of the following:
clarithromycin, atovaquone, azithromycin or dapsone (Montoya and Liesenfeld, 2004;
Bonfioli and Orefice, 2005).
One group of Spanish researchers reported that 16% of patients, in that study, died
within the first week of treatment for toxoplasmosis, regardless of treatment regimen.
50% of the patients who recovered after 21 days of treatment with pyrimethamine and
sulfadiazine chose not to continue maintenance therapy and relapsed after an average
of 12 months (Pedrol, 1990). None of the patients on maintenance therapy (twice
weekly pyrimethamine and sulfadiazine) relapsed after an average follow-up period of
10months. However, 40% of patients on pyrimethamine and clindamycin maintenance
therapy relapsed in this study. A similar study conducted in France reported that two
of six patients relapsed on the same regimen (Leport, et sl., 1989). Other drugs that
have activity against T. gondii include dapsone, azithromycine, clarithromycine,
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roxithromycine, atovaquone, minocycline and rifabutin (Montoya and Remington,
2000).
1.3.4 Drug resistance
There is very little or almost no data available to address the extent to which drug
resistance or strain sensitivity contributes to treatment failures for toxoplasmosis.
However, it has been reported that relapse rates, over a long term therapy for
toxoplasmic encephalitis in patients with AIDS, were 11% for pyrimethamine-
sulfadiazine and 22% for pyrimethamine-c1indamycin (Katlama, et al, 1996). It is not
known if that was due to the drug resistant. A resistant cell line has also been generated
to clindamycin in vitro (Tomavo and Boothroyd, 1995). Studies on drugs that are in use
in patients, or that show some promise for such use, or that represent lead compounds
for further development showed that no instance has yet been reported where
resistance to any of these drugs has arisen in a patient or in the field although different
strains do show varying degrees of sensitivity (McFadden, et al, 2001). The study of
drug resistance generated in vitro is an important topic which can provide key
information about the drug target. These targets range from metabolic pathways in the
cytosol to organellar functions encoded in the mitochondrion or plastid. Such
information makes predictions about how fast resistance will arise in the field but more
importantly, it helps identify targets that are crucial to the parasite and predicts which
combinations of drugs should give good results. The long-term use of antibiotics is
expected to impose strong selection for resistant organisms, and it was reported that a
single-point mutations in T.gondii can produce moderate levels of drug resistance to
Pyrimethaminein RH strain parasites (Reynolds, et el., 2001).
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1.4New drug development
At the present time, chemotherapy is still the mainstay to control most parasitic
diseases such as leishmaniasis and trypanosomiasis, since antiparasitic vaccines are not
yet available against these infections (Berman, 1997; Murray, 2001). There is currently
an urgent requirement for new drugs effective against parasitic and bacterial diseases.
In developing countries, cases of parasitic diseases such as Leishmaniasis reach 12
million annually. It is important to continue to search for new antiprotozoan molecules
because, for some serious parasitic infections, such as leishmania and trypanosomes
resistance has developed to the presently available drugs. There is also a need for a new
treatment for patients with leishmaniasis co-infections, particularly those with AIDS,
since there is a high incidence of relapse after treatment with the current drugs
(Desjeux, 1999; Laguna, et al. 1999; Ramos, et sl., 1994). Moreover, the treatment of
pregnant women, particularly during the first trimester, is often impossible and there is
a lack of forms easily usable in children. A better knowledge of the metabolic pathways
of protozoa (particularly the apicoplast of Apicomplexan parasites) would certainly
open the posssibility to identify new drugs. To reduce and delay the appearance of
resistances, mass-treatments of populations should be avoided and targeted treatments
prefered, as well as the use of combinations of molecules having different modes of
action. The current drugs are, for these reasons, far from being satisfactory drugs and
identifying suitable potential drug targets is essential for effective drug development
(Smith, 2003).
However, despite the wealth of knowledge generated at the basic research level, drug
development against these diseases is still a serious problem as most of the deadly
parasitic diseases are distributed in poor countries where is no purchasing power. As
such, there is no financial incentive for drug companies to develop the drugs. The
development process itself is extremely expensive, so most scientific research stops at
the publication stage or falls through the gaps at different stages of the process of the
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drug development pipeline (Figure 1.11). Many people and organisations around the
world came together to create the Drugs for Neglected Diseases Initiative (DNDi),
which is a not-for-profit organisation designed to mobilise resources for Research and
Development (R&D) for these diseases (Pecoul, 2004).
Gap 1. Basic research is
published but preclinical
research is not considered
worthwhile
Gap 2. Validated candidate drugs
~
don't enter clinical development
I
because of profit-based company
choices--
Gap 3. Drugs never reach the
patient (registration problems, lack
of production, high prices of drugs
FIGURE 1.11 Diagrammatic representation of the Drug Development Pipeline:
Reproduced from Pecoul, (2004).
The fact that the cell biology of protozoan parasites and mammalian cells differ
considerably and this distinctness extends to the biochemical level, can provide the
promise the potential drug targets. Chemical or genetic manipulation methods to
validate these drug targets are now available (Barrett, et al., 1999). In some parasitic
protozoa such as leishmania and trypanosomes, glucose metabolism is considered a
good chemotherapeutic target, due to the fact that the glycolytic enzymes have
structural differences compared with their mammalian counterparts (Aronov, et al.,
1999; Verlinde, et al., 2001). The enzymes involved in trypanothione metabolism have
also been reported to be a promising drug targets for rational approach to drug design
for these parasites (Schmidt and Krauth-Siegel, 2002; Fries and Fairlamb, 2003).
Cysteine protease inhibitors have also shown to be effective against some species of
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trypanosomes and leishmania in vivo and in vitro. and they are now undergoing
clinical trails against Chagas disease (Sajid and McKerrow. 2002; Troeberg. et al., 1999).
Inhibitors of protein kinases have been discovered and appeared to be a potential drug
targets as cyclic-dependent kinases are essential to these parasites. These inhibitors
have showed good activity against amastigotes in macrophages (Doerig. et al. 2002).
Membrane transporters are now considered as one of the most promising potential
drug targets. since the parasite plasma membrane is the interface between the parasite
and the host. The transmembrane transporters are responsible for importing nutrients
as well as host metabolites, so it might be easy to kill the prasite by blocking these
transporters and they could represent good drug targets. Specific transporters can also
be used to deliver selective drugs to the parasite. Purine and pyrimidine nucleotides are
fundamental to life as they are involved in nearly all biochemical processes. The
metabolism of purine and pyrimidine in parasitic protozoa has been studied for the last
thirty years. The results of these studies showed that mammalian cells can synthesize
the purine ring de novo from simple precursors. However. protozoan parasites are
incapable of synthesizing the purine ring de novo and so must salvage preformed
purines from their hosts (Hassan and Coombs. 1988). Furthermore, purine transporters
are of considerable pharmacological importance. because both purine analogues and
non-purine analogues drugs are taken up by some of these transporters. and loss of
permease function can lead to drug resistance (Baldwin. et el., 1999; De Koning and
Jarvis. 1999).
1.5 The ENT and CNT nucleoside transporters families
The plasma membranes of all types of cells are the barrier between the organisms and
their environment. Membrane transporters are responsible for the uptake of essential
nutrients. modulation of concentrations of physiologically relevant chemicals. and
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active release of substances such as signaling molecules and waste products. Passive
transport is a means of moving biochemicals, and other atomic or molecular substances.
across membranes. Unlike active transport, this process does not involve chemical
energy. Passive transport is dependent on the permeability of the cell membrane.
which. in turn. is dependent on the organization and characteristics of the membrane
lipids and proteins. The four main kind of passive transport are diffusion, facilitated
diffusion. filtration and osmosis. Diffusion is the net movement of material from an
area of high concentration of that material to an area with lower concentration.
Facilitated diffusion is movement of molecules across the cell membrane via special
transport proteins that are embedded within the cellular membrane. Filtration is
movement of water and solute molecules across the cell membrane due to hydrostatic
pressure generated by the cardiovascular system. Osmosis is the diffusion of a solvent
across a membrane to a region of higher solute concentration.
Mediated transport is another type of transport mechanism. In this mechanism the
transport requires the assistance of a transport protein in the membrane to cross the
lipid biolayer (Muller and Baker. 1990). Membrane transporters are integral membrane
proteins that mediate the facilitative or active transport requirements across
membranes and they are often highly selective about the chemicals they allow to cross.
In the case of active transport, the proteins are capable of transporting their substrates
against the concentration gradient. One example is the sodium-potassium pump in
nerve cells: Na" is maintained at low concentrations inside the cell and K+is at higher
concentrations. The reverse is the case on the outside of the cell (Campbell and Reece,
2004).
Natural nucleosides and nucleobases are very important metabolites and have a vast
number of physiological roles in many organs, systems and species. The uptake of
nucleosides or nucIeobases is essential for nucleic acid synthesis in many human cell
types and in parasitic organisms that cannot synthesize nucleotides de novo. The
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transporters responsible are also the route of entry for cytotoxic nucleoside or
nucleobase analogues for treatment of many diseases such as parasitic infections, cancer
and viral chemotherapy.
There are two main classes of transport proteins that mediate the movement of
nucleosides and free purine and pyrimidine bases across eukaryotic plasma membranes.
These two unique families are non-homologous and classified by their mechanism of
translocation of substrate. The first family is the equilibrative nucleoside transporter
(ENT) family that allows the movement of these molecules along concentration
gradients into or out of cells (Baldwin, et sl., 2004). The second family is the
concentrative nucleoside transporter (CNT) family, which actively transport
nucleosides into cells by coupling their transport to the inward movement of sodium
ions (Gray, et sl., 2004). The identification and classification of these families has been
based primarily on sequence homology. The equilibrative nucleoside transporters
(ENT) family and the concentrative nucleoside transporters (CNT) family were thought
to transport primarily nucleosides (Baldwin, et el., 1999). However, with increasing
knowledge of the ENT family, it has clearly become that ENT members can transport
nucleobases as well (Hyde, et el., 2001; De Koning, et sl., 2005).
The concentrative nucleoside transporters are found in many different mammalian
tissues such as in intestine, kidney and liver (Baldwin, et al., 1999). The first members
of this family were probably identified about 30 years ago, when Strauss and colleagues
described the uptake of thymidine and adenosine by murine bulk nonadherent spleen
cells. The results showed that the two uptake systems are markedly different (Strauss,
et al., 1976). Since that time, a lot of work has been done to identify and characterize
many members of this family. The most recent name and classification was given to
this family was (SLC28) which consists of three subtypes of sodium-dependent
concentrative nucleoside transporters, SLC28Al, SLC28A2and SLC28A3which used to
be named as CNT1, CNT2 and CNT3, respectively (Gray, et sl., 2004). CNTI or cit-type
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transporters (Concentrative. Insensitive to nitrobenzylthioinosine NBMPR and accepts
Thymidine as permeant) are specific for pyrimidine nucIeosides and were identified in
rat liver tissue (Huang. et al.• 1994). A similar transporter was identified in human
intestine and called hCNTI (Ritzel. et al. 1997). The CNT2 or cif-class transporters
(Concentrative. Insensitive to nitrobenzylthioinosine NBMPR and accepts Formycin B
as permeant) are specific for purine nucleosides and uridine, were also found in rat
intestine by cloning and called rCNT2. or sodium-linked purine nucleoside transporter
SPNT (Ritzel. et al., 1998;Yao, et al., 1996).A similar transporter has been identified in
human kidney and designated hCNT2 (Che, et al., 1995). The third subtype is CNT3 or
db-type transporters (Concentrative. Insensitive to nitrobenzylthioinosine NBMPR
and accepts a Broad range of permeants) (Figure 1.12). which is the most recent
subtype to be identified by molecular cloning from human (hCNT3) and mouse
(mCNT3). CNT3 transports both pyrimidine and purine nucleosides into cells in a
sodium-linked manner (Ritzel. et al., 2001b; Cass and Young. 2001). The phylogenetic
tree for the CNT family shows three clusters. One includes the NupC proteins of E. coli
and B. subtilis, the second includes all mammalian symporters, and the third includes
functionally uncharacterized bacterial homologues (Saier, et al., 1999). Although the
CNT transporter family is widely distributed in both bacteria and eukaryotes, no
members of this family have been found in protozoa.
Equilibrative nucleoside transporters (ENTs) are a family of proteins with no apparent
sequence homology to other types of transporters. which transport mainly nucleosides,
such as adenosine or nucleoside analogues used in chemotherapy across cell membranes
(Hyde. et sl., 2001). It is now known that the ENT transporter family are widely
distributed in mammals. plants. yeasts. insects. nematodes and protozoa. but absent
from prokaryotes. However. a possible homology with outer membrane channels
involved in the transport of nucleosides into gram-negative bacteria has been
postulated (Acimovic and Coe, 2002).
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FIGURE 1.12 Diagrammatic representation of the Nucleoside transport systems in
mammalian cells. Showing both the equilibrative and concentration nucleoside
systems: Reproduced from Baldwin, et al. (1999).
The early classification of the ENTs family in mammalian cells was based on their
sensitivity to inhibition by nitrobenzylthioinosine (NBMPR), and divided ENTs into
Equilibrative Sensitive (es) and Equilibrative Insensitive (eJ) (Figure l.12). Both systems
were found to have broad substrate specificity for purine and pyrimidine nucleosides
with a low or moderate affinity (Km values of - 20-400 IlM), with different sensitivity
to inhibition by NBMPR. Adenosine was found to display the highest affinity for the
ENT family members with a Km of 20-50 IlM. However, the affinity of nucleosides for
es-type transporters, including adenosine, appeared to differ between cell types such as
in bovine chromaffin cells (Km of 1-2 IlM). The es-type transporter has a high affinity
for NBMPR inhibition of nucleoside transport with K values of 0.1-10 nM (Plagemann,
et al., 1988; Griffith and Jarvis, 1996). In contrast to es-type, the ez-type transporter
appeared to be resistant to inhibition by nanomolar concentrations of NBMPR, and in
general possess a lower affinity for substrates than the es-type transporter.
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The SLC29 family, which is the new name of the human equilibrative nucleoside
transporters, is part of a larger group of concentrative and equilibrative nucleoside and
nucleobase transporters found in many eukaryotes (Baldwin, et sl., 2004). The first
examples of es-type and ei-type human equilibrative nucleoside transporters have been
identified by cloning and designated hENTl and hENT2, respectively. hENTI
(SLC29Al) mRNA is expressed in many tissues, including erythrocytes, placenta, brain,
heart, liver, lung and colon (Cass, et sl., 1999). The hENTl was shown to be a typical
es-type, with broad selectivity for purine and pyrimidine nucleosides and inhibited by
NBMPR, dipyridamole and dilazep (Griffiths, et el., 1997a; Griffiths, et sl., 1997b). A
transporter similar to hENTl has been identified from the rat (rENf), and proved to
have similar kinetic properties but it was not inhibited by dipyridamole (Yao, et sl.,
1997). Another homologue ofhENTl has been identified from a mouse (mENTl). Like
hENTI, hENT2 (SLC29A2) mRNA has also been found in many tissues, but is
particularly present in skeletal muscle (Crawford, et sl., 1998). The hENT2 appeared to
be a typical el-type transporter and has similar broad selectivity for purine and
pyrimidine nucleosides, and might also transport the purine nucleobase hypoxanthine
(Osses, et sl., 1996). Homologues to hENT2 have also been identified in the rat and
mouse, designated rENT2 and mENT2, respectively. The most recent isoforms have
been identified are ENT3 and ENT4. The cloning of cDNAs encoding mouse and
human ENT3 has been reported (Hyde, et sl., 2001), and it has been suggested that
hENT3 is a broad selectivity, low affinity nucleoside transporter that might also
transport adenine. In addition, transport activity was relatively insensitive to the
nucleoside transport inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep and
was sodium ion-independent (Baldwin, et el., 2005). The hENT4 gene was originally
identified by genome database analysis and appeared to be a low affinity monoamine,
rather than a nucleoside, transporter and has been alternatively designated plasma
membrane monoamine transporter (PMAT) (Acimovic and Coe, 2002). It has been
confirmed that, by examining the effect of mutating the targeting motif on the
subcellular location of hENT3, this transporter is indeed intracellular and partially co-
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localizes with lysosomal markers. Relocation of the hENT3 to the cell surface in the
absence of the motif has allowed detailed characterization of its functional properties
when expressed in Xenopus oocytes.
Recently, several studies have tried, by site directed mutagenesis and other techniques,
to elucidate the domains of ENT transporters involved in substrate binding and
interactions with the standard inhibitors. This was recently reviewed by De Koning et
al. (2005). In addition, progress has been made in identifying the functional groups of
the substrates that are recognised by the hENI and hENT2 binding sites (Vickers, et sl.,
2002; Vickers, et al, 2004). This studies rrevelealed that both transporters were
sensitive to modifications at C(5') and hENT2 displayed more tolerance to removal of
C(5')-OH than hENTl; addition of an O-methyl group at C(5') greatly reduced
interaction with either hENTI or hENT2. The changes in binding energies between
transporter proteins and the different uridine analogs suggested that hENTI formed
strong interactions with C(3')-OH and moderate interactions with C(2')-OH and C(5')-
OH of uridine, whereas hENT2 formed strong interactions with C(3')-OH, weak
interactions with C(5')-OH, and no interaction with C(2')-OH.
1.6 Purine transport in protozoa - the role of the ENT family
Transport mechanisms in parasites have been studied for many years as transporters
play a central part in the biochemistry of all parasitic protozoa. Transport studies are
important to understand how parasites acquire nutrients from their hosts and take up
drugs, which are an important determinant of therapeutic efficacy (Landfear, 2000). On
the basis of sequence homology, protozoan nucleoside transporters characterised to
date have all been classified as belonging to the equilibrative nucleoside transporter
(ENT) family, which includes the human equilibrative nucleoside transporters (Hyde,
et el., 2001).
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Almost nothing was known about the mechanism of nucleobase transport in parasites
until the recent studies on trypanosomes when two purine nucleobase transporters
were identified in procyclics of T. brucei brucei. The first (HI) is a high-affinity
transporter specific for purine nucleobases such as hypoxanthine (IG. of 9.3 llM), and it
does not transport pyrimidine nucleobases or purine and pyrimidine nucleosides (De
Koning and Jarvis, 1997a). The second purine nuc1eobase transporter, which was
identified and characterized in our laboratory and cloned by Richard Burchmore and
designated ThNBTl or H4, transports all natural purine nucleobases, with high affinity
for adenine and hypoxanthine (Kn values of 2.1 and 0.66 llM, respectively), as well as
uracil and allopurinol (Burchmore, et el; 2003; Chapter five). The bloodstream form
has also two purine nucleobase transporters: H2 which displays a very high affinity for
all natural purine nucleobases, such as hypoxanthine (Kn of 123 nM), and their
analogues such as allopurinol, as well as for guanosine. The second transporter
expressed in bloodstream forms, H3 (De Koning and Jarvis, 1997b), is very similar to
HI with respect to purine nucleobases (Kn value of 4.7llM for hypoxanthine).
An independent study has identified a very similar transporter to ThNBTl, designated
TbNT8.1 which was functionally expressed in Xenopus oocytes and nucleoside-
nuc1eobase transport-deficient yeast (Henriques, et sl., 2003). This transporter possess a
high affinity for all natural purine nucleobases Kn values of 3.1 jlM, 8.0 jlM, 12.4 jlM,
and 28.5 jlM for Hypoxanthine, adenine, guanine, and xanthine, respectively. A
number of very closely copies of genes to 1ONTB.} and 1ONBT}, have also been
identified and designated 1ONTB.2 and 1ONT8.3 (De Koning, et el., 2005).
The strict selectivity for purines (but not for uric acid) sets the nuc1eobase transporters
in parasitic protozoa clearly apart from those in fungi of mammalian cells (De Koning
and Diallinas, 2000). T. h. bruceithus express multiple nucleobase transporters, both in
procyc1ic and in bloodstream forms, each with high affinity for allopurinol (De Koning
and Jarvis, 1997a; De Koning and Jarvis, 1997b; Burchmore, et el., 2003). This
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observation is believed to be the reason allopurinol-resistance is very difficult to induce
in trypanosomes (Natto, et al., 2005).
Nucleobase transporters in protozoa usually display a higher affinity for their substrates
than do mammalian transporters. One well-characterised example is the T. brucei H2
transporter, when compared to the equilibrative nucleobase transporter of human
erythrocytes hRBC. The basis for the different affinities was shown to be the result of
very different interactions of the respective transporters with the purine ring (Wallace,
et el., 2002). In contrast to mammalian cells, the T. brucei brucei purine nucleobase
transporters, like their nucleoside transporters (De Koning, et sl., 1998; De Koning and
Jarvis, 1999; De Koning, et el., 2000b), are not inhibited by either
nitrobenzylthioinosine NBMPR, papaverine, dilazep, or dipyridamole and are not
sodium ion-dependent transporters (De Koning and Jarvis, 1997a; De Koning and
Jarvis, 1997b). HI and H2 are nucleobase/proton symporter as they are linked to a
protonmotive force (De Koning and Jarvis, 1997a; De Koning and Jarvis, 1997b), while
the energy-dependence of H3 is still unclear. The differences in affinities of parasite
and human nucleobase transporters could help in the design of chemotherapeutic
purine analogues that are selectively transported by the parasites.
An early study has demonstrated the transport of purine nucleosides adenosine, inosine
and guanosine by Trypanosoma congolense and Trypanosoma brucei In that report, it
was also demonstrated that the purine nucleobases hypoxanthine and adenine were
taken up by the same parasites. In both species adenosine strongly inhibited the uptake
of both of the other nucleosides and of both purine bases. In addition, the uptake of
adenosine by T. bruceiwas inhibited by dipyridamole (James and Born, 1980).
Two classes of nucleoside transporter genes have been identified in Trypanosoma
brucei, ThNT2 and ThATl, encoding transport activities known as PI and P2,
respectively. Both are high-affinity adenosine transporters with Km values of 0.15 and
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0.55 lIM for PI nd P2, respectively, (Carter and Fairlamb, 1993; De Koning, et el.,
1998). PI has broad specificity for purine nucleosides such as inosine (~ = 0.36 lIM)
and guanosine (Ki = 0.36 lIM)and it has very low affinity for purine nucleobases such as
adenine and hypoxanthine as well as the pyrimidine nucleoside uridine (Ki > 1mM (De
Koning, atal, 1997b; Sanchez, et el., 1999;De Koning, atal, 2005). The gene encoding
this transporter has been cloned by expression in Xenopus oocytes and was designated
ThNF2 (Sanchez, et sl., 1999). This PI-type transporter is expressed in both
bloodstream form (BF) and in procyclic form (PF) trypanosomes, and the PI
transporter was the first protozoan nucleoside transporter shown to be a proton
symporter (De Koning, et sl., 1998). P2 is the second nucleoside transporter and, in
contrast with PI, this transporter displays high affinity for aminopurines such as
adenine (Ki = 0.38 lIM) and adenosine, but has low affinity for oxopurines such as
inosine, guanosine, hypoxanthine, guanine and allopurinol (Carter and Fairlamb, 1993;
Maser, et sl., 1999; De Koning and Jarvis, 1999; De Koning, at al, 2005). This
transporter is expressed only in the BF stage of the life cycle. The ThATl, the gene
encoding the P2 transporter, was cloned by functional complementation in
Saccharomyces cerevisiae, which was naturally deficient in purine nucleoside uptake
(Maser, et al, 1999). Since P2 can mediate the uptake of antitrypanosomiasis
diamidines, such as pentamidine and berenil (diminazene aceturate), and
melaminophenyl arsenical, this transporter has become of a particular pharmacological
interest (Carter, et al, 1995; De Koning, et al, 2000a; De Koning and Jarvis, 2001). De
Koning and colleagues have studied the substrate recognition motifs of adenosine
transporters in bloodstream form T. brucei and reported that the predicted substrate
recognition motif of P2, but not of PI, corresponds to parts of the
melaminophenylarsenical and diamidine molecules, explaining the potent inhibition
observed with these trypanocides for P2-mediated adenosine transport (De Koning and
Jarvis, 1999). Pl and P2 systems have also been characterised in different species of
trypanosomes such as T. equiperdum (Barrett, et sl., 1995), T. evansi (Suswam, et sl,
2001).
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A cluster of six genes, designated 1ONT2 to 1ONI7has been reported (Sanchez, et al,
2002). The ORFs of these genes were about 85% identical to that of TbNT2. Functional
expression in Xenopus oocytes showed that TbNT2, TbNT5, TbNT6 and TbNI7 all
have high affinity for purine nucleosides such as adenosine, inosine and guanosine with
Km values of - 1 IlM). However, TbNT5, TbNT6, and TbNI7 also transported the
purine nucleobase hypoxanthine all with much lower affinity (Km = - 25 IlM). TbNT3
and TbNT4 did not appear to transport nucleosides or nucleobases and their function is
still unclear. mRNAs from all genes in the these transporters were expressed in BF, but
TbNT2, and TbNT5 mRNAs were also found inPF. It has been suggested that different
members of this transporter family have different substrate specificities and are
expressed in different stage in the life cycle (Sanchez, et sl., 2002). Further members
have been identified from the ENT family by examination of T. brucei database and
have been named as TbNT8, TbNT9, TbNTlO and TbNT11. TbNT8 is thought to
represent a family of clustered genes (Landfear, et sl., 2004), TbNT8.1 is one member of
this family and it has been discussed in the nucleobase transporter section. It has been
reported that TbNTI0 is a high affinity purine nucleoside transporter. Functional
expression in Saccharomyces cerevisiae revealed a high-affinity nucleoside transporter
for adenosine, inosine, and guanosine with Km values of about 1 IlM. Its mRNA was
. found to be expressed exclusively in the nondividing short stumpy stage (Sanchez, et
el., 2004a). It has also been reported that TbNTII transporters are represented by two
closely related genes, TbNTll.l and TbNTll.2, but they have not been functionally
characterised yet.
An important difference between purine nucleoside transporters in trypanosomes and
their counterparts in mammalian cells is that they are protonmotive force-driven
transporters and are not inhibited by NBMPR, dilazep, or dipyridamole at the
concentration required inhibiting NBMPR-sensitive mammalian nucleoside
transporters (De Koning, et el., 1998; De Koning and Jarvis, 1999). Furthermore, the
trypanosome nucleoside transporters, especially TbNT1, have high affinity for toxic
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purine nucleoside analogues (e.g.• tubercidin, ribavirin, and Formycin A). which are
poor ligands for the mammalian transporters (De Koning and Jarvis. 1999).
In general. there is a very little known about purine nucleobase transporters and their
kinetic properties in leishmania species. The first purine nucleobase transporters have
been identified in Leishmania braziliensis panamaensis (Hansen. et sl., 1982). This
report suggested that three transporters could be identified in promastigote forms of
Leishmania braziJiensis.The first transporter. designated Locus 1. transported inosine.
Locus 2. the purine bases hypoxanthine and adenine and Locus 3, adenosine. The same
group found that adenine and hypoxanthine inhibited the uptake of one another
competitively which suggests that they are using the same transporter (Hansen. et sl.,
1982).
We have conducted a comprehensive study of purine nucleobase uptake in Leishmania
major promastigotes. We have identified and characterized in great detail a single
transporter. designated LmajNBTI. with high affinity for all physiological purine bases
and moderately high affinity for allopurinol. Studies with pH]allopurinol confirmed
that this transporter is its sole route of entry into promastigotes. as no study has
addressed allopurinol uptake by this parasite (Chapter three). Sanchez and colleagues
cloned and expressed the first gene for a L. major nucleobase transporter. designated
LmaNT3. The LmaNT3 permease shows 33% identity to the L. donovani nucleoside
transporter LdNfl.l. and is. thus. a member of the equilibrative nucleoside transporter
(ENT) family (Sanchez. et al. 2004b). LmaNf3 is a high affinity transporter for
hypoxanthine. xanthine. adenine and guanine. which is very similar to the LmajNBTI
transport activity reported in our study (Chapter three).
We have also investigated nucleobase uptake in L. mexicana amastigotes and identified
the first nucleobase transporter in Leishmania amastigotes, and characterization the
transport of allopurinol. Our data are consistent with a single broad specificity
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nucleobase transporter mediating the uptake of all natural purine nucleobases and
allopurinol. The functional characterization of this transporter. LmexNBTI. was shown
to be virtually identical to LmajNBT1. The binding interactions between the purine
nucleobases and this transporter were compared with those of the LmajNBTI
transporter in L. major promastigotes and found to be very similar (AI Salabi and De
Koning.2005).
Early studies reported that L. donovani promastigotes possess two purine nucleoside
transporters with nonoverlapping substrate specificity. designated LdNTl and LdNT2
(Iovannisci, et al. 1984; Aronow, et al. 1987). The first transported adenosine.
analogues of adenosine. formycin A and tubercidin and the pyrimidine nucleosides,
uridine, cytidine. and thymidine. while the second carried inosine. guanosine.
formycin B and their analogues. The two nucleoside transport systems of L. donovani
were not inhibited by 4-nitrobenzylthioinosine and dipyridamole. two potent
inhibitors of nucleoside entry into mammalian cells (Aronow. et al. 1987). However.
the transport of adenosine seemed to have different activities in various strains of L.
donovani (Ogbunude, et al. 1991) and L. major (Baer, et al. 1992) promastigotes,
though such variations have not been noted in inosine transport. Two closely linked
genes have been identified. designated LtfNTl.l and LdNTl.2 that encoded the
LdNfl.1 and LdNf1.2 transporters which mediated the uptake of adenosine and the
pyrimidine nucleosides with high affinity (LdNT1.1; Km values of 0.17 and 5.6 jlM for
adenosine and uridine, respectively; LdNT1.2; Km values of 0.66 and 40 jlM for
adenosine and uridine, respectively). A single gene encoding the functional inosine-
guanosine transporter LdNT2 (Km values of 0.3 and 1.7 jlM for inosine and guanosine.
respectively). and has been cloned by functional rescue of the mutant phenotype
designated LdNT2 These transporters are members of the ENT family as the amino
acid sequences and topologies showed substantial homology to other members of the
family (Vasudevan, et al. 1998; Carter. et al. 2000b). The nucleoside transporters of L.
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donovanipromastigotes have been shown to be proton-dependent rather than sodium-
dependent (Stein, et sl, 2003).
Two adenosine transporters have also been reported in Leishmania donovani
amastigote named as Tl and T2 (Ghosh and Mukherjee, 2000). Tl is
adenosine/pyrimidine transporter and was very similar to the LdNTl activity which
was originally detected in promastigotes (lGn values of - 1 flM for adenosine). T2. the
second adenosine transporter. is inhibitable by inosine and exclusively presents in
amastigotes (lGn values of - 1 flMfor adenosine).
The first study of purine uptake in the apicomplexan parasite Toxoplasma gondii was
published by Schwab and colleagues. An adenosine transporter (TgAT1) was identified
in the plasma membrane of T.gondii tachyzoites with a lGn of 230 flM (Schwab. et al.
1995), which has low affinity for the nucleoside. This group described a similar
inosine-sensitive adenosine transporter in T. gondii. A low affinity transporter with
very similar inhibitor profile to this transporter activity was cloned by insertional
mutagenesis and selection on a cytotoxic adenosine analogue. adenine arabinoside and
designated TgAT (Chiang, et al. 1999). These two groups also reported that adenine
and hypoxanthine inhibited adenosine. suggesting that this transporter mediated both
nucleoside and nucleobase uptake but at a low level. This transporter was inhibited by
dipyridamole (ICso= 0.7 JlM) but not nitrobenzylthioinosine, and is also a member of
the ENT family (De Koning, et al. 2005). We decided to reinvestigate purine transport
in T. gondii tachyzoites for two reasons. First. because of the fact that ToxopJasma is a
purine auxotroph and there is no credible source of purines that could be salvaged by
the low affinity transporter TgATl. Second. because T. gondii are able to salvage
nucleobases efficiently but no high affinity transporter has been described for this
organism. We have identified a high affinity hypoxanthine/guanine transporter. which
is the first high affmity nucleobase transporter to be identified in an apicomplexan
parasite. designated TgNBTI (lGn for hypoxanthine of 0.91 JlM.We have also reported
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that Toxoplasma gondii tachyzoites possess two adenosine/inosine transporters
designated TgATl and TgAT2. In contrast to TgATl, TgAT2 displayed high affinity for
all natural pyrimidine and purine nucleosides (lGn values of 0.49 and 0.77 j.lM for
adenosine and inosine, respectively) and binds nucleoside analogues, such as tubercidin
(7-deazaadenosine) and AraA, with high affinity (Chapter seven or De Koning. et sl.,
2003). The genomic database ToxoDB contains complete or nearly complete genomic
sequences for T. gondii and contains at least three putative homologs of ENT
transporters: TgNTl. TgNT2 and TgNT3 (Chaudhary, et al. 2004).
1.7 Rational drug design based on selective transport
The development of new drugs with potential therapeutic applications is one of the
most complex and difficult processes in the pharmaceutical industry. Millions of dollars
and many of workers are devoted to the discovery of new therapeutical agents. Most of
the currently available antiparasitic drugs have been discovered empirically by
screening of large numbers of compounds for efficacy against parasites in animal
models. Few of these drugs have been rationally designed. This is largely because, until
recently, little was known about the basic biochemistry, physiology, and molecular
biology of parasites and of their interactions with their hosts.
A major challenge confronting the pharmaceutical scientist is to optimize the selective
and efficient delivery of new active entities and drug candidates. Successful drug
development requires not only optimization of specific and potent pharmacodynamic
activity, hut also efficient delivery to the target site. Following advances in rational
drug design, combinatorial chemistry and high-throughput screening techniques, the
number of newly discovered and promising active compounds has increased
dramatically in recent years, often making delivery problems the rate-limiting step in
50
CHAPTER I. GENERAL INTRODUcrION
drug research. To overcome these problems, a good knowledge of the pharmacokinetic
barriers encountered by bioactive compounds is required.
The rational design of a drug is usually based on the exploitation of fundamental
biochemical and physiological differences between pathogens and their hosts. Some of
the most striking differences between parasites and their mammalian host are found in
purine metabolism. Therefore, purine metabolism constitutes an excellent potential
target for the rational design of antiparasitic chemotherapeutic regimens. Whereas
mammalian cells can synthesize the purine heterocycle de novo, all protozoan parasites
studied to date except for the opportunistic Acanthamoeba (Hassan and Coombs, 1988),
are purine auxotrophs (Perrotto et sl., 1971; Schwartzman and Pfefferkorn, 1982).
These parasites lack the ability to synthesize purine nucleotides de novo. Instead, they
utilize purine salvage pathways to convert the host organism's purine bases and
nucleosides to the corresponding nucleotides. As the first step in purine salvage is
translocation of the purine across the cell membrane, the transport routes are potential
targets for chemotherapy.
Purine and pyrimidine antimetabolites are widely used to combat a variety of
infectious diseases and other pathologies. However, many therapies suffer from a lack
of selectivity, leading to severe side effects. The selectivity and efficacy of purine
antimetabolites is achieved in two ways. Firstly, the enzymes of the purine metabolic
pathways that convert the pro-drug to the cytotoxic metabolite, usually a nucleotide
analogue (Wang, 1984). Secondly, cell-surface transporters mediate access to the cell,
and such as, are potential targets for chemotherapy (Wallace, et el., 2002; Al Salabi, et
el., 2003). It has been demonstrated that blocking purine salvage in protozoa through
rational design of novel drugs is practicable (Somoza, et el., 1998). A number of groups
have also reported on the successful design of enzyme inhibitors directed against
trypanosomiasis (Li, et sl., 1996; Aronov, et al, 1999; Bressi, et al, 2000; Khan, et al.,
2000). Because most purines and their analogs are hydrophilic and diffuse very slowly
51
CHAPTER 1GENERAL INTRODUCTION
across cellular membranes, purine transporters play a primary role in their cellular
uptake and release. The uptake of purine nucleosides or nucleobases is essential for
nucleic acid synthesis inmany human cell types and in parasitic organisms that cannot
synthesize nucleotides de novo. The transporters responsible are also the route of entry
for many cytotoxic nucleoside analogues used in cancer and viral chemotherapy.
Many purine analogues have shown antiprotozoal activity, but no rational approach to
a purine-based chemotherapy for protozoan infections has been developed. Such an
approach needs to take account of the efficient uptake of the analogue by the parasite
and the conversion by the parasite's metabolism to a form harmful to the organism.
Selective toxicity therefore needs to be the result of either selective uptake or
differences in metabolic enzymes or a combination of the two. Understanding the
substrate selectivity of the transporters is critical for the development of new
therapeutic purine analogues with optimal pharmacokinetic properties. The utility of
many current drugs is limited by insufficient delivery to the target cells. To date, these
clinical efforts have failed. We believe that this is due to the fact that these compounds
have been non-selective inhibitors of multiple drug transport proteins.
Rationally designed chemotherapeutic agents are usually optimised at the level of the
intracellular target. Yet, the efficacy of the drug is in large part dependent on the speed
at which it enters the target cell, just as the specificity of the drug and side effects are
linked to specific accumulation by the target cell rather than host cells. Specific uptake
by a target cell requires intimate knowledge of plasma membrane transporters for the
class of drugs being developed. We have modelled the transporter-substrate
interactions of purine transporters and shown that these can predict the binding energy
of potential substrates by using the transporter kinetics and purine analogues. We have
shown that protozoan and human nucleobase transporters interact with their substrates
in a very different way, which can be exploited in the rational design of purine-based
chemotherapy (Wallace, et al. 2002).
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Another reason which makes us interested in the study of purine transporters in
protozoa is that these transporters have been implicated in the uptake of trypanocidal
drugs such as the case of purine nucleoside transporter in Trypanosoma species, and
changes to these carriers can lead to drug resistance in Trypanosoma equiperdum
(Barrett, et sl., 1995), Trypanosoma brucei (Carter and Fairlamb, 1993; Carter, et sl.,
1995; Carter, et al., 1999), and Trypanosoma evansi (Ross and Barns, 1996). For
example, pentamidine is poorly membrane-permeable and active transporters have
been described in Leishmania species and trypanosomes that allow pentamidine to
accumulate to high concentrations (Carter, et al, 1995; De Koning and Jarvis, 1999;
Basselin, et al, 2002; Bray, et el., 2003). Another example is the antileishmanial agent
allopurinol (Das, et el., 2001; Abrishami, et al, 2002; Momeni, et al., 2002), which is a
nuc1eobase analogue that is efficiently taken up by a high-affinity purine transporter in
L. major promastigotes (AI Salabi, et el., 2003) and L. mexicana amastigotes (AI Salabi
and De Koning, 2005). A recent study by De Koning's group compared the ability of a
new class of tricyclic purine antimetabolites to interact with transporters from human
erythrocytes or Trypanosoma brucei. The results showed that these compounds display
a remarkable selectivity for the parasite's transporters. The adenine analogue showed
greater trypanocidal activity than the hypoxanthine or guanine analogues in vitro
(Wallace, et al., 2004).
1.8 Purine analogyes as therapeutic agents
Despite promising leads in the search for new chemotherapeutic agents, there remains
an urgent need to develop more effective and less toxic drugs. Purine nucleobases and
nucleosides have fundamental roles in many biological processes and as a result, purine
antimetabolites are active chemotherapeutic agents for many infectious diseases and
other pathologies. To the extent that these analogues disrupt nucleic acid synthesis or
structure, they naturally act predominantly on fast-dividing cells such as cancer cells,
viruses and protozoan parasites.
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Purine analogues have long been a rich source of chemotherapeutic agents. Modified
purine nucleosides, as well as their corresponding purine heterobase moieties have
provided a plethora of potent antiviral, anticancer and antiparasitic drugs. Nucleobase
analogues are being widely used against infectious agents and malignancies (De Koning
and Diallinas, 2000). The purine nucleobases offer a distinct advantage over their
nucleoside counterparts since they are readily incorporated into the nucleotide pool by
phosphoribosyltransferases while, in contrast, nucleosides may first be hydrolyzed in
the bloodstream forms of T. brucei
Some purines have been highly successful in antineoplastic and antiviral therapies and
multiple lead compounds aginst protozoa have been identified (Kaminsky, et al, 1994;
Seley, et sl; 1998; Wanner, 2004; Wallace, et el; 2004). The nucleoside analogues 8-
methyladenosine and 2-amino-7-[(1,3-dihydroxy-2-propoxy) methyl] purine (S2242)
have been reported as promising anti-poxvirus agents (De Clercq and Neyts, 2004).
Purine analogues and their combinations have emerged as effective new therapies for
chronic lymphocytic leukemia patients (Wendtner, et al., 2004). Ring-expanded
nuc1eosides (RENs)which are analogues of coformycin also carry promise against many
viral infections belonging to the families of hepatitis, herpes, and respiratory infections,
most notable being the hepatitis B (HBV), hepatitis C (HCV), and the West Nile
Viruses (WNV) (Hosmane, 2002).
Unique features of the purine salvage pathway of protozoan parasites constitute the
basis for the susceptibility of these genera to several pyrazolopyrimidine analogues of
naturally occurring purine bases and nucleosides (Marr and Berens, 1983; Ullman,
1984). The intact parasites efficiently metabolize these analogues to the nucleotide
level, whereas mammalian cells are essentially incapable of these metabolic
transformations. One of these pyrazolopyrimidines, allopurinol (4-
hydroxypyrazolo[3,4]pyrimidine, HPP) (Berens, et sl., 1995), a drug that is nontoxic to
humans and is widely used in the treatment of hyperuricemia and gout, has
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demonstrated significant therapeutic efficacy in patients with either cutaneous
leishmaniasis (Martinez, and Marr, 1992) or chronic Chagas disease (Gallerano, et al.
1990).
Recently, series of tricyclic purine analogues showed to display a promising activity in
vitro against T. brucei and appear to be selectively accumulated by the parasite. These
tricyclic analogues represent a significant lead against human African trypanosomiasis
(Wallace, et sl., 2004).
In addition, purine antimetabolites have long been considered as a promising class of
compounds for new drug development against African trypanosomiasis (Avila and
Avila, 1981; Ogbunude and Ikediobi, 1982; Avila, et sl., 1983; Berens, et al, 1984; El
Kouni, 2003), and leishmaniasis (Peters, et el., 1980; Kager, et el., 1981; Berman, et el.,
1983; Walton, et el., 1983; Morishige, et sl., 1995; Becker, et sl., 1999). Using purine
analogues as potential antiparasitic agents, was also demonstrated in the treatment of
malaria (Gati, et el., 1987; Gero, et sl., 1988; Gero, et sl., 1989) and other parasitic
diseases including schistosomiasis (Iaffe, 1975; El Kouni, et sl., 1983; El Kouni, et al,
1985; El Kouni, et sl., 1987; El Kouni, et sl., 1989; El Kouni, 1991), and toxoplasmosis
(Luft, 1986; Sarciron, et al., 1998;El Kouni, et sl., 1999).
1.9 Project aims
1. Identify and characterize purine nucleobase and nucleoside transporters in
protozoan species such as Trypanosoma, Leishmania, and Toxoplasma.
2. Identify the extent to which these are involved in the uptake of anti-parasitic
agents such as allopurinol.
3. Test whether these transporters can be used to facilitate the selective targeting of
these parastites by other purine antimetabolites and assess theefficacy of such
compounds as chemotherapeutic agents.
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4. Assess wheteher purine nucleobase and nucleoside transporters activities are
different in various life cycle stages.
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CHAPTER II MATERIALS AND METHODS
2.1 Organisms and culture conditions
2.1.1 Leishmania majorpromastigotes
Promastigote forms of Leishmania major (Friedlin strain) were grown in Homem
culture medium (see Appendix I) (Invitrogen, Carlsbad, CA), supplemented with 10%
Heat-inactivated Fetal Calf Serum (Gibco) at 25°C, in a 5% C02 atmosphere. Cells in
mid-log stage of growth were serially passaged after 3 days of growth. Promastigotes
were centrifuged at 2500 g for 10 minutes at room temperature, and cells were then
washed twice with assay buffer pH 7.3 (see Appendix I). Parasites were re-suspended at
_108 cells/ml, and left for 10minutes before use in uptake assays.
2.1.2 Leishmania mexicana amastigotes
The MNYClBZl62/M379 strain of Leishmania mexicana was provided by Professor
Graham Coombs (Glasgow University). Amastigotes were maintained by twice weekly
serial passage in Schneider's Drosophila Medium (GibcoBRL), supplemented with 20%
Heat-Inactivated Fetal Calf Serum (HI-FCS; Gibco), containing 0.3 % Gentamycine.
The pH of the medium is 6.8 when made up; adding 1.1% 1.0 M of HCI gives 5.5
approximately (pH 5.5-6.0 proved to be satisfactory for the growth of amastigotes).
Cultures were maintained at 33°C in a C02 incubator. Amastigotes were harvested by
centrifugation for 10minutes at 2500 g at 33°C, and washed twice with the CBSSbuffer
pH 6 (see Appendix I), and re-suspended at -108 cells/ml in the same buffer (Ghosh
and Mukherjee, 2000).
2.1.3 Tzypanosoma brocei brocei procyclics
Procyclic forms of T. brucei brucei strain 427 were grown in vitro (Brun and
Schonenberger, 1979) in SDM-79 medium (see Appendix I), supplemented with 10%
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(v/v) fetal calf serum (Gibco), in a 5% C02 atmosphere incubator. Cells in mid-
logarithmic stage of growth were serially passaged after 2-3 days of growth, typically at
a density of 108 cells/ml culture medium. Cells were harvested and washed twice by
centrifugation at 2500 g for 15 minutes at room temperature in assay buffer pH 7.3, and
seeded at 1 or 2xl08 cells/ml as required for uptake assays.
2.1.4 TTJ!Panosoma brocei broceibloodstream forms in vitro
Bloodstream forms of T. h. brucei strain 427 were grown in vitro using HMI-9 medium
(see Appendix I), supplemented with 20% (v/v) fetal calf serum (Gibco) at 25°C in a 5%
C02 atmosphere as described by Hirumi and Hirumi (1989). Cells in mid-logarithmic
stage of growth were serially passaged about twice a week. Cells were harvested and
washed twice by centrifugation at 2500 g for 15 minutes at room temperature in assay
buffer pH 7.3, and adjusted at 1 or 2x108 cells/ml as required for uptake assays.
2.1.5 TTJ!Panosoma brocei broceibloodstream forms in yiyo
Bloodstream forms (usually from frozen stocks but sometimes inoculation is with fresh
blood from infected mice or rats) of the T. brucei broceistrain EATRO 427, TREU 927,
TbATl-/- and its parent line (ThATI-WT), were intraperitoneally injected in adult
female ICR Swiss mice or Wistar rats. Parasitaemia was monitored by daily
examination of blood from tail venepuncture. The microscope field diagram from
Herbert & Lumsden (1976) was used to estimate the number of total parasites based on
number of parasites per microscope field. The blood from infected rats was collected
when peak of parasitemia is reached by cardiac puncture under terminal anesthesia by
exposure to C02. The blood was collected into a tube containing CBSSbuffer with 500
units/ml of heparin and centrifuged at 2500 g for 15 minutes at 4QCto separate the
different components. The parasite-containing buffy coat layer that forms at the
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intersection between the red blood cell and the plasma, was collected and applied to a
DE52 (Whatman, Maidstone, United Kingdom) anion-exchange column (Lanham,
1968) which was adjusted exactly at pH 8.0 and washed with about 200 ml of PSG
buffer (see Appendix: I) at pH 8.0. The trypanosomes from the column were washed
twice in assay buffer at 2200 g for 10minutes at 4°C, and then suspended in the volume
required. The cells were usually left at room temperature for 10-15 minuets prior to use
in transport experiments.
2.1.6 Isolation of short-stumpy bloodstream forms
Adult female mice (lCR Swiss strain) were immunocompromised with
cyclophosphamide (200mglKg) by intraperitoneal injection. Mice were injected
intraperitoneally (JP) after 24 hours with -1 x 106 of Trypanosoma brucei strain 927
wild type stabilates. The blood was collected from some of the mice after 4 days and
then, using air dried blood smear slides for routine Giemsa staining and NAD
Diaphorase assay, the levels of stumpy form trypanosomes were checked
microscopically. The procedure was repeated after 9 days with the remaining mice, the
trypanosomes population should be predominantly stumpy form. The blood was
centrifuged at 2500 g for 15 minutes to separate the different components. Bloodstream
stumpies from the buffy coat layer were purified by DE52 chromatography (Lanham
and Godfrey, 1970).
NAD Diaphorase assay was performed to confirm the presence of stumpy forms.
Briefly, reaction solutions were made fresh just before use containing 4 mg of NADH-
disodium-hydrate (Sigma-Aldrich), 0.8 ml of 0.1 M phosphate buffer (pH 7.3), and 1.2
ml of water, and Thin air dried blood smears were prepared (using fresh slides for
staining or stored for a brief time on a plastic tray in an ice box). The slides were fixed
at 4 °C for exactly 5 minutes by pipetting 0.1 M cacodylate buffer (pH 7.2) with 2.5%
final concentration of glutaraldehyde, and then were rinsed quickly in distilled water.
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Some slides were incubated for about an hour with the reaction solutions and the other
without substrate (control) which is the same, but without NADH. The slides were
then mounted in glycerol and viewed under oil at x 1000 or by immunofluorescence
microscopy.
2.1.7 Toxoplasmagondii tachyzoites
The RH strain of T.gondii (Pfefferkorn, et al, 1988) was kindly donated by Dr Elmer
Pfefferkorn (Dartmouth College, New Hampshire, USA). T. gondii tachyzoites were
maintained by twice weekly serial passage in African Green Monkey kidney fibroblasts
(Vero cells) and grown in vented tissue culture flasks (Greiner, UK) at 37°C in a 5 %
C02/95 % 02 humidified incubator. Host cells were removed from tachyzoites by
filtration through 47 mm diameter, 3 um pore-size Nuclepore® polycarbonate filters
(Whatman International Ltd, UK). Isolated tachyzoites, containing typically less than
0.1 % host cell contamination as judged by microscopic observation, were washed three
times in assay buffer pH 7.3 by centrifugation at 1500 g for 15 min at 4°C. Tachyzoites
were counted using a Neubauer haemacytometer (Weber Scientific Ltd, UK) and re-
suspended in assay buffer at a density of 1.5 - 2.5 x 108mI-I.
2.1.8 Yeast Strains
The Saccharomyces cerevisiae strain MG887-1 (fcy2-) used in this project was
engineered to be auxotrophic for uracil by Gillissen and colleagues who excised the
truncated URA3 gene with EcoRI and SmaI from p8ura3 (Gillissen, et al, 2000). This
strain dose not possess a functional endogenous uptake system for adenine,
hypoxanthine, guanine, or cytosine (Horak, 1997). This yeast strain was used as a
heterologous expression system for the cloned members of the ENT transporters in our
laboratory. The complete TbNBTJ, AT-like A, AT-like B, or AT-like D genes open
reading frame was excised from pGEMTeasy using Noil and subcloned into the Nod
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site of the yeast expression vector pDRI95. A uracil auxotrophic fcy2 mutant MG887-I
was transformed with the resultant constructs (pDRI95:TbNBTI, pDRI95:AT-like A,
pDRI95:AT-like B, and pDRI95:AT-like D) and selected on uracil-free medium.
Transformed yeast was plated onto yeast nitrogen base without ammonium salts and
amino acids, supplemented with 4 mM hypoxanthine as the sole nitrogen source.
Information about Saccharomyces cerevisiae MG887-1 transformants used in this study
is described in chapter six; as well as Lynsey Wallace's PhD thesis 2004 and Burchmore
et aJ (2003). S. cerevisiae MG887-1 was grown on solid YPAD medium plates (see
Appendix I) at 30°C and sub-cultured to a fresh plate once a week.
2.1.9 Bacterial Strains
Two bacterial strains of Escherichia coli were used in our laboratory for routine
cloning and subcloning of the genomic sequences of T. b. brucei JM109 competent
cells and TOPIO electrocompetent cells were obtained from Promega or prepared in
our laboratory. Preparations of chemically-competent E. coli cells GMI09) and
electrocompetent E. coli cells (TOPIO), and transformations of E. coli either by Heat-
shock method (for JM109 cells) or by Electroporation (for TOPIO cells), were routinely
done in our laboratory (see Appendix for the solutions and methods used).
2.2 Materials
2.2.1 Radiolabeled compounds
[2-3H]Adenosine (0.92 TBq/mmol) and [8-3H]hypoxanthine (1.18 TBq/mmol) were
purchased from Amersham Pharmacia Biotech, UK. [2, 8-3H]Adenine (1.19 TBq/mmol)
was bought from NEN and from PerkinElmer Life Sciences, and [2, 8-3H]inosine (1.23
TBqlmmol) and [G-3H]Allopurinol (1.9 Ci/mmol) were obtained from Moravek
Biochemicals, U.S.A.
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2.2.2 Purine and pyrimidine nucleobases and nucleosides and analogues
2-Thiouridine was a generous gift from Dr. D. Davis (University of Utah, USA). 7-
Deazaadenosine was from Fluka, cytidine and adenine-S-Ben-arabinofuranoside (AraA)
were from ICN, and thiopurinol (4-mercapto-tH-pyrazolo(3,4-~ pyrimidine),
aminopurinol (4-aminopyrazolo(3,4-a) pyrimidine), 4-thiouridine and 3-deazauridine
were from Aldrich, and pentamidine from Rhone-Poulenc Rorer. 9-Deazaguanine was
generously provided by Howard Cottam of the University of California, San Diego. All
other compounds such as unlabeled allopurinol, nucleosides, nucleobases and
ionophores were from Sigma.
2.2.3 Media and growth chemicals
HOMEMmedium and fetal bovine serum, were purchased from Invitrogen (Carlsbad,
CA), Schneider's Drosophila medium and HMI-9 medium were from Gibco, and
SDM79 medium was obtained from Life Technologies. ~-NADH was obtained from
Sigma-Aldrich. Alamar Blue™ was obtained from Trek Diagnostics (UK).
2.2.4 Enz.ymes. primers and reagents used for molecular technique
SuperScript™ II Reverse Transcriptase was purchased from Invitrogen. l kb DNA
Ladder obtained from BioLabs or Invitrogen and Taq DNA Polymerase was purchased
from Promega. All other enzymes for molecular techniques were obtained from either
Invitrogen or Promega, and chemicals from Sigma. A set of primers used for peR
amplifications of AT-like sequences (AT-A rr, AT-A Rt, AT-B Ft, AT-B RI, AT-D F2,
AT-D F3, AT-D R2, and AT-D R4) from T. brucei cDNA was designed by Lynsey
Wallace. Primers used for PCR amplifications as controls (P2 F, P2 R, NBTt R, NBTt F,
ThATt Fl , and ThATt Rl) were designed by Richard Burchmore, and Primers used as
controls for genomic DNA (OL908, OL930, OL929, OL909) were kindly donated by
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Gareth Westrop (see Appendix II for sequences and annealing temperatures for these
primers).
2.3 Transport assays
2.3.1 Transport assays for Leishmania majorpromastigotes
Assays for transport of pH]adenine, PH]hypoxanthine and (3H]allopurinol by L. major
promastigotes was performed exactly as described for Trypanosoma hrucei (De Koning,
2001; Wallace, et al, 2002), using a rapid oil-stop protocol (Figure 2.1). Briefly,
promastigotes were harvested and washed twice with the assay buffer pH 7.3 and re-
suspended at -108 cells/m!. Cells were then incubated with the radioligand in the
presence or absence of inhibitor, ionophores were usually preincubated with the cells
for 2-5 min. All ionophores were dissolved in ethanol and the uptake was measured
against controls containing the same percentage of solvent, and spun through oil for 30
s at 13,000 rpm, after a predetermined time as appropriate for each experiment, but
always within the linear phase of transport. All experiments were performed in
triplicate at room temperature and non-mediated transport, in the presence of
saturating permeant concentrations, was subtracted. Zero-uptake values were obtained
in presence of 1 mM unlabeled permeant at DoC.Radioactivity in the cell pellet was
determined, after solubilisation in 2% SDS,by liquid scintillation counting.
2.3.2 Transport assays for Leishmania mexicana amastigotes
Transport of purine nucleosides/bases (adenosine, adenine, hypoxanthine and
allopurinol) into extracellular Leishmania mexicana amastigotes- like form was
performed using a modified oil-stop technique. Amastigotes forms of L. mexicana were
harvested by centrifugation (2500g, 10 minutes) and washed twice in CBSSbuffer pH
6.0. Cells were washed and resuspended in CBSS buffer at 32°C and used at
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approximately 107 cells/ml. Transport was measured at 32°C, 100 J.ll of cell suspension
was added to a microcentrefuge tube containing 200 J.lIoil [7:1 (by vol.) dibutyl-
phthalate/mineral oil; d = 1.018 g/ml] and 100 J.ll [3H]adenine (0.1 J.lM) or
[3H]hypoxanthine (0.03 J.lM)or [3H]allopurinol (1 J.lM) and incubated for the indicated
times. Incubations were terminated by adding 1ml ice-cold 4 mM of unlabeled
permeant in CBSS buffer, and cells were separated from extracellular label by
centrifugation (12000 x g. 30 s). The tubes were frozen in liquid nitrogen and the tips,
containing the cell pellet, were cut off. The pellet was dissolved in 250 J.lI2% SDS.
After addition the scintillation fluid (Optiphase HiSafe III), radioactivity was
determined in (1450 MicroBeta Trilax) scintillation counter. Zero uptake values were
obtained by exposing the cells to a mixture of [3H] permeant and 1 mM unlabeled
permeant, both kept on ice until use. Non-mediated transport was determined by
processing cell samples that had been mixed with [3H] permeant in the presence of 4
mM permeant. Transport values were calculated after subtraction of the non-mediated
values. In inhibition studies, test compounds were mixed with [3H]permeant.
2.3.3 Transport assays for t:r_ypanosomes
The uptake of radiolabeled permeants by procyclic or bloodstream forms T. b. brucei
(strain 427 or 927). was assessed exactly as described in section 2.3.1 for Leishmania
majorpromastigotes. using a rapid oil-stop protocol. Bloodstream forms were harvested
and washed at 4°C and cell suspensions were left for 20 minutes at room temperature
before use.
2.3.4 Transport assays for Toxoplasma gondii
Transport of purine nucleosides and nucleobases (adenosine, adenine, hypoxanthine
and inosine) into extracellular T.gondiitachyzoites was performed using a modified
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Oil mixture
Inhibitor + radiolabeled permeant
& Centrifugation
Cells & Incubation
Stop Solution &
Centrifugation
Freeze in liquid
nitrogen
Cut the bottom [cell pellet]
Dissolve cell pellet
Add scintillation fluid
FIGURE 2.1 Schematic representation of the rapid oil-stop protocol used in our project
with some modifications when required.
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oil-stop technique previously described for transport measurements with Leishmania
and Trypanosoma brucei. Briefly, 100 ul of assay buffer containing radiolabeled
nucleoside!base and, where appropriate, various concentrations of test compound, was
layered over 200 ul of a 7:1 mixture of di-n-butylphthalate (BDH Ltd, UK) and light
mineral oil (Sigma, UK). Transport assays, performed at room temperature, were
initiated by addition of tachyzoites (100 ul) to the permeant. Assays were stopped by
the addition of 1 ml ice-cold 4 mM (hypoxanthine, adenine) or 10 mM (inosine,
adenosine) unlabeled permeant. Parasites were centrifuged through the oil layer at
16,000 x g for 1 min using a Heraeus Biofuge centrifuge (Iencons PLS, UK).
Subsequently, each tube was flash-frozen in liquid nitrogen and the bottom of the tube,
containing the cell pellet, cut into 6 ml scintillation vials. Tachyzoite pellets were lysed
in 250 ~ 5% (w/v) TCA for 90 min before being mixed with 3 ml Ecoscint A
scintillation fluid (National Diagnostics, Atlanta, GA, USA). Radioactivity was
determined by using a 1219 RackBeta Spectral scintillation counter (LKB Wallac,
Finland). All assay data points were performed in triplicate.
2.3.5 Transport assays for yeast
Transport of radiolabeled permeants in Saccharomyces cerevisiae MG887-1
transformants was determined using a modified oil-stop technique as described for
transport assays with Leishmania and Trypanosoma. Briefly, a yeast starter culture was
grown at 30°C in 5 ml Synthetic Complete minimal medium lacking uracil (SC-URA)
(see appendix I) for 6 hours; 45 ml of the same medium was then added and the culture
was incubated overnight at 30°C overnight in a shaker-incubator to a density of 1-2
OD units at 600 nm. Yeast cells were harvested by centrifugation at 1800 g for 5
minutes at 4°C, and the pellet was then washed twice with yeast assay buffer (without
glucose). The cells were then re-suspended in assay buffer wlo glucose at a density of-
108 Iml. The cell suspension was usually divided to three tubes which were kept on ice,
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using each tube after incubation for 10 minutes at room temperature for one set of
triplicates to minimize variation as much as possible.
2.4 Data analysis
Kinetic parameters were calculated using the FigP computer program (Elsevier Biosoft)
and the Prism3 and Prism4 software packages (GraphPad Software, San Diego, CA), by
using non-linear regression and variable slope. In most cases, Hill coefficients were
found to be close to -1, consistent with monophasic competitive inhibition. In some
cases, the Hill slope was <-1, apparently as a result of uptake of permeant by multiple
transporters with different affinity for the inhibitor. In these cases, the data were fitted
to equations for one-site competition and two-site competition and the results
compared with an F-test.
All experiments were performed in triplicate and kinetic parameters are presented as
means ± S.E of at least three independent experiments. Kr values were calculated from
the equation: Kr = ICsot[1 + (UKm)], in which L is the permeant concentration (Cheng
and Prusoff, 1973). The Gibbs free energy of the transporter-ligand interaction was
then calculated from the equation: ~Go = - RTln(J<i),in which R is the gas constant and
T the absolute temperature. It should be noted that these equations are only valid for
competitive inhibition. In our experiments, transport of permeant refers to mediated
transport minus radioactivity associated with the cells due to diffusion or binding.
Therefore, the amount of radioactivity associated with the cell pellet in the presence of
saturating levels of unlabeled permeant was subtracted from each data point. Errors
given in tables and shown as bars in graphs are standard errors of the means (SEM). It
should be noted that these equations are only valid for competitive inhibition, as
described previously (De Koning and Jarvis. 1999;Wallace, et el., 2002).
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2.5 Drug sensitivity assay for Leishmania mexicana amastigotes
There are many methods for determining toxicity. Observation of the parasites for
motility and viability after exposure to the potential drugs could be a simple method;
however, it is time consuming. Alamar blue assay provides a simple assay to test
compounds for anti-leishmanial activity in large-scale screening system. The
advantages of using Alamar blue assay to measure cytotoxicity of compounds against
the protozoa include: (I) the effect of drugs can be quantified without the need for cell
counts, (II) non-radioactive, (III) simplicity, (IV) cheap, (V) non-toxic (Ahmed, et al,
1994; Mikus and Steverding, 2000; Nakayama, et al.• 1997;Nociari, et al, 1998; Raz, et
sl., 1997; Habtemariam, 2003). The drug sensitivity assay with Alamar Blue was
performed as described for T. brucei (Raz, et el., 1997) and Leishmania major
promastigotes (Mikus and Steverding, 2000) in 96-well plates with some modifications.
Briefly, 100 pl of Schneider's Drosophila Medium (Gibco), used for culturing
amastigotes, was added to each well in 96-well plate. leaving the first column empty.
200 ~ of different test compounds was added, at double final concentration, to the first
column. Doubling dilutions were performed, passing 100 ~ from the first column to
the next and repeating this across the plate but leaving the last well drug-free as
negative control. Amastigotes form Leishmania mexicana were inoculated into each
well at a final density of lxl06/ml culture medium. 20 III of alamar blue reagent (TREK
Diagnostic Systems. Ltd) was added after 48 h and fluorescence development
determined after a further incubation time of 72 h. The plates were read using a LS55
Luminescence Spectrometer (Perkin Elmer) at wavelengths of 530 nm for excitation
and 590 nm for emission.
2.6 Reverse Transcriptase {RU - peR
The reverse transcription polymerase chain reaction (RT-PCR) is a technique for
enzymatically amplifying defined sequences of RNA (Rappolee, et al, 1988). As RNA
69
CHAPTER 11MATERIALS AND METHODS
can not serve as a template for peR, the first step in this assay is the reverse
transcription of the RNA template into complementary DNA (eDNA). Compared to
the other commonly used techniques for quantifying mRNA levels, Northern blotting
and in situ hybridisation (Parker and Barnes, 1999), RNase protection assay (Hod, 1992;
Saccomanno, et al., 1992), the RT-PCR can be used to quantify mRNA levels from
much smaller samples. In fact, this technique is the most sensitive, as it permits the
analysis of different samples from as little as one cell in the same experiment, and the
most flexible of the quantification methods (Wang and Brown, 1999).
2.6.1 RNA extraction from different strains and life cycle stages of z: brucei
Parasites from different life cycle stages of T. brucei (Procyclic from a 2 day old culture
of T. brucei strain 427, long-slender bloodstream forms of T. brucei strain 427 in HMI-
9 medium, and long-slender or short-stumpy bloodstream forms of T. brucei strain 927
isolated from a DE52 column) were counted using a Neubauer haemocytometer. 1 ml
containing lxl0' cells was transferred to sterile RNase free eppendorftubes. Cells were
harvested by centrifugation at 1000 g for 3 minutes at 4°C. 1 ml of Tri reagent (Sigma)
was added and mixed gently by pipetting. Cells were left to lyse completely at room
temperature for 5 minutes. 200 ~ of RNase free chloroform (Sigma) was added and the
suspension was vortexed for 15 seconds, the tube was then centrifuged at 13,000 g for
15 minutes at 4°C and the upper aqueous layer (containing RNA) was transferred to
fresh eppendorf tube. An equal volume of isopropanol was added and mixed, fallowed
by incubation at room temperature for 10minutes. The tube was centrifuged at 13,000g
for 15 minutes at 4°C to pellet the RNA, which was then washed with 500 IIIof 75%
ethanol and centrifuged at 7500g for 5 minutes at 4°C. Ethanol was removed and
allowed to air dry at room temperature for 10 minutes. The pellet was resuspended in
30 III of DEPC (diethylpyrocarbonate)-treated dH20 and incubated at 55°C for 10
minutes. Concentrations of RNAwere measured using either Nanospec or Agilent 2100
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Bioanalyzer. RNA samples were stored at - 70°C for experimental use. Note: all
materials from reagents to equipment used were exclusive for RNA work to avoid any
contaminations.
2.6.2 First-Strand cDNA l)'llthesis
First strand cDNA synthesis was done using a SuperScript™ II Reverse Transcriptase
(RT) (Invitrogen), which is a DNA polymerase that synthesizes a complementary DNA
strand from single-stranded RNA, DNA, or an RNA:DNA hybrid. This enzyme is
genetically engineered by the introduction of point mutations to have reduced RNase
H activity, while maintaining full polymerase activity. This structural modification
eliminates degradation of RNA molecules during first-strand cDNA synthesis. This
enzyme provides greater first-strand cDNA yields, more full-length cDNA and activity
up to 50°C.Using sterile RNase free eppendorf tubes, 1 pl of oligo (dT) 12-18, 1 ng to 5 J-lg
of total RNA (depending on the concentration of RNA), 1 J-liof 10 mM dNTP Mix (10
mM each dATP, dGTP, dCTP and dTTP), and sterile distilled water to 12 J-llwere
added. The mixture was heated to 65°C for 5 minutes and quick chilled on ice and the
contents of the tube was collected by brief centrifugation. 4 J-liof 5x First-Strand
Buffer,2 J-llof 0.1 M DTT, and 1 J-llof RNaseOUT (Invitrogen) were then added, and
the contents of the tube were mixed gently and incubated at 42°C for 2 minutes. 1 ~l of
SuperScript II RT was added and mixed by pipetting gently up and down and then the
tube was incubated for 50 minutes at 42°C. Finally, the reaction was inactivated by
heating at 70 °C for 15minutes. Control tubes were treated exactly in the same way but
without adding the SuperScript II RT enzyme. Samples of cDNA and the controls were
stored at -20°C to use as a template for amplification in PCR.
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2.6.3 Genomic DNA extraction from different life cycle stages of 1:brucei
Procyclic or bloodstream forms of T. bruceiwere centrifuged at 3500 rpm for 15min at
4 cc. Cell pellets were then re-suspended in 450 III DNA extraction buffer (see
Appendix I). 50 J.Ll10%SDS was added followed by 25 III (10 mg/ml) proteinase K.
Tubes were then incubated for 2 hrs at 37°C while mixing gently on a rocking
platform. 500 IIIof liquid phenol was added and vortexed thoroughly (solution becomes
milky in appearance), followed by centrifugation for 5 minutes at 13,000 g. The top
layer was transferred into a fresh tube and an equal volume of phenol-chloroform
(50:50) was added, usually about 500 Ill. The tube was vortexed thoroughly and
centrifuged for 5 minutes at 13,000 g. and the upper aqueous layer was transferred to a
fresh tube and equal volume (500 Ill) chloroform was added. Tube was vortexed
thoroughly and centrifuged for 5 minutes at 13000 g, and the top layer was then
transferred to fresh tube (400 Ill). 40 Jll of 3 M Na-acetate plus 1 ml of 100% ice cold
ethanol were added, and the tube was then left at -20°C for about 30 minutes. The
tube was centrifuged for 15 minutes at 13,000 g to pellet DNA, and then washed with
70% ethanol. The pellet was dried in a 37°C incubator for 10-15 minutes and re-
suspended in 50 J.Ll of dH20 or TE buffer and then stored at -20°C.
2.6.4 Polymerase Chain Reaction (PCR) for DNA
The PCR was performed in a reaction mixture of 20 pl containing 2 III of lOx Taq
buffer, 1 J.Llof 25mM MgCh, 0.4 III of 10 mM dNTP mix (200 IlM of each of dATP,
dCfP, dTIP, dGTP), 1 IIIof each primer (2.5 11M),0.4 Taq DNA polymerase (5U/lll). 1
IIIof either eDNA, the negative control (from first-strand reaction), or genomic DNA
(positive control) was added, followed by autoclaved distilled water (dH20) to a final
20 IIIvolume. A negative control was performed in all of our PCR reactions which was
exactly the same reaction mixture tube but without eDNA, or using the sample from
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the negative control (from first-strand reaction). PCRs were performed using the PTC-
200 Peltier Thermal Cycler (MJ Research). Two different programmes were used for
the annealing temperature and the cycle conditions, depending on the primers used.
PCR conditions consisted in a hot-start denaturation for 2 minutes 94°C, followed by
30 cycles of 94°C for 30 seconds, annealing temperature for 30 seconds (temperature
dependent on the particular primers), and extension at 72°C for 2 minutes, followed by
a final extension step at 72°C for 10minutes.
2.6.5 Agarose Gel Electrophoresis of DNA
Agarose powder was mixed with TBE (Tris-borate-EDTA) electrophoresis buffer to the
needed concentration (usually 0.8% or 1.2%), then heated in a microwave oven until
completely melted. Ethidium bromide (final concentration of 0.3 pg/ml) was added to
the gel at this point to facilitate visualization of DNA after electrophoresis. After
cooling the solution to about 60°C, itwas poured into a casting tray containing a sample
comb and allowed to solidify at room temperature. Samples containing DNA or
controls mixed with loading buffer (5-7 ~) were then pipeted into the sample wells
(usually 10 1I1per well). The voltage used to run the gels was normally 60 V, and gel
visualization was by using UV transilluminator (UVP Products). 1 kb DNA Ladder
(BioLabsor Invitrogen)was used for determining the size of double-stranded DNA.
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CHARACTERISATION OF A NOVEL NUCLEOBASE TRANSPORTER IN LEISHMAMA
MAlaR PROMASTIGOTES
CHAPTER IlL NUCLEOBASE TRANSPORTER 1NL.MAJOR PROMASTIGOTES
3.1 Summary
Despite the severe side-effects and emerging resistance, pentavalent antimony drugs
such as Pentostam (sodium stibogluconate) or Glucantime (N-methylglucamine
antimoniate) are still widely used to treat human leishmaniasis (Croft. 2001; Sundar.
2001b; Croft. et sl., 2005; Soto, et al,2005). Indeed, the hypoxanthine analogue
allopurinol is one of only a hand-full of drugs clinically used against various forms of
leishmaniasis. which. either alone or in combination with other drugs, has proved
effective against cutaneous (Martinez and Marr, 1992; Baum and Berens, 1994; Becker,
et al. 1999). ocular (Abrishami, et al, 2002) or visceral leishmaniasis (Llorente, et al.,
2000; Das, et al. 2001; Momeni, et el., 2002; Pasa, et al, 2005). Several of these reports
describe combinations of allopurinol with low doses of other antileishmanials that are
more effective than the usual dosage of the other drug alone and the reduced dosage of
pentamidine or antimony reduces or eliminates harmful side effects. Combination
therapy also delays onset of drug resistance.
Purine nuc1eobase transporters play central roles in the biochemistry of parasitic
protozoa such as Leishmania.because these parasites cannot synthesize purines de novo
and are absolutely reliant upon purine salvage from their hosts (Carter, et el., 2003). In
contrast, almost all mammalian cells can synthesis purines de novo and this difference
between parasitic and mammalian cells results in purine salvage being a potential target
for chemotherapy (Craig and Eakin. 1997). Furthermore, nucleobase transporters are
important to the pharmacology of these significant human pathogens, because they
mediate the uptake of purine analogues. as well as some non-purine drugs, that are
selectively cytotoxic to the parasites. In the last few years major progress has been
made in the biomedical and molecular characterisation of the purine nuc1eobase
transporters. However, little is known about the way their expression or activity is
regulated and a thorough understanding of these processes is vital for the effective
exploitation of transporters to deliver chemotherapeutic agents.
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The metabolism of allopurinol in Leishmania species to the active metabolite, 4-
aminopyrazolo(3,4-d)pyrimidine ribonucleoside triphosphate, has been described
(Nelson, et sl., 1979a; Marr and Berens, 1983). To date, however, no study has
addressed allopurinol uptake by this parasite, even though the issue is important in
understanding the selectivity of the drug as well as the potential for the development of
resistance. In the related kinetoplast, Trypanosoma brucei, allopurinol is taken up
through high affinity purine nucleobase transporters (De Koning and Jarvis, 1997a; De
Koning and Jarvis, 1997b; Natto, et sl., 2005). We have therefore conducted a
comprehensive study of purine nucleobase uptake in Leishmania major promastigotes.
We have identified a single transporter, designated LmajNBTl, with high affinity for
all physiological purine bases and moderately high affinity for allopurinol. Studies with
(3H]allopurinol confirmed that this transporter is its sole route of entry into
promastigotes.
In this chapter, the uptake of (3H]adenine, [3H]hypoxanthine, and (3H]allopurinol were
investigated. These compounds were all taken up by a single high-affinity transporter,
designated LmajNBT1. with Km values of 4.6 ± 0.9, 0.71 ± 0.07, and 54 ± 3 ~M,
respectively. Guanine and xanthine fully inhibited [3H]adenine transport, with Ki
values of2.8 ± 0.7 and 23 ± 8 ~M.
A model for the interactions of LmajNBTl with its substrates was constructed using the
techniques developed to study Trypanosoma brucei and human purine transporters (De
Koning and Jarvis, 1999; Wallace, et al, 2002) to allow wider predictions about the
potential of drug uptake by LmajNBT1. The resulting model predicts that this
transporter could mediate the uptake of an extensive range of nuc1eobase and
guanosine analogues. In addition, it was shown that the architecture of the L. major
and T. brucei nucleobase transporters are similar enough to bind purine bases in almost
identical fashion. though the nuc1eobase transporter expressed in human erythrocytes
and other cell types binds the same substrates in an entirely different way. This implies
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that many nucleobase analogues could be selectively internalised by both protozoan
pathogens but remain excluded from many host cells. Though functional relationships
such as highlighted in this study do not necessarily reflect evolutionary relationships,
they have more pharmacological relevance than gene sequence alignments. This work
has, in part, been previously published as Al Salabi et al. (2003) Mol. Pharmacol.
63:814-820 (see Appendix III).
3.2 Results
3.2.1 Adenine transport by Leishmania majorpromastigotes
At the start of this project, the number of nucleobase transporters in L. major and their
kinetic properties were unknown. Thus, initial studies were performed to investigate
nucleobase transport in L. major and to compare the transport properties with those
reported for T. brucei. Transport of 1 J.1M(3H]adenine by mid-log phase L. major
promastigotes (Figure 3.1) at 22°C was linear for at least 25 s (Figure 3.2, inset), with a
rate of 1.1± 0.1 pmol(107 cellsjls", whereas in the presence of 1mM unlabeled adenine
no uptake of [3H]adenine was detectable over 120 s (Figure. 3.2), indicating that
transport was saturable. (3H]Adenine uptake, measured over 10 s, followed Michaelis-
Menten kinetics (Figure 3.3, inset) and displayed an apparent Km and Vmax values of 4.6
± 0.9 J.1Mand 3.2 ± 0.3 pmolf IO" cells)-ls-l, respectively, (n = 3). This experiment was
performed at 0.1 J.1Mof label and assumed to be linear over the short incubation period
(10 s), Considering the much longer linear uptake phase at 1 J.1Mof label, it is felt this is
a reasonable assumption.
Transport of (3H]adenine was inhibited by a range of purine nucleosides and
nuc1eobases (Table 3.1), but not by the pyrimidines uracil, cytosine, thymine and
thymidine at concentrations up to 1mM (P> 0.05; Unpaired Student's T-test). Nor was
[3H]adenine transport significantly inhibited by 25 JlM dilazep or dipyridamole (Figure
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3.4). The adenine transporter generally displayed far higher affinity for nucleobases
than for their corresponding nucleosides, as illustrated in Figure 3.3 for adenine and
adenosine, which displayed a IGvalue of> 5 mM (n = 3). Allopurinol was a moderately
effective inhibitor of [3H]adenine transport (Figure 3.3) with a IGof 56 ± 2 11M(n = 3).
All inhibition profiles displayed Hill coefficients near -1 and maximum inhibition was
invariably equal to the level of inhibition of the control (1 mM unlabelled adenine).
These observations are consistent with a single transport activity for [3H]adenine.
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FIGURE 3.1 Growth curve of L. major promastigotes in Homem medium + 10% heat-
inactivated fetal calf serum at 25°C.
FIGURE 3.2 Timecourse of 1 11M[3H]adenine uptake by L. major promastigotes in the
presence (D) or absence (.) of 1 mM unlabelled adenine. The inset shows the linear
phase of this curve (25 s). The line was calculated by linear regression (r = 0.97).
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FIGURE 3.3 Inhibition of 0.1 JlM [3H]adenine uptake over lOs by various concentrations
of adenine (a), allopurinol (0) and adenosine (.), with ICsovalues of 5.9 JlM, 52 JlM
and 3.9 mM, respectively (for this experiment). Data were expressed as percentage of
the control, defined as uptake in the absence of inhibitor. The inset shows the
conversion of the adenine inhibition plot to a Michaelis-Menten curve (in pmolf IO?
cells)-ls-l).
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FIGURE 3.4 Inhibition profile of the L. majornucleobase transporter LmajNBT1. Uptake
of [3H]adenine (0.1 JlM) by L. major promastigotes was measured in the presence of
pyrimidines (1 mM) and potential inhibitors (25-50 11M) and expressed as percentage of
control, defined as [3H]adenine uptake in the absence of inhibitor.
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[3H]-adenine [3H]-hypoxanthine [3H]-allopurinol
(~M) n (~M) n (~M) n
Km 4.6±0.9 3 0.71 ± 0.07 4 54 ± 2.9 3
Vrnaxa 3.2 ±0.3 3 2.8±0.6 4 0.24± 0.06 3
/(jvalues
adenine 3.0 ± 0.5 3
hypoxanthine 1.3 ± 0.3 3 0.30± 0.09 3
allopurinol 56 ± 1.5 3
guanine 2.8±0.7 4
xanthine 23±8 3
adenosine 5150 ± 550 3
inosine 125 ± 15 3
guanosine 68 ± 17 4
purine 6.7 ± 0.4 3
I-deazapurine 26 ± 4.1 3
3-deazaguanine 48±5 3
6- thioguanine 6.2 ±0.8 3
7-deazaguanine 426 ± 140 3
9-deazaguanine 204±4 3
TABLE3.1 Kinetic constants of purine nucleobase uptake in L. major promastigotes.
Kinetic parameters were determined through competitive inhibition of the indicated
[3H]-permeants, as described in Materials and Methods, with 8-11 inhibitor
concentrations over the relevant range. In a few cases, extrapolation was required due
to limitations of solubility of the inhibitor (Figure 3.3) and based on the assumption of
a Hill slope of -1 and eventual 100% inhibition. Extrapolation was not attempted when
inhibition at the highest inhibitor concentration was <50%. Permeant concentration
was 0.1 ~M (adenine and hypoxanthine) or 0.5 ~M (allopurinol). 8 expressed as
pmot(l O' cellsjls'.
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3.2.2 A single transporter is responsible for uptake of purine nucleobases
The inhibition of adenine transport by other purine bases does not establish whether
these bases are in fact transported across the plasma membrane by this adenine
transporter. nor whether additional transporters for purine nucleobases are expressed
in L. major promastigotes. To further investigate these issues, additional transport
studies were performed using [3H]hypoxanthine and [3H]allopurinol.
[3H]Hypoxanthine uptake (O.IIlM) was linear for at least 15 sec (Figure 3.5, inset), with
a rate of 0.22 ± 0.02 pmolf lO?cellsjls", whereas in the presence of 1 mM unlabelled
hypoxanthine no uptake of [3H]hypoxanthine was detectable over 120 s (Figure 3.5),
indicating that transport was saturable. The apparent Km value was 0.71 ± 0.07 IlM and
[3H]hypoxanthine transport was inhibited by adenine with a IGvalue of 3.0 ± 0.5 IlM
(Figure 3.6). The Km is therefore almost identical to the /G value for hypoxanthine
inhibition of adenine transport. and the IG value for adenine inhibition of
[3H]hypoxanthine transport is equal to the Km for adenine uptake (Table 3.1).
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FIGURE3.5 Time course of 0.1 IlM [3H]hypoxanthine uptake in the presence of
unlabelled hypoxanthine (D) over 15 s was linear (r = 0.92) and not significantly
different from zero (P> 0.05) or in the absence (.) of 1 mM unlabelled hypoxanthine.
The inset shows that the uptake was linear over 15 s (r = 0.96) as calculated by linear
regression
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FIGURE 3.6 Transport of 0.1 )lM [3H]hypoxanthine over 10 s was inhibited by indicated
concentrations of unlabelled hypoxanthine (.) or adenine (0), with leso values of 0.91
)lM and 4.1 )lM, respectively. The inset depicts the conversion of the hypoxanthine
inhibition data to a Michaelis-Menten plot of total hypoxanthine uptake, with a .Km
value of 0.69 )lM and a Vrnax of 3.4 pmolfltl' cellsrs' for this experiment.
In addition, purine nucleosides inhibited transport of 0.1 )lM [3H]hypoxanthine in a
manner similar to [3H]adenine: 1 mM adenosine, 1 mM inosine and 250 )lM guanosine
inhibited hypoxanthine uptake by 32 ± 13, 94 ± 1% and 87 ± 1%, respectively (n = 3).
These results indicate that adenine and hypoxanthine most likely compete for uptake at
a single transport unit. Likewise, 1 )lM [3H]allopurinol, which was taken up with a rate
of 0.026 ± 0.002 pmolfl O?cellsr-s' (Figure 3.7), was inhibited by hypoxanthine (Figure
3.8) with a Ki value very close to the Km for [3H]hypoxanthine uptake (Table 3.1). It
thus appears that L. major expresses a single high affinity transporter for purine
nucleobases. Given the substrate profile of this transporter, it was designated L. major
Nucleobase Transporter 1 (LmajNBT1). This transporter was not sensitive to the
transporter inhibitors dilazep and dipyridamole: which inhibited 0.1 u.M
[3H]hypoxanthine transport by just 20 ± 4% and 26 ± 4%, respectively, at 50 )lM (n =3).
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FIGURE 3.7 Timecourse over 240 s, at a final [3H]allopurinol concentration of 1 ~M. 107
promastigotes were incubated for up to 240 s without inhibitor (.), in the presence of
250 ~M hypoxanthine (D) or 1 mM allopurinol (.). The rate of uptake was calculated
by linear regression (r = 0.96). Allopurinol transport was not significantly different
from zero in the presence of hypoxanthine or unlabelled allopurinol. The intercept of 1
~M allopurinol was 0.82 ± 0.29 pmolfl O?cells):' and not significantly different from
zero (P < 0.05).
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FIGURE 3.8 Uptake of 0.5 ~M [3H]allopurinol over 120 s was inhibited by up to 1 mM
unlabelled allopurinol (.) or hypoxanthine (D). The allopurinol inhibition plot was
converted to a Michaelis-Menten plot (inset), with a Km value of 50 ± 3.6 ~M and a Vrnax
ofO.39 ± 0.01 pmolflff cellsr-s:' for this experiment.
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3.2.3 Ionic requirements for adenine transporter
In contrast to most of mammalian cells, the T. brucei brucei purine nucleobase and
nucleoside transporters are not sodium ion-dependent (De Koning and Jarvis, 1997a;
De Koning and Jarvis, 1997b; De Koning, et sl., 1998). The adenosine transporter PI
was the first nucleoside transporter in T. brucei bloodsteam forms that appeared to be
proton-linked as it has been reported that the proton-gradient uncoupler CCCP dose-
dependently reduced adenosine transport, reaching> 75% inhibition at 20 ~M. The 50%
effective concentration of CCCP was 2.5 ± 0.4 ~M. In addition, similar reductions in
adenosine transport were seen with the ionophore nigericin and the Na+/I(+exchanger
gramicidin. In contrast, neither monensin, a Na' ionophore, nor replacement of Nat
with NMG+had any effect on adenosine transport rates (De Koning, et sl., 1998). It has
also been demonstrated that the hypoxanthine transporters (H1 and H2) in T. b. brucei
procyclic and bloodstream forms are nucleobase/proton symporter as they are linked to
a protonmotive force (De Koning and Jarvis, 1997a; De Koning and Jarvis, 1997b).
Furthermore, the proton ionophore carbonyl cyanide chlorophenylhydrazone (CCCP)
inhibited up to 70% of (3H]uracil flux indicating that uracil uptake in T. b. brucei
procyclics may be a nucleobase-Hs-symporter model for this carrier (De Koning and
Jarvis, 1998). In addition, it was reported that nucleoside transporter family members
from Leishmania donovani (LdNf1.1 and LdNf1.2) are proton-dependent (Stein, et sl.,
2003).
In this study, we investigated whether adenine uptake in L.major promastigotes was
dependent on the ionic gradients defining membrane potential. The proton uncoupler
CCCP (carbonyl cyanide chlorophenylhydrazol), the membrane depolarization agent
gramicidin and the K+/H+-exchanger nigericin were tested. All inhibited adenine
uptake in a dose-dependent manner (Figure 3.9).
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FIGURE3.9 Effects of different concentrations (0.2-20 ~M) of the proton uncoupler
CCCP (carbonyl cyanide chlorophenylhydrazol) on LmajNBTl-mediated 0.1 !-1M
[3H]adenine transport. A. using unpaired student's T-test for statistical significance
analysis; **, P < 0.02, ... , P < 0.001, and n.s., not significant. B. ICsoplot for effect of
CCCP using the values listed in Table 3.2.
The result was not unexpected as earlier studies show that solute transport in
protozoan is usually dependent on the proton gradient rather than sodium gradient.
Certainly the results with CCCP were very similar to the earlier results with various
proton symporters of T. brucei. CCCP ICso=5.1 ~M for LmajNBTl (Figure 3.9.8), CCCP
ICso= 3.8 ~M for TbUl (De Koning and Jarvis, 1998), CCCP ICso=2.5 ~M for TbH1 (De
Koning and Jarvis, 1997a).
Nevertheless, LmajNBTl-mediated adenine transport was less sensitive to gramicidin
than the corresponding transport activity in T. b. brucei procyclics (Table 3.2). The
findings reported here are broadly supportive of protonlnucleobase symport in L. major
promastigotes but additional studies will be required for the necessary degree of
certainty for such a conclusion.
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Compound P.I. Concentration Uptake [% of control]
[min] [~M]
LmajNBTl TbH1
n p p
CCCP 2 0.2 86±4 4 n.s. 81 ± 2 < 0.01
1 70±5 3 <0.05 70±5 < 0.01
5 51 ± 3 5 < 0.001 55 ±3 < 0.001
20 35±4 4 < 0.001 31 ±1 < 0.001
Nigericin 3 1 92± 1 3 n.s. 104 ± 2 n.s.
5 71 ±3 3 <0.02 80±4 <0.02
20 63±4 3 < 0.01 50 ± 1 < 0.001
Gramicidin 3 0.2 98±3 4 n.s. n.d.
1 88±3 6 n.s. 40±5 < 0.001
5 67±4 7 < 0.001 n.d
10 n.d 33± 1 < 0.001
20 57±5 6 <0.05 n.d
25 n.d 32±2
50 50 ± 16 3 <0.05 n.d
TABLE3.2 Effects of agents affecting transmembrane ionic gradient on adenine
transport. Promastigotes of L. major cells were preincubated (P.I.) under the indicated
conditions, and the influx of 0.1 flM adenine for 10 s was subsequently determined as
described in (chapter two). Results are expressed as means ± S.E. of 3-7 independent
experiments, each preformed with 6 replicates per concentration group. Data for the T
b. brucei HI transporter was obtained from (de Koning and Jarvis, 1997a). Statistical
significance was measured against uptake in presence or absence of the inhibitors. n.s.,
not significant. n.d. not determined.
3.2.4 Structure-activity relationships of LmajNBTl
The fact that LmajNBTl displays broad selectivity for purine nucleobases and mediates
the uptake of allopurinol suggests that it may also transport other potential purine
antimetabolites. The antineoplastic drug 6-thioguanine, for instance, displayed a JG
value of 6.2 ± 0.8 ~M for LmajNBTI, and is probably efficiently taken up through this
transporter. It has been demonstrated that models for the interactions between a
transporter binding pocket and its permeant can be constructed through the study of
competitive inhibition by structural analogues, and that such models have predictive
value with respect to substrate recognition (De Koning and Jarvis, 1999;Wallace, et al.,
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2002; De Koning, et sl., 2003; De Koning, et al, 2005). A model for permeant
recognition by LmajNBTl is displayed in Figure 3.IOA. The proposed hydrogen bond
between LmajNBTl and N3 follows most directly from the observation that N3 is
essential for high affinity binding; 3-deazaguanine displays >10-fold lower affinity than
guanine (Table 3.1). Conversion of the .Ri values to Gibbs free energy as described in
data analysis in chapter two, yields an energy difference o(~Go) of 7.0 kJ/mol (Table
3.3), the apparent energy of the H-bond lost in 3-deazaguanine. Similar comparisons of
guanine with 7-deazaguanine and 9-deazaguanine reveal H-bonds of 12.5 and 10.6
kl/mol with N7and N(9)H, respectively. The O(~Go)of 3.3 kl/mol between purine and
I-deazapurine is small but highly significant (P < 0.02) and shows that a weak
interaction is formed between NI of the purine ring and an H-bond donor in the
LmajNBTl binding site. In contrast, no significant difference in affinity was observed
between purine and adenine, or between guanine and 6-thioguanine, showing that the
functional groups at position 6 do not contribute to binding. The O(~Go)of 5.6 kl/mol
between purine and hypoxanthine must therefore be the result of binding through
N(I)H. Since the weak bond with the unprotonated NI of purine (3.3 kl/mol) is lost in
hypoxanthine, the Gibbs free energy ofthe H-bond with N(l)H must be 8.9 kl/mol,
Corroborating evidence for this model is obtained from the .Ri values of other
compounds listed inTable 3.1. The structure of allopurinol differs from hypoxanthine
in that N7 has shifted to position 8, and the O(~Go)of 10.8 kl/mol is virtually identical
to the estimated bond energy for N7 (Figure 3.10A). The low affinity for nucleosides
(O(~Go)>10 kl/mol) is consistent with the proposed H-bond to N(9)H. The O(~Go)of
xanthine versus hypoxanthine (8.6 kl/mol) is identical to the estimated bond energy for
N3, which is protonated in xanthine. Figure 3.10 also explains the total lack of
recognition of pyrimidine nucleobases. Finally, the sum of the individual bond energies
is within 10% of the observed ~Go for adenine and hypoxanthine as calculated from
their Km values. For hypoxanthine, l:(~Go) = -39.0 kl/mol, while the ~Goobs= -35.1
kj/mol and for adenine these values are -33.4 and -30.5 kl/mol, respectively.
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LmajNBT1 H2
Compound (~Ql) o(~C» (~c» o(~C» Control
Hypoxanthine -35.1 -39.5
Guanine -31.7 3.4 -36.8 2.7 Hypoxanthine
Adenine -30.5 4.6 -31.4 8.1 Hypoxanthine
Xanthine -26.5 8.6 -28.9 10.6 Hypoxanthine
Allopurinol -24.3 10.8 -30.8 8.7 Hypoxanthine
Guanosine -23.8 7.9 -28.3 8.5 Guanine
Inosine -22.3 12.8 -23.7 15.8 Hypoxanthine
Adenosine -13.1 17.4 -17.4 12.9 Adenine
Purine -29.5 0.9 -27.0 4.4 Adenine
1-Deazapurine -26.2 3.3 -26.6 0.4 Purine
3-Deazaguanine -24.7 7.0 -28.5 8.3 Guanine
6-Thioguanine -29.7 2.0 -36.3 0.5 Guanine
7-Deazaguanine -19.2 12.5 -24.3 12.5 Guanine
9-Deazaguanine -21.1 10.6 -29.1 7.7 Guanine
TABLE3.3 Gibbs free energies (kl/mol) of substrate interacting with LmajNBT1 or the
Trypanosoma brucei brucei H2 transporter. Gibbs free energy of substrate-transporter
interactions was calculated from the Km and JG values listed in Table 3.1, using the
Nernst equation as described in Materials and Methods. The difference with a control
compound. either hypoxanthine as the highest affinity compound, the corresponding
physiological nucleobase (in the case of chemical analogues) or (in the case of
nucleosides) the corresponding nucleobase yielded the o(LlGO),the loss in binding
energy relative to the control compound. The values for the T. b. bruceiH2 transporter
were transcribed from (Wallace, et al., 2002).
The proposed model for substrate binding by LmajNBT1 differs greatly from the one
recently reported for the human facilitative nucleobase transporter hFNTI (Figure
3.10.8), though they are both high affinity purine nucleobase transporters (Wallace, et
al., 2002). However, the architecture of the LmajNBT1 binding site appears to be very
similar to that of T. brucei H2 (Figure 3.1OC;Wallace, et al., 2002). Both transporters
bind their highest affinity substrate, hypoxanthine, through the same interactions with
the purine ring and even the individual bond energies are very similar. The only
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substantial difference between the two transporters appears to be in the binding of
adenine, where a weak H-bond with the amine group is now formed with NI instead.
It is certainly possible that this reflects merely a minor shift of position of one amino
acid residue in the binding site. Alternatively an H-bond acceptor such as aspartate
may have been replaced by an H-bond donor such as serine.
A. L. major NBTl
12.5
N
~ 106,. ,N .. 10.6
_Jo/J--t
~
.
/(::: 7.3
C. T. brucei H2
FIGURE 3.10 Model for the interactions between the LmajNBTI (A), hFNTI (B) and
TbH2 (C) transporters and their permeants, adenine and hypoxanthine. Estimated
Gibbs free energy for proposed bonds are indicated as - kj/mol. The models for hFNTI
and TbH2 were adapted from (Wallace, et sl. 2002).
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The substrate recognition similarities of the two transporters extend to having far
higher affinity for guanosine than for any other nucleoside, despite the fact that
guanine is a lower affinity substrate than hypoxanthine. The only feasible explanation
for this is that the optimal configuration for nucleoside binding is stabilised by an
internal H-bond between the 5'hydroxyl and 2-NH2 groups. The fact that this confers
higher affinity than for the other purine nucleosides shows just how similar the
binding site environment of LmajNBTI and ThH2 is. Table 3.3 lists the IlGoand 8(IlGo)
of H2 alongside those of LmajNBTl.
3.3 Discussion
Purine nucleobase and nucleoside analogues are being used against a wide variety of
diseases and infections (De Koning and Diallinas, 2000; Chen, et sl., 2002; De Clercq,
2002; Galmarini, et sl., 2002; El Kouni, 2003; De Clercq, 2004; Parker, et sl., 2004; De
Clercq, et al, 2005; Jordheim, et al, 2005). The hypoxanthine analogue allopurinol has
shown considerable promise for the treatment of Leishmaniasis, and several nucleoside
analogues have shown anti-protozoal activity, but no rational approach to a purine-
based chemotherapy for protozoan infections has been developed. Such an approach
needs to take account of (1) efficient uptake of the analogue by the parasite and (2)
conversion by the parasite's metabolism to a form harmful to the organism. Selective
toxicity therefore needs to be the result of either selective uptake or differences in the
metabolic enzymes for pathways. This study deals with the issues related to specific
and efficient uptake of purine analogues by the protozoan parasite Leishmania major.
We have investigated the transport of (3H]adenine, [3H]hypoxanthine and
[3H]allopurinol and found that all three bases were taken up by the same transporter,
LrnajNBTl. This conclusion is based on (1) consistently monophasic inhibition profiles
with Hill slopes of -1, leading to 100% inhibition of permeant uptake by the unlabelled
inhibitor, (2) near identity of .Km values for hypoxanthine uptake and the JG value for
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hypoxanthine inhibition of adenine uptake (and the equivalent observations for
(3H]adenine and (3H]allopurinol) and (3) internally consistent IGand llGo values with a
range of structural analogues, allowing the construction of a quantitative model for
substrate recognition. The only previous report to date of nucleobase transport in
Leishmania, by Hansen, et al (1982), also found that hypoxanthine and adenine were
probably transported by a single transporter in Leishmania braziliensis panamensis. In
contrast, nucleoside transporters have been relatively extensively studied in
Leishmania donovani (Vasudevan, et el., 1998, 2001; Carter, et sl., 2000b; Ghosh and
Mukherjee, 2000; Galazka, et al. 2006) and found to display high affinity for their
substrates. with Km values typically between 0.3 and 5.0 JlM. In view of the much
higher IGvalues for nucleosides reported here for LmajNBTl. it is unlikely that this
transporter plays a significant physiological role in nucleoside salvage.
Allopurinol uptake has not previously been studied in Leishmania species. The
discovery that. in contrast to T. brucei (De Koning and Jarvis. 1997b; Natto, et al.
2005). allopurinol is taken up by only a single transporter. raises concerns about the
ease with which resistance may develop. particularly since Leishmania species also
express high affinity purine nucleoside transporters (Carter. et el.; 2000b; Vasudevan, et
al. 1998; Landfear, et al. 2004; De Koning. et al. 2005) and LmajNBTI is thus unlikely
to be an essential gene. It would therefore be prudent to use allopurinol mainly as part
of combination chemotherapy.
Allopurinol displayed only a moderate affinity for LmajNBT1 and its maximal rate of
uptake is at least 10-fold lower than for adenine or hypoxanthine, but it is clinically
active against leishmaniasis at high doses. It could be speculated that other purine
analogues, if salvaged more efficiently, could have a higher efficacy. We have therefore
studied the substrate selectivity of LmajNBT1 in detail, constructing a quantitative
model that allows predictions of the affinity of the transporter for potentially
therapeutic analogues. While such models yield estimates of Km rather than Vmax, it
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does allow rational design or selection of purine analogues that are likely to be
accumulated efficiently inside the parasite.
Therapeutic action will then depend on such enzymes as the
phosphoribosyltransferases. among others. that convert the analogues into nucleotides,
though some purines. including kinase inhibitors. may not need any metabolic
conversion for their mode of action. The purine metabolic pathways of Leishmania
have been studied in detail (Hassan and Coombs. 1988; Berens. et al. 1995) and most of
the key enzymes have been characterised. cloned (Allen. et al. 1995; Thiemann. et al.
1998; [ardim, et al. 1999;Sinha. et al. 1999;Cui. et al. 2001; Zarella-Boitz, et al. 2004)
and. in some cases. crystallised (Phillips. et al. 1999; Shi, et al. 1999). potentially
allowing the design of specific inhibitors or subversive substrates. Compliance with the
LmajNBTl model would ensure selective and efficient salvage of such designer drugs.
And since the substrate recognition models for the nucleobase transporters of L. major
and T. brucei are almost identical. purine antimetabolites developed against either
species may well be active against other members of the family Trypanosomatidae.
Relationships between transporters are usually defined by their degree of sequence
homology. and transporters are classified into families on this basis. However. such
classification provides limited information. The family of the Equilibrative Nucleoside
Transporters (ENT) is a case in point. As reviewed by Hyde. et al (2001). this family
includes high affinity and low affinity transporters. equilibrative transporters and
proton symporters, transporters that recognise only one or two specific nucleosides,
and those that have broad specificity including nucleobases. It follows that only limited
functional information can be gleaned from sequence similarities. and an additional
classification based on substrate recognition would be of value. A striking illustration is
provided by the adenosine transporters of T. brucei, PI and P2. encoded by the genes
ThNT2and ThAT). respectively. Though the genes are closely related (57% identity at
amino acid level) and both transport adenosine with similar affinity and rate. PI also
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transport guanosine and inosine, which are not substrates of P2 (Carter and Fairlamb,
1993; De Koning and Jarvis, 1999). Conversely, P2 efficiently transports adenine as well
as trypanocidal drugs such as melaminophenyl arsenicals and diamidines (Barrett and
Fairlamb, 1999; De Koning, 2001). These important pharmacological differences are
readily explained by their proposed substrate binding models (De Koning and Jarvis,
1999; De Koning, et el., 2005) but, at present, cannot be predicted from their primary
sequences. Therefore, though ThATl and ThNT2 are genetic homologues, they are not
functionally homologous.
After this work was published, Landfear's group has cloned and expressed the first gene
for a L. major nucleobase transporter, designated LmaNT3. The LmaNT3 permease
shows 33% identity to L. donovani nucleoside transporter 1.1 (LdNT1.1) and is
proposed to be a member of the equilibrative nucleoside transporter (ENT) family
(Sanchez, et sl., 2004b). This transporter is quite similar to the LmajNBTl we
characterised, as the functional expression studies in Xenopus laevis oocytes showed
that LmaNT3 mediates high levels of uptake of hypoxanthine, xanthine, adenine and
guanine. Moreover, LmaNT3 possess a high affinity for hypoxanthine, xanthine,
adenine and guanine with Km values of 16.5 ± 1.5, 8.5 ± 0.6, 8.5 ± 1.1 and 8.8 ± 4.0 llM,
respectively. However, given that the order of affinities for the various substrates was
reportedly different for LmaNT3 and LmajNBTl, the possibility that these are
genuinely different transporter activities cannot be excluded. The fact that the two
studies used different expression systems (promastigote and Xenopus oocytes) is a
confounding factor and definitive conclusions cannot be drawn at this time.
The genes encoding LmajNBTl and ThH2 have yet to be positively identified, but the
current study clearly establishes them as functional homologues and speculates that the
environment of the binding sites of the two transporters is very similar: their
functional differences could be explained with a single amino acid substitution or even
a slight positional shift in one residue. In contrast the best studied nucleobase
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transporter in the human host, FNTl (Wallace, et al, 2002), and the Toxoplasma gondii
hypoxanthine transporter TgNBTl (De Koning, et sl, 2003) interact in an entirely
different way with their permeants.
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4.1 Summary
Most of the currently available antileishmanial drugs have been discovered empirically,
as until recently insufficient information was known about the biochemistry,
physiology and molecular biology of these parasites and the interactions with their
hosts (El Kouni, 2003). The limitations of the current treatment for leishmaniasis, as a
result of drug resistance, the severe side effects of most of the existing therapeutic
agents, and the urgent need for new therapeutic approaches, are well documented
(Croft, 2001; Sundar, 2001a; Yardley and Croft, 2000; Leandro, et sl., 2003; Croft, et sl.,
2006).
The development of a rational therapeutic strategy for the treatment and prevention of
parasitic disease depends on exploitation of fundamental biochemical disparities
between parasite and host, such as the inability of protozoan parasites to synthesize
purines de novo (Berens, et sl., 1995). Current antiprotozoal agents often derive
selectivity from selective accumulation by the parasite rather than the host cell (De
Koning, 2001). The selectivity and the efficacy of purine antimetabolites can be
achieved by the cell-surface transporters that mediate access to the cell, as substrate
recognition by nucleobase transporters is strikingly different in humans and
kinetoplastids such as Trypanosoma brucei (Wallace. et sl., 2002) and Leishmania
majorpromastigotes (A1Salabi,et el., 2003).
Purine and pyrimidine antimetabolites have been highly successful against many viral
infections as well as malignancies (Kolb, 1997). and show great promise against
protozoal infections as well (De Koning and Diallinas, 2000; El Kouni, 2003; De
Koning, et sl., 2005). Allopurinol, a purine nucleobase analogue, is clinically used
against various manifestations of Leishmaniasis (Das, et sl., 2001; Abrishami, et al.
2002; Momeni, et sl., 2002).
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Whereas purine transporters in promastigotes have now been studied in detail
(Landfear, et sl., 2004; De Koning, et sl., 2005), very little is known about such
transporters in the infective amastigote forms. The only study of purine transporters in
arnastigotes demonstrated that there are at least two high-affinity adenosine
transporters in L. donovani amastigotes, Tl and T2 (Ghosh and Mukherjee, 2000).
Purine nucleobase transport has yet to be described in this intracellular form, despite a
clear interest from physiological and pharmacological perspectives.
In the previous chapter, we have shown that allopurinol is efficiently taken up by a
high-affinity purine nucleobase transporter in L. major promastigotes, LmajNBTl (AI
Salabi, et el., 2003). We here report the first identification and characterization of a
purine nucleobase transporter in Leisbmsnis amastigotes. Uptake of [3H]hypoxanthine
by L. mexicana amastigotes was mediated by a single high-affinity transporter,
LrnexNBTl, with a Km of 1.6 ± 0.4 J.1Mand high affinity for adenine, guanine and
xanthine but low affinity for nucleosides and pyrimidine nucleobases. Allopurinol, an
antileishmanial hypoxanthine analogue, was apparently taken up by the same
transporter. Using (3H]allopurinol, a Km value of 33.6 ± 6.0 J.1Mwas obtained. All
evidence was compatible with a model of a single purine nucleobase transporter being
expressed in amastigotes. Using various purine nucleobase analogues, a model for the
interactions between hypoxanthine and the transporter's permeant binding site was
constructed. The binding interactions were compared with those of the LmajNBTl
transporter in L. major promastigotes and found to be very similar. This work has, in
part, been previously published as AI Salabi et a1. (2005) Antimicrob. Agents.
Chemother. 49:3682-9 (see Appendix III).
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4.2 Results
4.2.1 Purine transport in axenic amastigotes of Leishmania
Total uptake of adenosine in axenic amastigote forms of L. mexicana was determined
using a rapid stop/oil spin protocol adapted from similar protocols with various other
protozoa (De Koning and Jarvis, 1997a; De Koning and Jarvis, 1999; De Koning, et el.,
2000b; Al Salabi, et sl., 2003; De Koning, et al., 2003; Chapter two). Figure 4.1 A
demonstrates that the transport of 1 11M[3H]adenosine transport was linear for at least
120 s at 0.021 ± 0.001 pmolfl O' cellsrs' (linear regression; 12 = 0.97). The addition of
1 mM unlabeled adenosine inhibited the uptake of 111M [3H] adenosine by 87% (12 =
0.99), indicating that the vast majority of adenosine transport occurs via a mediated
pathway (Figure 4.1A). These observations are consistent with the earlier report for
adenosine transporter in amastigote forms of Leishmania donovani (Ghosh and
Mukherjee, 2000).
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FIGURE 4.1 Linear purine transport in axenic amastigotes of Leishmania mexicana. A.
Timecourse of 1 ~M [3H]adenosine uptake by L. mexicana amastigotes in the presence
(D) or absence (.) of 1 mM unlabelled adenosine. B. Uptake of 1 ~M [3H]hypoxanthine
was linear over 120 s (12 = 0.97) as calculated by linear regression, in the presence (0) or
the absence (.) of 1 mM unlabelled hypoxanthine. C. Uptake of 1 ~M [3H]adenine was
linear over 120 s. (12 = 0.94) as calculated by linear regression, in the presence (D) or the
absence (.) of 1 mM unlabelled adenine. In some cases, an apparent positive intercept
can be observed for the time courses in the absence of inhibitor. This is most likely the
caused by extracellular binding of radiolabel, which is displaced by the including of 1
mM non-radiolableled substrate.
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Uptake of [3H]hypoxanthine at 1 ~M by the axenic amastigotes of L. mexicana was
linear for up to 120 s (Figure 4.l~ and faster than [3H]adenosine uptake. at 0.031 ±
0.001 pmol(107 cells)-Is-l(r = 0.98). In the presence of 1 mM unlabelled hypoxanthine.
[3H]-hypoxanthine transport was not significantly different from zero (P= 0.7. F-test).
indicating high affinity transport that is completely saturated at 1 mM. (3H]adenine
uptake (1 ~M) was likewise linear over 120 s, and the least efficiently accumulated of
the three purines tested at 1 ~M of label, with a rate ofO.012 ± 0.001 pmolflfl" cellsrts',
which was almost 95% inhibited by 1mM unlabeled adenine (Figure 4.1C). Subsequent
experiments were performed with [3H]hypoxanthine using 60 s incubations. well
within the linear phase of uptake and therefore measuring true initial rates of
transport.
4.2.2 A high affinity purine nucleobase transporter in amastigotes
[3H]Hypoxanthine transport (0.1 ~M) measured in the presence of up to 1 mM of
unlabelled hypoxanthine was monophasic and complied with simple Michaelis-
Menten kinetics. yielding a Km value of 1.6 ± 0.4 ~M and a Vmax value of 0.092 ± 0.057
pmol (107 parasites):' S-I(n = 4) (Figure 4.2 and inset). The variation in Vmax values was
considerably larger than that observed for the Km. This has been observed also in
previous studies (De Koning et al. 1998; Burchmore, et al. 2003; De Koning. et al.
2003) and can most probably be attributed to differences in transporter expression
levels under slightly different culture conditions (mid-log or late-log stage growth) (De
Koning, et al. 2000).
The transport of (3H]Hypoxanthine was inhibited by a range of purine nucleobases and
nucleosides (Table 4.1) but not sensitive to pyrimidines uracil. thymine. cytosine. and
uridine, which inhibited 0.1 JlM (3H]hypoxanthine transport by just 27 ± 7%. 41 ±
11%. 41 ± 15%. and 16 ± 2%. respectively. at 1 mM (n =3). The hypoxanthine
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transporter, designated L. mexicana nucleobase transporter 1 (LmexNBT1), appears to
be mildly selective for oxopurines over aminopurines, judging from the JG. values for
guanine and adenine (1.7 ± 0.1 and 4.2 ± 0.8 ).lM,respectively). None of the inhibition
plots suggested the presence of more than one hypoxanthine transporter in L. mexicana
amastigotes, as Hill slopes were consistently near -1 and complete inhibition to control
values (transport at 0 "C, 0 s) was generally observed.
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FIGURE 4.2 Transport of 0.1 ).lM [3H]hypoxanthine over 60 s was inhibited by the
indicated concentrations of unlabelled hypoxanthine with an ICso value of 0.81 11Mfor
this experiment. The inset depicts the conversion of the hypoxanthine inhibition data
to a Michaelis-Menten plot of total hypoxanthine uptake, with a Km value of 1.6 11M
and a Vrnax of 0.28 pmol(1Q7cellsjls" for this experiment.
4.2.3 [3H]allopurinol transport by L. mexicana amastigotes
Allopurinol is a close structural analogue of hypoxanthine and in L. major
promastigotes is indeed accumulated through the hypoxanthine transporter LmajNBTl
(AI Salabi, et sl., 2003). We therefore investigated whether a similar situation exists in
amastigotes. As L. major amastigotes cannot be kept in axenic culture, we used
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amastigotes from L. mexicana. Using these cells, transport of allopurinol was clearly
less efficient than of hypoxanthine, with a rate for 5 JlM [3H]allopurinol of 0.0061 ±
0.0002 pmolt l O?cellsrs' (linear regression of 6 points over 4 minutes; r = 0.99), which
was completely inhibited by 1 mM hypoxanthine (uptake not significantly different
from zero; P = 0.33, F-test). Transport of [3H]allopurinol (5 JlM) was still detectable,
however, in the presence of 1 mM unlabelled allopurinol (0.00052 ± 0.00014 pmolf IO"
cellsrs' (linear regression of 5 points over 10 minutes; P= 0.03, F-test), though greatly
reduced. These results indicate that the allopurinol transporter has a higher affinity for
hypoxanthine than for allopurinol.
L. mexicens amastigotes L. majorpromastigotes
[3H]-hypoxanthine [3H]-allopurinol [3H]-adenine [3H]-allopurinol
Km' 1.6 ± 004 4 33 ±6.0 3 4.6 ±0.9 3 54 ± 2.9 3
Vmaxb 0.092± 0.05 4 0.051 ± 0.01 3 3.2 ±0.3 3 0.24 ± 0.06 3
Adenine! 4.2 ± 0.8 5
Hypoxanthine! 3.8 ±0.6 3 1.3 ± 0.3 3 0.30 ± 0.09 3
Guanine! 1.7 ± 0.1 4 2.8±0.7 4
Xanthine! 13 ± 2 3 23 ±8 3
AllopurinoP 39±6 3 56 ± 1.5 3
AminopurinoF 170 ± 20 4 ND
Purine! 3.4 ± 0.2 3 6.7 ± 0.4 3
1-Deazapurine? 54±5 3 26 ± 4.1 3
3-Deazaguanine 130 ± 14 3 48 ± 5.0 3
6-Thioguanine! 10 ± 1.2 3 6.2 ±0.8 3
7-Deazaguanine >1000 3 430 ± 140 3
9- Deazaguanine 204 ± 28 4 204±4 3
Adenosine! 950 ± 240 3 5150 ± 550 3
Inosine! 380± 26 3 125 ± 15 3
Guanosine! 210 ± 48 3 68 ± 17 4
TABLE4.1 Kinetic constants of purine nucleobase uptake in L. mexicana amastigotes
and L. major promastigotes. Kinetic parameters were determined through competitive
inhibition of [3H]-hypoxanthine (amastigotes) or [3H]adenine (promastigotes). In a few
cases, extrapolation was required due to limitations of solubility of the inhibitor and
based on the assumption of a Hill slope of -1 and eventual 100% inhibition.
Extrapolation was not attempted when inhibition at the highest inhibitor
concentration was < 50%. Permeant concentration was 2 JlM (allopurinol) or 0.1 - 0.5
I-LM(hypoxanthine), except for determinations of Km. (data for L. major promastigotes
was taken from (Chapter three). a expressed in JlM, bexpressed as pmolf lf)? cellslls'.
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Competition experiments showed that transport of 2 J.lM[3H]allopurinol over 120 s was
indeed inhibited more strongly by hypoxanthine than by allopurinol (Figure 4.3A),
with a K: value of 3.8 ± 0.6 J.lM for hypoxanthine and a Km of 33 ± 6.0 f.lM for
allopurinol (n = 3)(Figure 4.3~. These data are all consistent with a single high-affinity
transporter for purine nucleobases including allopurinol. While the Vmax values of
LmexNBTI for hypoxanthine and allopurinol are similar (Table 4.1), the efficiency of
uptake, expressed as .Kn/ Vmax, is considerably higher for hypoxanthine.
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FIGURE 4.3 Transport of (3H]allopurinol by L. mexicana amastigotes. A. Inhibition of 2
f.lM(3H]allopurinol transport over 120 s by up to 100 J.lMof unlabelled allopurinol (.)
or hypoxanthine (0). B. Michaelis-Menten plot of allopurinol uptake, derived from the
data in frame A.
4.2.4 Structure-activity relationships of purine analogues and the LmexNBTl
The inhibitory effects of purine analogues for LmexNBTl were tested by measuring
initial uptake rates of 0.1 11M [3H]hypoxanthine in the presence of varying
concentrations of the test compound. Results were plotted as log inhibitor
concentration versus hypoxanthine uptake and Ki values, calculated from the ICso
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values, were used to calculate the estimated Gibbs free energy of binding L1Go
(reviewed by De Koning, et el., 2005). The results, summarized in tables 4.1 and 4.2,
show that the LmexNBT1 transporter shows broad specificity for purine nucleobases
but displayed low affinity for the corresponding nucleosides.
LmexNBT1 displayed equal affinity for guanine (Figure 4.4A) and hypoxanthine
(Figure 4.2), showing that the 2-amino group of guanine did not contribute to binding,
nor posed a steric hindrance to binding. However, affinity for xanthine (Figure 4.4A)
was markedly reduced (B(L1GO) = 5.5 kl/mol compared to hypoxanthine). As this is
unlikely to be the result of steric hindrance at position 2, this must be the result of
protonation of the pyrimidine nitrogen at position 3 of the purine ring that occurs in
xanthine.
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FIGURE4.4 Inhibition of 0.1 ~M [3H]hypoxanthine uptake in axenic amastigotes of L.
mexicana by A: guanine (.), xanthine (D) and 3-deazaguanine (~). B: 6-thioguanine
(a), 7-deazaguanine (D) and 9-deazaguanine (A). C: Purine (.), adenine (D) and 1-
deazapurine (0). Data were expressed as percent of control being uptake in the absence
of any inhibitor, typically 0.005 - 0.02 pmoV1Q7 cells/s), showing total hypoxanthine
transport as opposed to [3H]hypoxanthine transport only.
A comparison between guanine and 3-deazaguanine (Figure 4.4A) shows that the
unprotonated N3 contributes 11.2 kl/mol to the binding energy of guanine (Table 4.2).
As only 5.5 kj/mol is lost in xanthine it can be postulated that weak hydrogen bonds
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Compound ~(GO) 5(~GO) Control
Hypoxanthine -34.4
Adenine -31.9 2.5 Hypoxanthine
Allopurinol -26.2 8.2 Hypoxanthine
Aminopurinol -22.3 9.6 Adenine
Xanthine -28.9 5.5 Hypoxanthine
Guanine -34.2 0.2 Hypoxanthine
Inosine -20.3 14.1 Hypoxanthine
Adenosine -17.9 14.0 Adenine
Guanosine -21.9 12.3 Guanine
Purine -32.5 -0.6 Adenine
1-Deazapurine -25.3 7.2 Purine
3-Deazaguanine -23.0 11.2 Guanine
6-Thioguanine -29.7 4.5 Guanine
7-Deazaguanine >-18 17.2 Guanine
9-Deazaguanine -21.9 12.3 Guanine
TABLE 4.2 Gibbs free energies (kl/mol) of substrate interacting with LmexNBTl
transporter. Gibbs free energy of substrate-transporter interactions was calculated from
the Km and IG values listed in Table 1, using the Nernst equation as described (De
Koning and Jarvis, 1999; Wallace, et al., 2002). The difference with a control
compound, either hypoxanthine as the highest affinity compound, the corresponding
physiological nucleobase (in the case of chemical analogues) or (in the case of
nucleosides) the corresponding nucleobase yielded the O(.1GO),the loss in binding
energy relative to the control compound.
totalling - 6 kj/rnol can be established between the LmexNBTl binding pocket and
N(3)H and/or the 2-keto group of xanthine. From inhibition plots with 9-deazaguanine
(Figure 4.4.8), the Gibbs free energy of H-bonds with N(9)H was similarly estimated at
-12.3 (Table 4.2). The IG-value for 7-deazaguanine could not be clearly determined,
due to very low affinity and solubility limitations, but is shown to be over 1 mM,
which would indicate a O(.1GO)> 15 kj/mol for N(7). Furthermore, the substitution of
the 6-keto group for a thione group (6-thioguanine) reduced the .1Goby 4.5 kj/mol (6-
thioguanine vs guanine; Figure 4.4.8). This could be an indication of a hydrogen bond
interacting with the keto group, as thiones are much weaker H-bond acceptors (Pitha,
et al., 1975), though the possibility of a steric effect by the larger sulfur atom provides
an alternative explanation. Indeed, the 8(~GO) between hypoxanthine and purine,
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which lacks both the 6-keto and lactam hydrogen on NI, is only 1.9 kl/mol (Table 4.2).
However, this needs to take into account the strong hydrogen bond with the
pyrimidine NI, estimated at 7.2 kl/mol from the comparison between purine and 1-
deazapurine (Figure 4.4G), bringing the actual contribution of the 6-ketolN(I)H
combination to 9.1 kl/mol of which 4.5 kl/mol could be tentatively assigned to the keto
group from the o(~GO)of 6-thioguanine. Finally, adenine (Figure 4.4G) and purine
proved to have the same affinity for LmexNBTI (Table 4.1), confirming the preference
for a hydrogen bond acceptor at position 6 of the purine ring. The above observations
were combined into a model for the binding of purine substrates by LmexNBT1 and
compared to the model for substrate binding by the equivalent transporter of L. major
(Figure 4.5).
L mqjor NBTl L mexicana NBTl
FIGURE 4.5 Schematic representation of the LmajNBT1 (A) and LmexNBTI (B)
transporters and the interactions with their permeants, adenine and hypoxanthine.
Estimated Gibbs free energy for proposed bonds are indicated as - kj/mol. The model
for LmajNBT1 was adapted from (AI Salabi, et al, 2003).
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4.2.5 Antileishmanial activity of some nucleobases analogyes
Allopurinol is well known to possess antileishmanial activity but we previously noted
that, at least in promastigotes, aminopurinol and the pyrimidine nucleobase 5-
fluorouracil displayed substantially higher activity (Papageorgiou, et al., 2005). We
therefore tested the same compounds on the human-infective amastigotes stage, using
pentamidine as positive control and the same technique based on the fluorophore
Alamar Blue (Figure 4.6). The method was validated using cell counts in parallel to the
fluorescence assay, yielding the same ICsovalues (Figure 4.6, inset). As with L. major
promastigotes, aminopurinol and 5-fluorouracil were 1O-20-fold more active against
axenic 1.mexicana amastigotes than allopurinol. ICsovalues (J..lM,n = 3) were 5.6 ± 1.0,
630 ± 87, 65 ± 5 and 36 ± 6 for pentamidine, allopurinol, aminopurinol and 5-
fluorouracil, respectively.
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FIGURE 4.6 Effect of various drugs on L. mexicana amastigotes in axenic culture.
Amastigotes (2xlOS) were incubated with doubling dilutions of pentamidine (a),
allopurinol (D), aminopurinol (~) and 5-fluorouracil (0) for 72 h and for an additional
48 h in the presence of Alamar Blue reagent as described in Chapter two. EDsovalues
for pentamidine determined by fluorescence or cell counts (inset) were identical.
106
CHAPTER Iv.NUCLEOBASE TRANSPORT 1NL. MEXICANA AMASTIGOTES
4.3 Discussion
Purine and pyrimidine antimetabolites are widely used to combat a variety of
infectious diseases and other pathologies (De Koning and Diallinas, 2000). Current
evidence indicates that purine analogues alone or in combination with other
chemotherapeutic agents are very effective against almost any fast growing cells (El
Farrash, et sl., 2003; Namazi, 2004). Allopurinol, a purine analogue, has been used to
treat leishmaniasis alone (Pfaller and Marr, 1974; Marsden, et sl., 1984) or combined
with other drugs (Martinez and Marr, 1992; Martinez, et sl., 1997; Denerolle and
Bourdoiseau, 1999; Momeni, et sl., 2002; Pasa, et al, 2005). It should be pointed out,
however, that the efficacy of allopurinol monotherapy remains unclear. A large-scale
WHO-sponsored randomized trial showed no difference between allopurinol and
placebo-treated groups (Velez, et el., 1997) and it may be that the value of allopurinol
in the treatment of leishmaniasis is solely by synergistically enhancing the action of
other treatments and there is much, though largely anecdotal evidence for this. One
such report, by Chunge and colleagues (Chunge, et el., 1985) describes the treatment of
5 patients with visceral leishmaniasis unresponsive to sodium stibogluconate that were
cured by a combination of the same drug plus additional allopurinol. In vitro as well,
allopurinol has been reported to augment the antileishmanial effects of pentavalent
antimonials (Berman and Lee, 1983). Other pyrazolopyrimidines such as 9-
deazainosine displayed favorable therapeutic indexes in L. donovani-infected hamsters
(Berman, et sl., 1987) and also offer promise as potential chemotherapeutic agents
(Marr, et sl., 1984). However, it is widely acknowledged that the potential for
damaging side effects can pose a challenge to the development of purine-based drugs
(El Kouni, 2003).
The selectivity and efficacy of purine antimetabolites can be achieved through the
enzymes of the purine metabolic pathways that convert the pro-drug to the cytotoxic
metabolite, usually a nucleotide analogue, and understanding substrate specificity of
the enzymes involved is important in both drug efficacy and selectivity. The
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metabolism of allopurinol in Leishmania species to the active metabolite 4-
aminopyrazolo(3,4-~pyrimidine ribonucleoside triphosphate, which is incorporated
into RNA, has been well studied (Marr, et al, 1978; Nelson, et al, 1979a; Marr, 1983;
Marr and Berens 1983). The drug is selective because mammalian cells do not show this
conversion or incorporation (Nelson, et al.• 1973).
In addition. many antiprotozoal drugs achieve their selectivity through uptake by cell-
surface transporters on the target cell rather than the host's cells (De Koning, 2001).
The main human nucleobase transporter, hFNT1, displays very low affinity for
allopurinol (Razavi, et al.• 1993; Wallace. et al, 2002), whereas allopurinol uptake in
Trypanosoma bruceiwas mediated by high affinity nucleobase transporters (De Koning
and Jarvis. 1997a;Natto, et sl., 2005). We have demonstrated that a strategy of purine-
based chemotherapy, designed for specific uptake by protozoan parasites, is feasible and
depends on detailed knowledge of the substrate recognition motifs of the respective
transporters (Wallace, et al, 2002;Wallace, et sl., 2004; De Koning. et al. 2005).
The characterizations of [3H]hypoxanthine, [3H]allopurinol and [3H]uracil transports in
L. majorpromastigotes have recently been reported (Chapter two; Papageorgiou, et al.,
2005), but the presence of nucleobase transporters in amastigotes has not yet been
reported. The issue is important in understanding the selectivity of the drug as well as
the potential for the development of resistance as allopurinol-resistant Leishmania lines
have been described (Cavaliero, et al. 1999; Kamau, et el., 2000) and appears to be
easily inducible. We consider that this resistance might be related to loss of transporter
function as allopurinol was taken up by a single nuc1eobase transporter in L. major
promastigotes (AI Salabi, et sl., 2003), in sharp contrast to the situation in T. b. brucei,
where the presence of multiple allopurinol transporters appears to preclude transport-
related resistance (Natto, et sl., 2005). We have therefore conducted a study of purine
nucleobase uptake in Leishmania mexicana amastigotes, with particular emphasis on
allopurinol uptake. We found that hypoxanthine and allopurinol are taken up by a
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single plasma membrane transporter, LmexNBTl, and characterized its substrate profile
in detail.
LmexNBTl proved extremely similar to LmajNBTl. A comparison of their substrate
binding models (Figure 4.5) reveals that the positions and even the relative strengths of
the hydrogen bonds are almost identical between the two transporters, suggesting a
very similar architecture for the two transporters. This level of conservation is
remarkable in that it signifies conservation both throughout the lifecyc1e and between
Leishmania species from different continents. Furthermore, the binding site
architecture of these transporters appears to be very similar to that of the 112
hypoxanthine/allopurinol transporter in bloodstream T. b. brucei, but very different
from the binding motif of hFNTl (AI Salabi, et sl., 2003; Wallace, et sl., 2004). This
suggests that these related kinetoplastids would accumulate similar purine
antimetabolites, which could be designed to be excluded from human cells. At this
moment, none of the genes for these transporters involved have been identified with
any certainty, precluding an assessment of whether the high level of functional
conservation between the various T. brucei and Leishmania transporters are matched
by genetic conservation. However, all protozoan purine transporter genes cloned to
date were members of the Equilibrative Nucleoside Transporter family (De Koning, et
al, 2005) and the percentage identity between the T. h. bruceiTbNBTIIH4 or TbNT8.1
nuc1eobase transporters and the L. major LmNT3 nucleobase transporter was only 50%
(Burchmore, et el, 2003; Henriques, et sl., 2003; Sanchez, et sl., 2004b).
LmexNBTl showed only moderate affinity for allopurinol and aminopurinol. Yet, it
seems unlikely that transport rates are a limiting factor in the efficacy of
pyrazolopyrimidines against leishmaniasis, the conversion to the aminopurinol riboside
triphosphate being a more likely bottleneck: aminopurinol, despite having lower
affinity for LmexNBTl, was tenfold more active against axenic amastigotes in culture.
Nelson and coworkers reported the direct incorporation of aminopurinol into the
aminopurine nucleotide pool, and subsequently into the RNA, of both Leishmania and
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T. cruzi (Nelson, et al, 1973b; Marr, et al, 1978; Nelson, et al., 1979a) by means of
phosphoribosylation - a conversion that does not happen in humans (Nelson, et sl.,
1973).
This begs the question as to why aminopurinol has not been used against leishmaniasis,
particularly as it has been long known that aminopurinol is more potent than
allopurinol against Leishmania promastigotes in vitro (Avila, et sl., 1982) as well as T.
cruziin mice (Avila, et sl., 1983). In mammals, aminopurinol is used as an experimental
drug, which reduces the release of lipoproteins by the liver, lowering plasma
cholesterol levels (Shiff, et el., 1971). Chronic use, however, induces a 'fatty liver'
(Murakoshi, et al, 1985) and adrenal cell hypertrophy by depleting adrenal cholesterol
(Kovanen, et al, 1980;Mazzocchi, et al., 1988).Aminopurinol given to mice for 10 days
at 1 mglkg induced no toxic effect, but an increase to 10 mglkg caused high mortality
rates and hepatomegaly (Avila, et al, 1983).A toxicological study in rodents, dogs and
cats found tolerance to high single doses of aminopurinol but mouse LDso values of 25
mglkg when 5 consecutive daily doses were given (Philips, et el., 1956). The
hepatotoxic effects lead to the abandonment of aminopurinol as a potential anti-
leukemia drug (Shaw, et al, 1960), but levels active against T. cruziin mice (Avila, et
al, 1983)were found to be non-toxic to humans (Shaw, et al, 1960).
In summary, we have undertaken the first study of nucIeobase transport in Leishmania
amastigotes and identified a high affinity nucIeobase transporter that is responsible for
the uptake of allopurinol and other purine bases. As the evidence is consistent with a
model for a single hypoxanthine/allopurinol transporter, the potential for the rapid
development of allopurinol resistance by loss of such a transporter would appear to be a
potential concern. However, the use of purine analogues in combination chemotherapy
with another antileishmanial may well be synergistic and prevent or even overcome
early onset of resistance to either drug.
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THE SUBSTRATE RECOGNITION MOTIF OF THE H4 NUCLEOBASE TRANSPORTER IN
TRYPANOSOMA BRUCEI PROCYCUCS EXPLAINS ITS BROAD SPECIFICITY
CHAPTER V.NUCLEOBASE TRANSPORTER INTRYPANOSOMA BRUCEI PROCYCUCS
5.1 Summary
The mechanism of purine nucleobase transport in bloodstream forms of the protozoan
parasite Trypanosoma brucei brucei was previously investigated, and two different
hypoxanthine transporters, H2 and H3, were identified. Itwas found that these distinct
systems had different affinities and substrate specificities. The H2 transporter displayed
a much higher affinity and a broader specificity than H3 (respective apparent Km values
of 123 ± 15 nM and 4.7 ± 0.9 11M, and Vmax values of 1.1 ± 0.2 and 1.1 ± 0.1 pmol(10'
cells)? S-I, respectively. For instance, the H2 transporter was inhibited by purine
nucleobases and analogues as well as by some pyrimidine nucleobases such as uracil
and one nucleoside guanosine, whereas H3 was not inhibited by any nuc1eosides or
pyrimidines (De Koning and Jarvis, 1997b).
Prior to the findings of this study, purine nuc1eobase transport in procyc1ic T. b. brucei
had been studied, and it was thought that only one distinct hypoxanthine transporter,
named HI, was expressed in this stage of the life cycle. HI displayed Km and Vmlx values
of 9.3 ± 2.0 11Mand 4.5 ± 0.8 pmolfl O' cells)'! S-I, respectively and possessed high
affinity for all natural purine nuc1eobases such as adenine, guanine, and xanthine as
well as the purine analogue allopurinol with Kivalues of 3.6 11M,1.8 11M,7.2 11M,and
5.0 11Mrespectively. This transporter was not inhibited by nucleosides and pyrimidine
nucleobases (De Koning and Jarvis, 1997a).
A recent study from our group has led to the identification of the gene TbNBTJ from
Trypanosoma brucei brucei. This gene encodes a 43S-residue protein of the
Equilibrative Nucleoside Transporter family (Burchmore, et sl., 2003). The gene was
expressed in both the procyclic and bloodstream forms of Trypanosoma brucei.
Expression of TbNBTl in a Saccharomyces cerevisise strain lacking an endogenous
purine transporter allowed growth on adenine as sole purine source and introduced a
high affinity transport activity for adenine and hypoxanthine, with Km values of 2.1 ±
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0.6 and 0.66 ± 0.22 flM, respectively, as well as high affinity for xanthine, guanine,
guanosine, and allopurinol and moderate affinity for inosine.
As mentioned above, the HI was thought to be the only nucleobase transporter present
in procyclic forms of Trypanosoma brucei. However, the nuc1eobase transporter
characterized in yeast expressing TbNBTI possessed> Hl-fold higher affinity than HI
and was expressed in procyclics. Thus, there was a need to re-investigate the
hypoxanthine uptake systems using very low concentrations of [3H]hypoxanthine in
procyclic forms of Trypanosoma brucei Using these conditions, we detected a
previously unknown high affmity transport activity, which we designated H4, and
reconfirmed the presence of the lower affinity HI transporter.
In this chapter, we report the identification and characterization of this novel
nuc1eobase transporter Trypanosoma brucei procyclic forms. The kinetics profile
obtained from the characterization of H4 was identical to the one observed in parallel
from the yeast-expressed nucleobase transporter TbNBTl. Moreover. introduction of
tetracycline-inducible RNAi constructs in procyclic trypanosomes, reduced H4-activity
by -90%. These finding confirmed that the TbNBTl gene encodes the first high affinity
nucleobase transporter from protozoa to be identified at the molecular level and that
H4 is likely to be the gene product of TbNBT1.
5.2 Results
5.2.1 Characterization of two hypoxanthine transporters in procyclic z: brucei
Total uptake of a final concentration of 30 nM (3H]hypoxanthine in procyclic forms of
Trypanosoma brucei was examined using a rapid-stop oil-spin technique (De Koning
and Jarvis. 1997a). All experiments were performed using an incubation time of 30 s,
within the linear phase of uptake and therefore measuring true initial rates of
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transport. The uptake of 30 nM (3H]hypoxanthine measured in the presence of 0-1000
~M of unlabeled hypoxanthine revealed the presence of two distinct hypoxanthine
transporters in T. b. brucei procyclic cells (Figure 5.1). A previously reported lower
affinity transporter, HI (De Koning and Jarvis, 1997a), was observed alongside a higher
affinity hypoxanthine transport activity, which we designated H4. In the current set of
experiments, conducted at 30 nM [3H]hypoxanthine, HI and H4 activities were
separated by fitting inhibition plots to an equation for two-site competition (Figure
5.1A) and to Eadie-Hofstee plots (Figure 5.1.8), which produced kinetic constants in
good in agreement with each other. Under these conditions, the kinetic constants for
HI were very similar to those previously reported (De Koning and Jarvis, 1997a).
Figure 5.1 also shows that the uptake was saturable, with Km and Vm.x values of 15.2 ±
2.3 JlM and 2.4 ± 0.7 pmolflfl" cells)? S-I, respectively, for the lower affinity HI
component (mean values from seven separate experiments). Although the H4
transporter has a lower Vmax (0.27 ± 0.08 pmol (107 cells)" S-1 (n = 7», it was generally
responsible for >85% of (3H]hypoxanthine transport at 30 nM of label, due to its much
higher affinity for hypoxanthine (Km = 0.55 ± 0.07 JlM (n = 7).
To further investigate the presence of the two transporters, inhibition experiments
were performed on the uptake of 30 nM (3H]hypoxanthine in procyclic forms of
Trypanosoma brucei to study the selective inhibitors of H4. Uracil and guanosine do
not inhibit HI-mediated [3H]hypoxanthine transport up to 1 mM (De Koning and
Jarvis, 1997a), but dose-dependently inhibited H4 activity (Figure 5.lA). However,
affinities for adenine, guanine, xanthine, and allopurinol were similar for HI and 114
(Table 5.1 and De Koning and Jarvis, I997a). The Km value of H4 was also significantly
higher than previously reported for the T. b. brucei H2 transporter characterized in
bloodstream forms (De Koning and Jarvis, I997b) (H4 = 0.55 ± 0.07 JlMand H2 =0.12 ±
0.01 JlM; P < 0.01, unpaired Student's ttest). In addition, affinity for guanine was lower
and for inosine higher for H4 than for H2 (p < 0.05). Most significantly, however,
substitutions of N3 or N7 in guanine for CH (3-deaza- and 7-deazaguanine) have been
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shown to reduce affinity for H2 by 28- and 150- fold, respectively (Wallace, et al,
2002), but had little or no effect on affinity for H4 (Figure 5.2 and Table 5.2).
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FIGURE5.1 Hypoxanthine transport in Procyclic cells of strain 427 of T. b. brucei. A
shows the uptake of 30 nM [3H]hypoxanthine for 30 s, in the presence or absence of
various concentrations of unlabeled hypoxanthine (a), uracil (.), or guanosine (0).
Only the plot with hypoxanthine fitted a two-component inhibition model
significantly better than a model for a single transporter (p = 0.02, Ftest). B shows the
data with unlabeled hypoxanthine converted to an Eadie-Hofstee plot, showing two
transporter activities with Km values of 0.64 and 18.8 ~M, respectively, and Vmax values
of 0.22 and 2.7 pmolf lO? cells):" S-I, respectively. v, rate of [3H]hypoxanthine transport;
[s], permeant concentration.
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FIGURE5.2 Inhibition of 100 nM [3H]hypoxanthine uptake in Procyclic cells of strain
427 of T. h. brucei by increasing concentrations of unlabeled guanine (.: ICso= 4.2
J.LM),3-deazaguanine (0; ICso= 4.3 J.LM),or adenosine (.; ICso= 714 J.LM),and expressed
as percentage of control (no inhibitor).
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These results establish that H4 is a previously unknown transporter, distinct from either
HI or H2, and indeed from H3, which is a relatively low affinity hypoxanthine
transporter in T. b. b111ceibloodstreamforms (De Koning and Jarvis, 1997b).
5.2.2 Effect of TbNBTJ RNAi on H4 transport activity
Further evidence that TbNBTJ encodes the H4 transport activity derives from
experiments with RNAi. T. b. brucei procyclics were transformed with the vector p2T7
(LaCount, et sl., 2000), containing a 0.6-kb fragment of the TbNBTJ ORF under the
control of the tetracycline-inducible promotor. Northern blots revealed that TbNBTJ
mRNA levels in these cells were - 80% reduced after 5 days incubation with 1 pg/ml
tetracycline (Figure 5.3; Burchmore, et sl., 2003). Incubation with tetracycline also
greatly reduced the transport rate of the high affinity hypoxanthine transporter, and
while the Km did not significantly differ between tetracycline exposed and control cells
(0.24 ± 0.06 versus 0.17 ± 0.04 ~M), the Vrnax was reduced from 3.2 ± 0.2 to 0.20 ± 0.04
pmol (107 cells):" S-I (Figure 5.4).
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FIGURE5.3 High stringency hybridisation with TbNBTJ ORF. Genomic DNA of T b.
brucei strain 927, digested with the indicated restriction enzymes (A), total T. b. brucei
RNA (B) or total RNA from T. b. brucei strain 29-13, transformed with p2T7TbNBTl
(G) was isolated and hybridised with the TbNTJ ORF. Fragment sizes are indicated in
kb. The blots were washed with 0.1 x SSC at 60°C. BS, bloodstream forms; PC,
procyclics. Reproduced from Burchmore et a1.(2003).
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FIGURE 5.4 Effect of TbNBTJ RNAi on H4 transport activity. Expression of a double-
stranded RNAi fragment of TbNBTJ in T b. brucei procyclics was induced by
tetracycline. A. Transport of 0.1 ~M [3H]hypoxanthine in the induced (0) and
uninduced control (.) cells was measured over 30 s in the presence of 0-1 000 ~M of
unlabeled hypoxanthine. B. shows the conversion to a Michaelis- Menten plot. Km and
Vrnax values were 0.34 ± 0.14 ~M and 0.090 ± 0.011 pmolt IO?cells):" S-1 for the induced
cells and 0.25 ± 0.07 ~M and 1.07 ± 0.08 pmolfl O?cells):' S-1 for the uninduced control
cells.
5.2.3 Kinetic parameters of TbNBTJ in yeast and H4 in procyclic
The results described in the previous sections led to the working hypothesis that the
TbNBTJ gene encodes the H4 nucleobase transport activity. It must be pointed out,
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however, that the RNAi result is not entirely conclusive, as it has become clear, on
completion of the T. b. brucei genome, that the genes probably encoding the other
purine nucleobase transporters are very similar to TbNBTl (reviewed in De Koning, et
sl., 2005) and could have been affected by the rather large fragment used in the NBT1
RNAi experiment. We therefore made a detailed comparison of the selectivity profile
ofH4 and the TbNBTl activity expressed in yeast (Table 5.1). No significant differences
were found between the two sets of data, which are also depicted as a bargraph in
Figure 5.5. Though this approach cannot in itself be conclusive, it adds further weight
to the hypothesis. Final proof awaits the construction of a genetic knockout strain
lacking any copies of TbNBTl.
NBTI in Yeast. H4 in procyclics
[Kior Km] [Kior Km]
compound Avg SE n Avg SE n
Hvpoxanthine" 0.66 0.22 4 0.55 0.07 7
Adenine 2.1 0.6 3 2.6 0.4 3
guanine 1.4 0.3 3 2.6 0.6 3
xanthine 4.3 1.1 3 4.5 0.5 3
allopurinol 5.4 1.1 3 2.5 0.4 3
uracil 68.0 6.5 4 94.8 27.4 4
thymine NDb 293.0 62.0 3
cytosine NDb 1251.0 6.0 2
adenosine 1898.4 986.5 3 865.0 177.0 3
inosine 47.4 17.2 4 20.2 7.3 3
guanosine 5.3 1.5 3 4.7 1.4 4
3-Deazaguanine NDb 2.0 0.3 3
7-Deazaguanine NDb 4.9 0.4 3
TABLE5.1 Kinetic constants of TbNBTI expressed in yeast and for the H4 transport
activity in procyclic T. b. brucei. Km or IG·values in yeast were determined using either
0.1 11M[3H]adenine or [3H]hypoxanthine as radiolabel for f(j determinations and 25 nM
radiolabel to measure Km values. Experiments with procyclics used 30 or 100 nM
[3H]hypoxanthine for the determination of .Km and f(j values, respectively, and an
incubation time of 30 s. .Km values were derived from Michaelis- Menten or Eadie-
Hofstee plots; IVvalues were derived from ICso values as described previously (Wallace,
et el., 2002). a Km values. b ND, not determined.
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FIGURE 5.5 Kinetic constants of TbNBTl expressed in yeast and for the H4 transport
activity in procyclic T. b. brucei. .Km or JG values in yeast were determined using either
0.1 11M[3H]adenine or [3H]hypoxanthine as radiolabel for J(; determinations and 25 nM
radiolabel to measure .Km values. Experiments with procyclics used 30 or 100 nM
[3H]hypoxanthine for the determination of Km and JG values, respectively, and an
incubation time of 30 s.
5.2.4 Substrate recognition motifs of the T. b. broceiH4
The way the T. b. brucei H2 transporter binds hypoxanthine has been previously
described (Wallace, et sl., 2002). Our similar studies described the recognition motifs of
the purine nucleobase transporter in Leishmania major promastigotes LmajNBTl, the
nucleobase transporter of 1. mexicana amastigotes LmexNBTl (Al-Salabi and De
Koning, 2005) and the human FNTI nucleobase transporter (Al-Salabi, et al., 2003;
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Wallace, et sl., 2002). Apart from the obvious pharmacological advantages of
understanding what potential antimetabolites may be transported by pathogen and
cells, these models provide a functional fingerprint for the transporter, regardless of
whether it has been cloned or not. We were thus able to conclude that the LmajNBTl
and TbH2 nuc1eobase transporters were functional homologues, but bound their
substrates entirely different form the corresponding human transporter. It was
therefore of interest to see whether the essential architecture of substrate binding
would be preserved by a further member of the kinetoplastid nucleobase transporter
family.
Certain differences with the H2 binding motif are quickly obvious. Firstly, there was
no significant contribution through N3, as the Ki values of guanine and 3-deazaguanine
were almost identical (Figure 5.2 and Table 5.2). Similarly, the difference in Kivalue of
guanine with 7-deazaguanine was not statistically significant and at most 2-fold,
leading to a o(AGO)of just 1.6 kl/mol, Nor were Ki values of adenine and purine, or 6-
thioguanine and guanine statistically different, excluding important interactions with
position 6 of the purine ring of adenine or hypoxanthine.
However, the difference between J-deazapurine and purine was highly significant (P<
0.01; unpaired T-test), leading to an estimated 2.5 kl/mol for an interaction with the
unprotonated NI of adenine. As the Gibbs free energy of binding of hypoxanthine
exceeds that of adenine by 3.9 kj/mol, the unprotonated NI hydrogen bond profits only
adenine, and the keto group of hypoxanthine does not significantly contribute to
binding, the protonated Nl(H) must be 6.4 kl/mol. Furthermore the o(AGO)between
guanine and 9-deazaguanine of3.4 kJ/mol (P< 0.01; unpaired z-test) indicates a role for
N9(H) in binding purines.
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I1d
Kmor Ki SE B[l1d]
Compound [kj/mol]
n control
hypoxanthine 35.7 7 0.55 0.07
adenine 31.9 3 2.63 0.41 -3.88 hypoxanthine
guanine 31.9 3 2.56 0.56 -3.81 hypoxanthine
xanthine 30.3 3 4.98 0.53 -5.46 hypoxanthine
allopurinol 32.0 3 2.48 0.39 -3.73 hypoxanthine
uracil 23.0 4 94.8 27.4 -7.31 xanthine
thymine 20.2 3 293 62 -10.10 xanthine
cytosine 16.6 2 1251 6.00 -19.16 hypoxanthine
adenosine 17.5 3 865.0 177.0 -18.25 hypoxanthine
inosine 26.8 3 20.2 7.3 -8.93 hypoxanthine
guanosine 30.4 4 4.71 1.41 -1.51 guanine
3-deazaguanine 32.6 3 1.98 0.28 0.64 guanine
6-thioguanine 33.6 3 1.31 0.14 1.66 guanine
purine 30.1 3 5.27 1.00 -1.72 adenine
l-deazapurine 27.6 3 14.5 0.36 -2.51 purine
7-deazaguanine 30.3 3 4.90 0.42 -1.61 guanine
9-deazaguanine 28.5 3 10.0 1.1 -3.38 guanine
4-(3H)-pyrimidone 23.0 3 95.3 15.7 -12.78 hypoxanthine
5,6-dihydrouracil 10.9 3 12428 2833 -12.09 uracil
1-deaza5,6dihydrouracil 2 >10 000
2-amino purine 31.7 3 2.81 0.70 1.55 purine
06-methylguanine 33.2 3 1.53 0.48 1.52 2-aminopurine
TABLE 5.2 Gibbs free energies (kl/mol) of substrate interacting with Trypanosoma
brucei brucei procyclic H4. Gibbs free energy of substrate-transporter interactions was
calculated from the .Km and IV values, using the Nernst equation as described in
Materials and Methods. The difference with a control compound, either hypoxanthine
as the highest affinity compound or guanine, yielded the o(~GO), the loss in binding
energy relative to the control compound.
The interactions at NI and N9, and a possible weak contribution at N7, however, do
not provide the total hypoxanthine binding energy of 35.7 kl/mol calculated from the
Km value. It must therefore be surmised that the balance is the result of rt-stacking. a
common phenomenon for purines, which are completely flat and have a completely
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conjugated 1t-electron system. This is particularly hard to investigate using the
technique employed here. but one indication is given by the B(~GO) of 12.8 kl/mol
between hypoxanthine and 4-(3H)-pyrimidone. The latter molecule lacks the
imidazole part of hypoxanthine and thus any contributions from H-bonds at N9(H) and
N7. totalling at most 5 kl/mol. The remaining 7.8 kl/mol could only be the contribution
of the imidazole ring to rt-stacklng. It is likely that at least two aromatic amino acids in
the H4 binding pocket contribute to the binding of hypoxanthine.
In conclusion. it appears that H4 binds it substrate significantly different from H2.
employing x-stacking. rather than H-bonding, more widely. In particular. the H-bond
with N3 is absent in H4 and can be considered a distinguishing mark of this
transporter. among other protozoan nucleobase transporters analysed to date.
5.3 Discussion
Work from our group recently showed that the ENT-family gene TbNBT1, when
expressed in yeast. encodes a nuc1eobase transporter. with highest affinity for
hypoxanthine and adenine. which are transported efficiently (Burchmore, et al. 2003).
High affinity was also displayed for the other naturally occurring purine nucleobases,
guanine and xanthine. Interestingly. the kinetic profile. displaying a Km of 0.66 ± 0.22
J.1Mfor hypoxanthine did not match any of the known nucleobase transporters of T. b.
brucei. This chapter describes the identification of a novel nucleobase transport activity
in procyclic trypanosomes, and we present evidence that this is the activity encoded by
TbNBTl.
The only other potential nucleobase transporter from a protozoan that had been cloned
prior to TbNBTI is the T. b. brucei P2 aminopurine transporter encoded by TbAT!
(Maser. et al. 1999). which has a similar affinity for adenine and adenosine (Carter and
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Fairlamb, 1993; De Koning and Jarvis, 1999). On the basis of its very similar Vm.JA'"m
ratio for adenine and adenosine, this transporter must be classified as an aminopurine
transporter, rather than a nucleoside or nucleobase transporter. Since our study was
published, however, an additional nucleobase transporter gene from T. b. brucei and
one from Leishmania major have been reported (Henriques, et sl., 2003; Sanchez, et sl.,
2004b). The significance of the current study, therefore, lies more in the detailed
characterisation, which allowed a positive identification of the gene function in the
parasite. It was previously reported that a high affinity hypoxanthine transporter was
upregulated in T. b. brucei procyclics under conditions of purine stress (De Koning, et
sl., 2000b). It seems now highly probable that this transporter was TbNBTIIH4, which
is a far more efficient tool for salvaging low levels of purines than HI. Similar
mechanisms of upregulation of purine salvage enzymes have been reported for the
related Crithidia spp. (Hall, et sl, 1996;Gero, et el., 1997;Gottlieb, 1985;De Koning, et
al., 2000b). The current study is further of significance for its demonstration that even
very similar transporter activities, such as H2 and H4, can be told apart using a rational
approach towards substrate recognition, utilising a relatively small number of selected
purine analogues as markers for particular interactions between binding pocket of the
individual transporters and their substrate.
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CHAPTER VI NOVEL ENT NUCLEOSIDE TRANSPORTERS INT.BRUCEI
6.1 Summary
Trypanosomes, like all protozoan parasites, are incapable of de novo purine synthesis.
This difference in purine metabolism between these parasites and their mammalian
host makes purine metabolism an excellent potential target for the rational design of
antiparasitic chemotherapeutic agents. The transport of purines by the protozoan
parasite Trypanosoma brucei brucei has become of particular interest as these
transporters are the first step in the purine salvage pathways. Purine transporters are
essential for importing the purine nucleobases and nucleosides, which are vital
nutrients for the parasite to use as purine source. In addition, some of these
transporters facilitate the uptake of chemotherapeutic agents including both purine
analogues and non-purine drugs. The increasing understanding of the basis of substrate
recognition of these transporters can provide a lead to the rational design of a drug.
Several T. b. brucei nucleoside transporters have been cloned and found to be part of
the ENT gene family (Landfear, et el., 2004; De Koning, et al, 2005). In the last few
years, examination of the T. brucei database in our laboratory has revealed the
existence of several additional ENT-like sequences in the genome. Using the ThATI
protein sequence to probe the T. brucei genome, three ENT family members were
identified, named as Adenosine Transporter like-A (AT-A), Adenosine Transporter
like-B (AT-B) and Adenosine Transporter like-D (AT-D). The predicted amino acid
sequences of these genes were found to share a high identity to ThNT2 (47.8%%,
65.6% and 70.4%, respectively). The cloning of AT-A, AT-B and AT-D was performed
in our laboratory by Lynsey Wallace (see chapter seven and eight in Lynsey Wallace's
PhD thesis). In addition, a family of five more ENT-like sequences were identified in
silicoin our laboratory, designated as AT-E, AT-F, AT-G, AT-H and AT-I. All of these
genes possess the signature sequences of ENT-like genes such as ThATI, ThNT2-7,
ThNBTl and ThNBT8.1. However, these ENT family members, AT-E-I, have not been
cloned or functionally characterized to date. A phylogenetic tree with protozoan and
human ENT family transporters shows that AT-G aligned within a subgroup together
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with ThATl and the related AT-A and AT-E sequences, whereas AT-F and AT-H
grouped with the ThNBTl and NTB.1 nucleobase transporters (Figure 6.1).
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FIGURE 6.1 Phylogenetic relationship of ENT family transporters including protozoan
and human members. The tree was aligned using tree-puzzle program and the
alignment used was generated by using DIALIGN program (see Appendix II; Aligned
sequences of the ENT family transporters showing the identities and the similarities
between these members of the family). The lengths of the branches represent the
Phylogenetic distance. The tree shown in group lis the ThATl-like genes. The trees
shown in groups II and IVare nucleoside transporter genes. The tree shown in group
III contains the possible nucleobase transporter genes. Values at the nodes of the tree
are bootstrap values based on 10,000 replicates. Reproduced from De Koning, et al.
(2005).
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This chapter describes in great detail the functional characterisation and the substrate
selectivity of the Adenosine Transporter like-B (AT-B) and Adenosine Transporter like
D (AT-D) expressed in yeast, Saccharomyces cerevisiae strain MG887-l, and their
expression in different developmental stages in the life cycle of T. brucei
6.2 Results
6.2.1 Molecular cloning and sequence analysis of the ]bAT1-like Genes
The cloning of the genes encoding AT-D and AT-Bwas described in chapter seven and
eight in Lynsey Wallace's PhD thesis. This section provides a brief summary of that
work. A BLAST search of Wellcome Trust Sanger Institute T. brucei sequence data
bases by Richard Burchmore, using the protein sequence of the ThAT} transporter as
query, revealed the existence of several other AT-sequences including AT-D and B,
with 65.5% and 55.2% identity to the protein sequence of ThATl, respectively.
Oligonucleotide primers, designed from regions flanking the ORF, were employed in a
polymerase chain reaction (peR) using the proof-reading enzyme Piu to amplify DNA
fragments of the expected size from T. brucei 927 gDNA. Products from two
independent peR reactions were cloned into the peR cloning vector pGEM-T Easy.
To confirm that all inserts were of the correct predicted size, and possessed the
restriction enzyme sites predicted from the sequence retrieved from the genome
database, a series of restriction enzyme digests were performed. The cloned products of
two independent polymerase chain reactions for AT-D and AT-B were completely
sequenced on both strands (MBSUsequencing service, Glasgow, Scotland, UK). In both
cases, the two sequences results were found to be identical, and were also identical to
those in the genome database. Hydropathy plots for the amino acid sequences of AT-B
and AT-D were found to exhibit an apparent secondary structure consistent with a
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membrane location and a transport function. and predicted II transmembrane regions
with the N-terminal on the cytosolic side of the membrane.
The cloned AT-D and AT-B ORFs were excised from the pGEM-T Easy vector by
digestion with NotI restriction enzyme and subcloned into the NotI site of the
Iinearised, de-phosphorylated pDRI95 vector. Electrocompetent S. cerevisiae cells of
strain MG887-1 (ura~) were transformed with AT-like: pDRI95 constructs using the
lithium acetate method. Transformants were selected and cultivated on solid se
medium plates without uracil.
6.2.2 Re-confirmation of insert size and restriction sites
In order to reconfirm the presence of AT-D and AT-B inserts in pDRI95 vector before
the functional analysis. a series of diagnostic restriction enzyme digests were carried
out (Restriction maps shown in Figure 6.2). The products from these digests were
analysed on 0.8 % agarose gels in the presence of ethidium bromide (Figure 6.3).
Digestion of the AT-D:pDRI95 vector construct using NotIshowed two fragments; the
fragment represents the pDRI95 vector with a size of - 6.3 kb which was the predicted
size for this vector. The second fragment obtained represented the released insert AT-
D, with a size of - 1.4 kb. The control incubation of this construct in the absence of
NotIled to only one fragment representing the whole construct AT-D:pDRI95 (Figure
6.3A). In the case of AT-B, digestion resulted in the release of the insert AT-B as a
fragment with a size of - 1.4 kb, and another fragment for the vector with a size of -
6.3 kb (Figure 6.30).
These observations confirmed that both inserts, AT-D and AT-B, were of the correct
predicted size. correct orientation, and possessed the restriction enzyme sites predicted
from the genome database sequences and our own previous determination of the
sequence (L.Wallace's thesis).
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HindflJ XhoI XhoI[440] HindIll[550] BamHl HindllI Xhol BamHI[1290] BamHl
1#11 I I II 1#11 I II
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---
440bp 1290 bp 136 bp
FIGURE 6.2 Restriction maps showing the orientation of AT-B (A) and AT-D (B) in
pDR195 with restriction enzymes. Vector size is 6.3 kb. Reproduced from chapter eight
in Lynsey Wallace's PhD thesis.
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FIGURE 6.3 Agarose gel images confirming the presence of the insert within the vector.
A. Digested miniprep of AT-D:pDR195 vector with Not! (should release insert from
vector), using BioLabs 1 Kb DNA ladder. Digest with Not! results in two bands
representing the release of AT-D from the vector (1) and without Not! gives one band
for AT-D within the vector (~. B. Digestion of duplicate minipreps of AT-B in
pDR195, giving identical results: the release of the insert from vector (J and ~. The
Invitrogen 1 Kb DNA ladder was used to estimate size.
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6.2.3 Kinetic Characterization of the AT -B transporter gene inS. cerevisiae
Using a rapid-stop oil-spin technique developed for yeast as described in chapter two
and previously described in Burchmore, et a1 (2003). total uptake of a final
concentration ofO.25 J.1MpH]adenosine in S. cerevisiaestrain MG887-1 expressing AT-
B within pDR195 vector was examined. Accumulation was rapid and linear for over
120 s with a correlation coefficient of 0.96 (linear regression) (Figure 6.4). The uptake
was significantly different from zero with a Pvalue of 0.01 (Ftest). with a rate of 0.080
± 0.011 pmolflff? cellsr-s'. The transport activity was saturable in the presence of 1
mM unlabeled adenosine and was not significantly different from zero (P> 0.4; Ftest).
which confirms that all the adenosine uptake is transporter-mediated. Figure 6.3 Shows
the uptake of the 0.25 J.1MpH]adenosine in S. cerevisiaestrain MG887-1 with pDR195
only (control) was not significantly different from zero (P> 0.2; Ftest).
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FIGURE 6.4 Transport of [lH]adenosine by AT-B in S. cerevisiaestrain MG887-1. Uptake
of 0.25 J.1M[3H]adenosine was linear over 120 s (.: ;. = 0.96) as calculated by linear
regression. In the presence of 1 mM unlabelled adenosine (0) or the control (empty
vector. .). uptake was not significantly different from zero (P > 0.4 and P > 0.2.
respectively; F test). In some cases. an apparent positive intercept can be observed for
the timecourses in the absence of inhibitor. This is most likely the caused by
extracellular binding of radiolabel, which is displaced by the including of 1 mM non-
radiolableled substrate.
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Further experiments were performed in order to determine the kinetic parameters of
this adenosine transporter. The uptake of 0.015 JlM [3H]adenosine in S. cerevisiae
strain MG887-1 expressing AT-B was assessed using an incubation time of 60 s (initial
rate of uptake) in the presence of a range of concentrations (0-1000 JlM) of unlabeled
adenosine. Figure 6.5 (inset) shows that the uptake was saturable and complied with
simple Michaelis-Menten kinetics, with average Km and Vmax values of 0.44 ± 0.02 IlM
and 0.60 ± 0.05 pmolffO' cellsr-s', respectively (n = 4). This result indicates that the
AT-Bpossess a high affinity for adenosine.
The substrate specificity of the adenosine transporter by AT-B in S. cerevisiae was
investigated by studying the inhibition effects of purine and pyrimidine nucleosides
and nucleobases on adenosine uptake. Figure 6.5 also shows that the purine nucleoside
inosine inhibited the uptake of (3H]adenosine with a Ki value of 3.1 ± 0.7 JlM (n = 3).
Routine inhibition studies of this transporter were subsequently performed at 0.05 JlM,
as the radioactivity accumulated at 0.015 JlM (necessary concentration to determine
the lGn) was very low and only just allowed accurate determinations. The purine
nucleoside guanosine also inhibited the uptake of 0.050 JlM (3H]adenosine with a Ki
value of 2.4 ± 0.3 J.lM(n = 3). The inhibition profiles obtained using the initial rates of
the adenosine transporter by AT-B showed that this transporter possess high affinity
for purine nucleosides and relatively low affinity for purine nucleobases such as
adenine (Kivalue of 670 ± 155 JlM;n = 4) and hypoxanthine (Kivalue of 286 ± 28 JlM;
n = 3), and no affinity up to 1 mM for pyrimidines such as uridine, thymidine and
cytidine.
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FIGURE6.S High affinity adenosine transporter in S. cerevtsiee strain MG887-1
expressing AT-B. Inhibition ofO.015 ~M [3H]adenosine by increasing concentrations of
unlabeled adenosine (.; ICso= 0.86 J..LM)and inosine (0; ICso= 1.6 ~M), data were
expressed as percentage of control (no inhibitor). Michaelis-Menten plot (inset) shows
calculated Km and Vmax values for this experiment of 0.37 11Mand 0.66 pmolf lfl' cells):
1S-1, respectively.
To investigate whether separate transporters are involved in the uptake of purine
nucleosides such as adenosine, inosine and tubercidin, additional transport studies were
performed using [3H]inosine and [3H]tubercidin. The uptake of 50 nM [3H]inosine
using incubation time of 120 s (measuring the initial rates of uptake) was inhibited by
range of concentration between 0-1000 J..LMof unlabelled inosine and adenosine (Figure
6.6A). The mean Ki value for adenosine inhibiting inosine uptake from three separate
experiments was 0.48 ± 0.12 J..LM.Figure 6.6A (inset) shows the conversion of the
inosine inhibition data to a Michaelis-Menten plot of total inosine uptake. The mean
values from three separate experiments were 0.53 ± 0.06 11Mand 0.25 ± 0.05 pmolfl'O"
cellsrs' for Km and Vmax, respectively.
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FIGURE 6.6 Transport of labeled purine nucleosides by AT -B in S. cerevisiae strain
MG887-1. A. Transport of 50 nM [3H]inosine over 120 s was inhibited by indicated
concentrations of unlabelled inosine (.) or adenosine (D), with leso values of 0.90 IlM
and 0.54 IlM, respectively. The inset shows the conversion of the inosine inhibition
data to a Michaelis-Menten plot of total inosine uptake, with a Km value of 0.67 IlM and
a Vmax of 0.37 prnolt l O? cellsr-s' for this experiment. B. Timecourse of 1 IlM
[3H]tubercidin uptake in the presence (D) or absence (.) of 1 mM unlabelled adenosine.
Uptake of 1 IlM [3H]tubercidin was significantly different from zero with a Pvalue of <
0.0001 (Ftest), with a rate of 0.068 ± 0.003 pmolfl O?cellsrs' (Figure 6.6JJ). However,
in the presence of 1 mM unlabeled adenosine transport was not significantly different
from zero (P> 0.1; Ftest). The Km for [3H]tubercidin was determined at 15.1 ± l.SIlM
with a Vmax of 0.25 ± 0.06 pmolt lff cellsrs' (n = 3)(Figure 6.7A). Similarly, the Km for
[3H]-3-deazaadenosine was found to be 25.7 ± 4.0 IlM with a Vrnax of 0.16 ± 0.04
pmol(107 cellsrs' (n = 3; Figure 6.7B). We thus know Km values for four different
permeants of AT -Bin the S. cerevisiae expression system. Since the VmaJ Km gives a
measure of the efficiency of transport, it follows that AT -B transports adenosine - 2.6-
fold more efficiently than inosine. While the Vmax values are all rather similar, this
ratio reveals that the interactions at N7, and in particular at N3, are vital for efficient
translocation at this transporter (Table 6.1).
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FIGURE 6.7 Purine nucleosides uptake by AT-B in S. cerevisiae strain MG887-1. A.
Shows the conversion of the tubercidin inhibition data to a Michaelis- Menten plot of
total tubercidin uptake, with a ~ value of 17.0 ~M and a Vrnax of 0.33 prnolf l O?cellsrts
I for this experiment. B. Shows the conversion of the 3-deazaadenosine inhibition data
to a Michaelis-Menten plot of total 3-deazaadenosine uptake, with a ~ value of 18.1
~M and a Vrnax ofO.14 pmolt IO' cellsr+s' for this experiment.
Permeant Km Vrnax VmaJKm n
Adenosine 0.44 ± 0.02 0.60 ±0.05 1.4 4
Inosine 0.53 ± 0.06 0.25 ± 0.05 0.47 3
Tubercidin 15 ± 1.5 0.25 ±0.06 0.02 3
3-deazaadenosine 25 ± 4.0 0.16 ± 0.04 0.006 3
TABLE6.1 Km and Vmaxvalues and their ratios for some purine nucleosides were tested
on AT-B in S. cerevisiae strain MG887-1. Km and Vmax values were expressed in ~M
and pmolf l O' cellsrls', respectively.
134
CHAPTER VI NOVEL ENTNUCLEOSIDE TRANSPORTERS INT.BRUCEI
6.2.4 Characterization of the AT -D transporter gene in S. cerevisiae
Uptake of [3H] adenosine at 0.25 jlM by S. cerevisiaestrain MG887-1 expressing TbAT-
D:pDR195 was linear for at least 120 s, with a rate ofO.0079 ± 0.0005 pmolf l O' cellsr+s'
(linear regression; r = 0.99; Figure 6.8A). In the presence of 1 mM unlabelled
adenosine, uptake was inhibited by about 95% during this interval. As expected in
control cells not expressing AT-D but transformed with empty vector pDRI95, the
uptake of [3H] adenosine was not significantly different from zero, either in the
presence (P = 0.4, F test) or absence (P = 0.9, F test) of 1 mM unlabeled adenosine
(Figure 6.8A), and the observed positive intercept is most likely caused by extracellular
binding of radiolabel, which is displaced by the including of 1 mM non-radiolableled
substrate. Figure 6.8B confirms the linear adenosine uptake at the much lower
concentration of 0.015 IlM [3H]adenosine for 240 s (0.0003 ± 0.00003 pmolfl O?cellsjls:
1, linear regression; r = 0.96). The addition of 1 mM unlabeled adenosine and 1 mM
unlabeled adenine, inhibited the uptake by> 98% and 65%, respectively (Figure 6.8.8).
This indicates that AT -B has low affinity for adenine, as the transporter was clearly not
saturated by 1 mM of the nucleobase.
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FIGURE6.8 Linear adenosine transport by AT-D in S. cerevisiae strain MG887-1. A.
Timecourse of 0.25 J..lM[3H]adenosine uptake by S. cerevisiae transformed with AT-
D:pDRI95 in the presence (0) or absence (.) of 1 mM unlabelled adenosine or by the
empty vector (pDR195) in the absence (.) or presence of 1 mM unlabelled adenosine
(0). B. Timecourse ofO.0151lM [3H]adenosine uptake by S. cerevlsiaestrain MG887-1
expressing AT-D in pDRI95 in the presence (0) or absence (.) of 1 mM unlabelled
adenosine or presence of 1 mM unlabelled adenine (.).
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Subsequent experiments with [3H]adenosine were performed using a concentration of
0.05 11M,except for determination of Km (where 15 nM label was used), and an
incubation time of 60 s, within the linear phase of uptake and therefore measuring true
initial rates of transport. Figure 6.9 shows that [3H]adenosine transport measured in the
presence of various concentrations (0-1000 11M) of unlabeled adenosine was
monophasic and conformed to simple Michaelis-Menten kinetics (Figure 6.9, inset)
and displayed a Km value of 0.058 ± 0.01 11M(n = 4), which demonstrates that AT-D
possesses a very high affinity for adenosine but appears to have a low capacity ( Vmax =
0.011 ± 0.004 pmolf IO? cellsj+s": n = 4) when expressed in yeast. To further
characterise the substrate specificity of this transporter, inhibition experiments were
performed using 50 nM labelled adenosine. The inhibitory effects of potential
substrates for AT-D were tested by investigating the effect of varying concentrations of
test compounds.
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FIGURE 6.9 High affinity adenosine transporter in S. cerevtsiee strain MG887-l
expressing AT-D. Inhibition of 0.015 IlM [3H]adenosine by increasing concentrations
of unlabelled unlabelled adenosine (.: ICso= 0.09 IlM) or inosine (0; ICso= 2.3 IlM),
and expressed as percentage of control (no inhibitor). Michaelis-Menten plot (inset)
shows calculated Km and Vmax values for this experiment of 0.046 IlM and 0.021
pmolf lff cellsr+s'. respectively.
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The uptake of PH] adenosine was inhibited by purine nucleosides. Inosine displayed a
Ki value of 4.4 ± 1.5 ~M (n = 4; Figure 6.9). To assess whether inosine is transported
across the plasma membrane by this adenosine transporter, additional transport
experiments were performed using labelled inosine. Time course experiments using
0.25 ~M PH] inosine showed that the uptake was linear for at least 5 min (Figure
6.10A), with a rate of0.55 ± 0.02 pmol(lO' cellsr-s', and was not significantly different
from zero when adding 1 mM of unlabeled inosine (P < 0.28, t test). Figure 6.10B
shows that the uptake of 50 nM [3H]inosine was saturable when measured using 3 min
incubations in the presence of 0 - 1000 ~M of unlabeled inosine. The uptake was also
inhibited by the same concentration range of unlabeled adenosine (Ki = 0.025 ± 0.004
liM). The conversion to simple Michaelis-Menten kinetics resulted in average Km and
Vmax values of 2.7 ± 0.70 liM and 0.12 ± 0.039 pmol(10' cellsr's', respectively (Figure
6.10B, inset). These findings suggest that adenosine and inosine are both substrates of
the AT-D transporer, as the Kmvalue for inosine transport is almost identical to the J(;
value for inosine when inhibiting [3H]adenosine uptake and vice versa for adenosine
transport. We conclude that AT-D is a high affinity purine nucleoside transporter,
particularly as it transports adenine and hypoxanthine very poorly.
We next investigated whether this transporter displays high affinity for other natural
purine nucleosides, including guanosine, 2-deoxyadenosine and the pyrimidine
nucleosides cytidine, thymidine and uridine. The uptake of 50 nM [3H]adenosine was
inhibited by guanosine with a Ki of 5.7 ± 0.6 ~M (n = 3; Figure. 6.11), but not
significantly by xanthosine up to 1000 liM, (P < 0.20, using an unpaired student's t
test). The inhibition profile of adenosine transporter obtained, showed that AT-D
transporter possesses a very high affinity for purine nuceosides and low affinity for
purine nucleobases such as adenine (Ki = 167 ± 39 liM; n = 3) and hypoxanthine (Ki =
299 ± 74 liM; n = 3), as well as all pyrimidine nucleosides tested such as uridine (Ki =
219 ± 371IM; n = 3) (Figure 6.11).
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FIGURE 6.10 Inosine transport by AT-D in S. cerevisiaestrain MG887-1. A. Time course
for 0.25 ~M [3H]inosine uptake in presence (0) or absence (.) of 1 mM of unlabeled
inosine. B. Inhibition of 0.050 ~M [3H]inosine uptake by various concentrations of
inosine (.) and adenosine (0) with ICsovalues for this experiment of 1.8 and 0.014 ~M,
respectively. Data were expressed as percentage of control, defined as uptake in the
absence of inhibitor. The inset shows the conversion of the inosine inhibition plot to a
Michaelis-Menten curve, showing total inosine transport with .Km and Vmax values for
this experiment of 1.8 ~M and 0.05 pmolflff cellsr-s'. respectively.
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FIGURE 6.11 The effects of purine and pyrimidine nucleosides on the uptake of
[3H]adenosine by AT-D in S. cerevisiae strain MG887-1. Initial rates of 50 nM
[3H]adenosine uptake using incubation time of 60 s, were determined in the presence
of various potential inhibitors and expressed as a percentage of control (no inhibitor).
Inhibition of 50 nM [3H]adenosine uptake by guanosine (.) and uri dine (0) with ICso
values of 12.5 pM and 405 ~M, respectively (for this experiment).
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These values confirmed the specificity of AT-D for purine nucleosides (Table 6.2).
Even though, purine nucleosides inhibited AT-D does not mean that they are its
permeants. This would need further experiments with radiolabeled nucleosides.
Nonetheless, it is clear that the AT-D transporter displays a preference for binding
purine nucleosides rather than pyrimidines nucleosides or nucleobases.
TbAT -D in yeast [~M] TbAT-B in yeast [~M]
ComEound Kior Km n Kior Km n
Adenosine 0.058 ± o.oi- 4 0.41 ± 0.03" 5
Inosine 2.7 ± 0.7a 3 0.53 ± 0.060 3
Guanosine 6.1 ± 0.6 3 2.4 ±0.2 3
Xanthosine >1000 1 NEI,lOOO 4
Uridine 234 ±39 3 NEI,lOOO 4
Thymidine 505 ±34 3 NEI,lOOO 3
Cytidine 92 ±31 3 NEI,lOOO 3
Cordycepin 5.8 ± 1.4 3 31 ± 6.0 4
AraA 1.38 ± 0.2 3 ND2
Tubercidin 2.3 ± 0.2 4 15 ± 1.50 3
6-mercaptopurine riboside 10 ± 0.0 3 29±5 3
2' -deoxyadenosine 0.046 ± 0.006 3 1.0 ± 0.3 4
5' -deoxyadenosine 0.32 ± 0.07 3 0.9 ± 0.1 3
Nebularine 4.0 ± 1.0 3 31 ± 6.7 5
1-deazaadenosine 0.21 ± 0.07 4 1.3±0.4 4
3-deazaadenosine 0.25 ± 0.09 4 25 ± 4.0u 3
NA-01 (2-nitroAdo) 88 ± 0.0 1 ND2
NA-63 (2-nitroPurRib) 80 ± 0.0 1 ND2
7-deaza- 2'deoxy Ado 4.0 ± 0.6 3 927 ± 38 4
6-chloropurine riboside 12 ± 0.2 2 33 ± 4.4 4
Hypoxanthine 320 ± 80.1 3 284± 28 3
Adenine 147 ± 41 3 665 ± 154 4
Guanine ND2 ND2
Xanthine ND2 ND2
Allopurinol ND2 ND2
Uracil ND2 ND2
Thymine ND2 ND2
Cytosine NE2,10000 2 ND2
TABLE6.2 Kinetic constants of purine nucleoside uptake by AT-D and AT-B
transporters in S. cervisiae. Kinetic parameters were determined through competitive
inhibition of [3H]adenosineor as indicated. In a few cases, extrapolation was required
due to limitations of solubility of the inhibitor and based on the assumption of a Hill
slope of -1 and eventual 100% inhibition. Extrapolation was not attempted when
inhibition at the highest inhibitor concentration was < 50%. Permeant concentrations
were 0.25 - 0.015 I-lM(Routine inhibition studies or determination of the Km). a Km
values. 1NE, no effect at 1mM. 2 ND, not determined.
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6.2.5 Models for substrate recognition by AT-B and AT-D
The differences in substrate specificity of the PI and P2 transport activities have been
explained in terms of interactions between the transporters and defined functional
groups of the substrate (De Koning and Jarvis. 1999) and refined the PI model slightly
to explain its low-affinity binding of uridine (De Koning. et al. 2003). The substrate
recognition models for these transporters are displayed in Figure 6.12 and dearly
indicate that the main recognition points on the purine ring are N3 and N7 for PI-type
binding and NI and 6(NH2) for P2. explaining the discrimination of P2. but not of Pt.
for aminopurines over oxopurines (Carter and Fairlamb, 1993; De Koning and Jarvis.
1999). Estimates of bond energies ~Go (in kl/mol) have been calculated based on the Ki
values of competitive inhibitors of [3H]adenosine uptake as described (De Koning and
Jarvis. 1999;Wallace. et al. 2002; De Koning. et al. 2005).
However. this method is likely to give an overestimate of bond energies if the
translocation rate of the permeant and inhibitor are very different (De Koning. et al.
2005). This has been confirmed for Pl. using (3H]tubercidin (7-deazaadenosine) as
substrate in T. b. brucei bloodstream forms. When used as inhibitor of PI-mediated
[3H]adenosine uptake. the Ki value was determined as 78 ± 6.4 J.lM (De Koning and
Jarvis. 1999). but the reassessment with [3H]tubercidin determined its Las 6.5 ± 1.8
J.lM (n == 3) (De Koning, et sl., unpublished), revaluing the Gibbs free energy of the N7
interaction at 6.8 kl/mol, down from an estimated 13.4 kJ/mol based on the Ki value.
Even more important than the more accurate determination of the bond energy. is the
determination of Vmax for tubercidin (0.43 ± 0.10 pmol(107 cellsrs") and the Vmaxl ~
ratio of 0.077 for PI, showing tubercidin to be > 60-fold less efficient than adenosine as
permeant for this transporter, showing that the N7 interaction is more important for
efficient translocation than for high affinity. This observation is entirely in agreement
with the conclusion of Geiser. et a1 (2005) that tubercidin enters T. b. brucei
predominantly through the P2 system, which does not significantly interact with N7
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(De Koning and Jarvis, 1999). While it is thus much-preferred to use radiolabeled
permeant rather than competitive inhibitors to study transporter-substrate interactions,
radiolabel is rarely available for any but the most standard nucleosides. To further
improve the existing model of interactions between P2 and adenosine, we determined
Kivalues for l-deazaadenosine (54 ± 16 J..LM;n = 5), nebularine (purine riboside; 17 ± 2
J..LM;n = 6), 6-chloropurine riboside (15 ± 1 J..LM;n = 3) and 9-deazaadenosine (12 ± 3; n
= 3) using T. b. bruceibloodstream forms and 100 nM [3H]adenosine in the presence of
250 J..LMinosine as described previously (De Koning and Jarvis, 1999), leading to
estimates of 7.2 kl/mol, 10 kl/mol and 6.4 kl/mol, respectively, for the P2-interactions
with 6-NH2, NI and N9, respectively, leaving -10 kl/mol for the postulated rt-stacking
to make up the total bonding energy of 34.5 kj/mol based on the Km of adenosine
(Figure 6.12).
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FIGURE 6.12 Model of interactions between adenosine and PI, P2, and AT -D
transporters. The AT-D (Km = 0.058 ~M) has much higher affinity than PI (Km = 0.38
~M) or P2 (Km = 0.92 ~M), but only for adenosine suggesting that the AT-D binds
through PI motif and main P2 motif. The models for PI and P2 were adapted from (De
Koning and Jarvis, 1999).
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We have followed a similar approach to investigate the unusual selectivity of NT9/AT-
D. Table 6.3 lists the various analogues tested for inhibition of uptake of 50 nM
pH]adenosine in S. cerevisiae transformed with pDRI9S:AT-D. The preference for
purine nucleosides over the corresponding nucleobases is explained by interactions
with 3'-OH (Cordycepin (3'-deoxyadenosine) <5(.:\GO)(Ado) = 11.5 kj/mol) and S'-OH
(5'-deozyadenosine <5(.:\GO)(Ado) = 4.0 kj/mol) but not 2'-deoxyadenosine (P> 0.05,
paired T-test). The resultant estimate of Gibbs free energy for the ribose group of 15.5
kj/mol is very similar to the average <5(.:\GO)for adenine and hypoxanthine with their
corresponding nucleosides (16.0 kl/mol). NT9/AT-D also appears to interact with the
other contact points of PI-type transporters, N3 and N7. The <5(.:\GO)(Ado) was 3.4
kj/mol for 3-deazaadenosine, 9.1 kj/mol for tubercidin and 10.5 for 7-deaza-
2'deoxyadenosine. These interactions are sufficient to explain the generally high
affinity for purine nucleosides but do not explain the extraordinary high affinity for
adenosine. This, however, is explained by involvement of the same -NI=C6-NH2 motif
that confers selectivity of adenosine over inosine to P2. The <5(.:\GO)(Ado)for 1-
deazaadenosine was 2.9 kj/mol and the average 8(.:\GO)(Ado) for 6-chloropurine
riboside and nebularine was 12.0 kl/mol. We thus conclude that NT9-AT-D interacts
with adenosine through both the main PI and P2 motifs (Figure 6.12), combining high
affinity for purine nucleosides and some selectivity for adenosine over inosine.
6.2.6 Expression of AT-D and AT-B through the 7: bruceilife cycle
Although both transporters AT-D and AT-Bwere identified at the molecular level and
then functionally characterized in great detail in yeast, there is still a question to
answer, which is whether AT-D and AT-B are expressed at all during the T. broceilife-
cycle and if so, in which developmental stage?
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AT-D in yeast
Compound
t1(}
o[t1(}] Control[kj/mol]
hypoxanthine 20.7 12.27 Inosine
adenine 22.7 19.81 Adenosine
adenosine 42.5 0.00 Adenosine
inosine 33.0 9.55 Adenosine
guanosine 30.9 2.08 Inosine
uridine 21.5 21.01 Adenosine
thymidine 19.6 22.98 Adenosine
cytidine 23.9 18.60 Adenosine
cordycepin 31.0 11.50 Adenosine
AraA 34.8 7.76 Adenosine
tubercidin 33.4 9.13 Adenosine
2' -deoxyadenosine 43.5 -0.97 Adenosine
5' -deoxyadenosine 38.5 4.03 Adenosine
nebularine 32.0 10.53 Adenosine
I-deazaadenosine 39.7 2.88 Adenosine
3-deazaadenosine 39.2 3.36 Adenosine
NA-01 (2-nitroAdo) 24.1 18.48 Adenosine
NA-63 (2-nitroPurRib) 24.3 18.23 Adenosine
7-deaza -2'deoxy Ado 32.0 10.52 Adenosine
6-chloropurine riboside 29.0 13.52 Adenosine
TABLE6.3 Gibbs free energies (kl/mol) of substrate interacting with AT-D in S.
cervisiae. Gibbs free energy of substrate-transporter interactions was calculated from
the Km and JG values listed in Table 6.1, using the Nernst equation as described in
Chapter two. The difference with a control compound, either adenosine as the highest
affinity compound or inosine, yielded the o(~GO),the loss in binding energy relative to
the control compound.
African trypanosomes are protozoan parasites that coordinate life cycle differentiation
with cell cycle progression (Matthews and Gull, 1994; Mottram, 1994). The
trypanosome life cycle is complex, with several distinct stages being present in both the
insect vector and mammalian host. During the course of a bloodstream parasitaemia the
trypanosomes proliferate initially as morphologically slender forms. As cell numbers
increase in the blood, slender forms differentiate to morphologically stumpy forms
(Vickerman, 1965).
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As described in Chapter two, bloodstream form trypanosomes were grown in vivo in
mice which were immunocompromised with cyclophosphamide. Parasites were
collected at day nine postinfection. At this stage of parasitaemia, pleomorphic lines
were predominantly (> 80%) short-stumpy in morphology. Microscopic examination of
our preparations showed that stumpy forms were thick and short with an average
length of 18 urn and with no free flagellum, but a short one may be present. The
stumpy form is characterized by its morphology and through their expression of NADH
diaphorase activity (Vickerman, 1965). The NADH diaphorase assay is a reliable
cytochemical marker that confirms the identity of slender and stumpy cells. Figure
6.13A demonstrates the results from our NADH diaphorase assay as it shows stumpy
forms and negative control which was prepared from the same sample but in the
absence of the NADH substrate (Figure 6.13.8). Positive control was included in this
experiment using the procyclic form of T. brucei(Figure 6.13G).
FIGURE 6.13 Representative images of different life stage forms of T. brucei taken by
immunofluorescence microscopy using the NADH diaphorase assay which was
performed to determine the NADH dehydrogenase activity. Short-stumpy bloodstream
forms. A. Shows the short-stumpy bloodstream forms incubated for about an hour with
the reaction solution. B. Shows the negative control, using the same short-stumpy blood
sample, but without adding the NADH substrate. C. Represents the positive control
which procyclic forms were used in the same way with the NADH substrate. This assay
is to confirm the presence of short-stumpy parasites.
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Examination of RNA samples extracted from T. hrucei of various life cycle stages was
carried out to confirm the quality and reliability of the RNA samples used in RT-PCR
experiments. As described in Chapter two, concentrations of RNA samples extracted
from different strains and life cycle stages of T. hrucei procyclics of T. hrucei strain
427, bloodstream forms of T. hrucei strain 427 in HMI-9 medium, and long-slender or
short-stumpy bloodstream forms of T. hrucei strain 927), were analysed by the
Molecular Biology Support Unit (MBSU) of the University of Glasgow. RNA analyses
were carried out using either a NanoDrop® ND-lOOOSpectrophotometer (NanoDrop
Technologies) for quantity or using an Agilent 2100 Bioanalyzer (Agilent
Technologies) for quality control. The latter system automatically gives an extremely
accurate calculation of the ratio of ribosomal bands in total RNA samples and shows
the percentage of ribosomal impurities in mRNA samples. Most importantly, it
provides an accurate estimate of the concentration, and the integrity of the RNA is
verified. The system plots fluorescence intensity versus migration time and produces
electropherograms for each sample (peaks) such as 18S and 28S peaks (Figure 6.14A).
The data can also be displayed as a densitometry plot, creating a gel-like image (bands),
with the help of a ladder that contains fragments of known sizes and concentrations
(Figure 6.14JJ). The peak migrating just before 24 seconds is known as the spike control
and is found in the loading buffer used to run each sample. The Agilent Bioanalyzer
software uses this peak to align each sample to that of the ladder. The peak height is
typically between 15 to 20 fluorescence units. In samples containing high
concentrations this peak may go unnoticed due to the scaling of the graph. The low
baseline, and the sharp 18S and 28S ribosomal peaks indicate that the total RNA is of
good quality. Comparing our results with previous RNA analyses using northern
hybridisation (Figure 6.14C)., showed that the RNA samples used in our experiments
were very reliable, as tested for quality and quantity using highly accurate methods.
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FIGURE 6.14 Examination of RNA samples. The output from the Agilent 2100
Bioanalyzer (results displayed as an electropherogram) showing the control peak and
18S, 28S ribosomal peaks (A), and as a gel-like image shown RNA bands with ladder
that contains fragments of known sizes (B). Transfer of RNA to membrane for Nothern
blot, obtained from Chapter eight in Lynsey Wallace's PhD thesis (G).
As described in Chapter two, cDNAs were generated from RNA samples extracted from
different strains and life cycle stages of T. brucei (procyclics of T. brucei strain 427,
bloodstream forms of T. brucei strain 427 in HMI -9 medium, and long-slender or
short-stumpy bloodstream forms of T. brucei strain 927) by using a SuperScript™ II
Reverse Transcriptase (RT). cDNAs were then used as templates in polymerase chain
reactions with specific PCR primers for AT-B, AT-D, and controls (ThAT! and
TbNBTl). Details of the primers used for amplification of the AT-B, AT-D, and controls
are listed in Appendix II. Negative controls were also included in our PCR experiments
(from first-strand reaction) (see Chapter two). PCR products were analysed by
electrophoresis in agarose gel (usually 0.8% or 1.2%) containing 0.3 pg/ml of ethidium
bromide, using Invitrogen 1 Kb DNA ladder or BioLabs ! Kb DNA ladder. The results
obtained from agarose gels showed the amplification of AT -B fragment from short-
stumpy bloodstream form of T. brucei 927 with the expected size of - 1.4 kb (Figure
6.lSA). The AT-D fragment was amplified from procyclic form of T. brucei 427 with
the expected size of - 1.4 kb (Figure 6.15B). However, no bands were detected for AT-
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B or AT-D with long-slender bloodstream forms (Figure 6.1SG), confirming that the
10-20 % of this life cycle stage cells effect on the result from the 80 % of short-stumpy
forms. The same fragment of TbNBTl (positive control) was amplified in both stages of
the life cycle with a size of of - 0.7 kb. The Invitrogen 1 Kb DNA ladder was used to
estimate sizes in A and B.
A B c
¢::J q
- 1.4 kb
¢::J q
- 0.7 kb
q
- 0.7 kb
FIGURE 6.15 Agarose gel images confirming the detection of AT-B and AT-Dusing
specific peR primers listed in appendix II. A. Amplification of AT-B fragment from
short-stumpy bloodstream form of T. brucei 927 with the expected size of - 1.4 kb. B.
Amplification of AT-D fragment from procyclic form of T. brucei 427 with the
expected size of - 1.4 kb. C. Represents the gel using long-slender bloodstream forms,
showing no bands for AT-B or AT-D. The same fragment of TbNBTI (positive control)
was amplified in all stages of the life cycle with a size of of - 0.7 kb The Invitrogen 1
Kb DNA ladder was used to estimate sizes in our experiments.
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6.3 Discussion
While an increasing number of nucleoside transporters have been identified and
biochemically characterized in recent years. until recently very little was known about
protozoan purine transporters at the molecular level. including their cloning and
functionally expression. In 1993. two different types of nucleoside transporter were
identified in the protozoan parasite Trypanosoma brucei and designated PI and P2
(Carter and Fairlamb, 1993). The PI type transporter mediated the uptake of adenosine.
inosine and guanosine. The gene encoding this transporter has been cloned by
expression in Xenopus oocytes and was designated ThNT2 (Sanchez. et sl., 1999). Pl-
type transporters were found to be expressed in both bloodstream form (BSF) and in
procyclic form (PF) trypanosomes. The second type is the P2 transporter. which
transports the purine nucleoside adenosine as well as the purine nuc1eobase adenine.
but has low affinity for inosine. guanosine. hypoxanthine. guanine and allopurinol
(Carter and Fairlamb, 1993; De Koning and Jarvis. 1999; Maser. et el; 1999). In
addition. it was demonstrated that the P2 type system mediates the uptake of
antitrypanosomiasis drugs such as pentamidine. melarsoprol and diminazene aceturate
(Carter. et el., 1995; De Koning. et al., 2000a; De Koning and Jarvis, 2001). ThATl. the
gene encoding the P2 transporter, was the first T. b. broceinucleoside transporter gene
cloned (by functional complementation in Saccharomyces cerevisiae naturally deficient
in purine nucleoside uptake (Maser, et sl., 1999», and this transporter is expressed only
in the long-slender bloodstream stage of the life cycle. Sequence alignments. supported
by membrane topology predictions, reveal that all of the protozoan nucleoside and
nucleobase transporters identified to date belong to the ENT nucleoside transporter
family (Landfear, et sl., 2004; De Koning. et el., 2005) exemplified by the human
equilibrative nucleoside transporter hENTI (Griffiths, et al, 1997b).
A cluster of six genes has been identified on chromosome 2 of T. brucei that apparently
encodes ENT-family transporters, designated as TbNT2, TbNT3. TbNT4. TbNT5,
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ThNT6, and ThNI7 (Sanchez, et al., 2002). The predicted amino acid sequences of these
genes were found to have a high identity to each other. When expressed in Xenopus
laevis oocytes, the ThNf2, ThNfS, ThNf6, and ThNI7 showed high affinity for
adenosine and inosine. However, the ThNTS, ThNf6 and ThNI7 also appeared to be
capable of hypoxanthine transport, though with relatively low affinity (Sanchez, et sl.,
2002). The group of Landfear has identified further members from the ENf family by
searching of T. brucei database, named as ThNTS, ThNf9, TbNfIO and ThNfII
(Landfear, et el., 2004). It has been suggested that the ThNf8 represents a family of
clustered genes (Landfear, et sl., 2004). The TbNf8.1 is one member of this family and
it was found to be a nucleobase transporter (Henriques, et sl., 2003) very similar to
ThNTBI identified and characterized in our laboratory (Burchmore, et el., 2003). Both
TbNT8.1 and ThNBTI appeared to be expressed in procyclic and in bloodstream forms
(Burchmore, et el., 2003; Henriques, et sl., 2003). The TbNTJO has been expressed in
Saccharomyces cerevisiae, and shown to encode a high-affinity nucleoside transporter.
Its mRNA has been reported to be expressed in the nondividing short stumpy stage
(Sanchez, et el., 2004a). It has also been reported that TbNfII transporter are
represented by two closely related genes, TbNfII.1 and TbNfII.2, but they have not
been functionally characterised yet (Landfear, et el., 2004).
Our own laboratories, meanwhile, cloned a number of T. b. brucei genes provisionally
designated AT-A, AT-B, AT-C, AT-D until a more functional designation could be
proposed. AT-C was a nuc1eobase transporter, subsequently named TbNBTI
(Burchmore, et sl., 2003), and AT-A appears not to transport any nucleosides or
nucleobases but preliminary results indicate it may be a pentamidine transporter (De
Koning, unpublished). The current chapter has dealt with AT-B and AT-D, which were
called NfIO and NT9, respectively, by the Landfear group (Landfear, et el., 2004). Both
genes were expressed in our S. cerevisise expression system, that was also used for the
cloning and characterisation of TbNBTI (Burchmore, et sl., 2003) and were shown to
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be broad-specificity purine nucleoside transporters of the PI-type. Phylogenetic
analysis also clustered these genes in that category (De Koning, et sl, 2005).
A limited characterisation of the TbNTIO/AT-B gene has been reported by Sanchez, et
al (2004), showing adenosine, inosine and guanosine to be permeants with similar Km
values (- 0.5 - 1.0 J.lM). In contrast, this transporter did not mediate uptake of
hypoxanthine or other purine nucleobases in the yeast expression system used
(Sanchez, et sl., 2004a). Our own observations, summarized in Table 6.2, are entirely in
agreement with these earlier observations and confirm NflO/AT-B as a PI-type
transporter expressed specifically in short-stumpy bloodstream forms.
The same group has also mentioned in a recent review that Nf9/ AT-D, expressed in
Xenopus oocytes, is recognised by adenosine, inosine, guanosine and hypoxanthine
(Landfear, et sl., 2004), but no details or data were provided. We here report a full
characterisation of this unusual transporter. As other PI-type transporters, it is
predominantly a purine nucleoside transporter, with at best a secondary capacity to
transport nucleobases or pyrimidines. But NT9/AT-D displayed much higher affinity
for adenosine than any other nucleoside transporter yet reported, with a Km of 58 ± 13
nM. Unique among the T. h. hrucei nucleoside transporters, showed > 40-fold higher
affinity for adenosine over inosine, whereas all other P l-type transporters have failed
to discriminate to any large extend (Carter and Fairlamb, 1993; Sanchez, et sl., 1999;
Sanchez, et sl., 2002; Sanchez, et sl, 2004a; De Koning, et sl., 2005). This much-
increased selectivity seems to be the result of interactions at the -Nl=C6-NH2amidine-
like motif of adenosine, which has hitherto been associated with recognition by the P2-
transport activity rather than PI-type transporters (De Koning and Jarvis, 1999; Barrett
and Fairlamb, 1999; De Koning, et el., 2005). Yet, Nf9/AT-D still binds inosine with
high affinity, apparently utilising all the interactions previously determined for PI: N3,
N7, 3'-OH and 5'-OH (De Koning and Jarvis, 1999). It therefore follows that the
extraordinarily high affinity of Nf9/ AT-D is the result of adenosine binding through
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both the main PI and P2 motifs. Since the P2 motif does not contribute to inosine
binding, this transporter is most efficient at transporting adenosine, as judged by its
VrnaxIKm. Its expression in procyclics may reflect the low purine concentrations
procyclic trypanosomes will experience in their environment, the tsetse midgut. It is
known that procyclic T. b. bruceiup-regulate a high-affinity hypoxanthine transporter
during purine starvation (De Koning, et al, 2000b).
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Chapter Seven
IDENTIFICATION OF HIGH AFFINITY PURINE TRANSPORTERS IN THE APICOPLEXAN
PARASITE TOXOPLASMA CONDO
CHAPTER VII PURINE TRANSPORTERS INTOXOPLASMA GONDII
7.1 Summary
In the previous Chapters, we have identified the nucleobase transporters in parasites of
Trypanosomatidae protozoa such as Leishmania major promastigotes (Chapter three)
and Leishmania mexicana amastigotes (Chapter four), and Trypanosoma brucei brucei
(Chapters five and six), and characterized them in great detail. We have developed a
quantitative model for substrate binding by these transporters and postulated the
concept of functional conservation (as opposed to genetic conservation). This stage of
my project aims to further our understanding of the salvage of nutrients by the
intracellular Apicomplexan protozoan Toxoplasma gondii and compare its salvage
mechanisms with those of extracellular parasites such as T. brucei Specifically.
transport proteins for nucleobases and nucIeosides have been identified and
characterized with respect to substrate recognition and kinetic parameters.
Purine salvage pathways in the Apicomplexan parasites Toxoplasma gondii have been
previously studied in great detail and these reports have shown that T. gondii, like
other members of protozoan parasites, cannot synthesize purines de novo and must
salvage them from the host (Perotto, et al, 1971; Schwartzman and Pfefferkorn, 1982;
Berens, et sl., 1995). Therefore purine transporters and salvage enzymes are potential
targets or conduits for the development of improved anti- Toxoplasma drugs (Ullman
and Carter, 1995; Baldwin, et sl., 1999; Chaudhary, et el., 2004).
T. gondii has two purine salvage pathways. Hypoxanthine and guanine are rapidly
taken up by extracellular tachyzoites (Schwartzman and Pfefferkorn, 1982) and
incorporated into their nucleotides by a phosphoribosyltransferase (Krug, et al, 1989;
Heroux, et al., 2000; White, et al., 2000). The enzyme responsible for
phosphoribosylation of 6-oxypurines, hypoxanthine-xanthine-guanine-
phosphoribosyltransferase (HXGPRT), has been analysed in detail both as a drug target
itself (Wang, 1984;Ullman and Carter, 1995), and also as a tool in genetic manipulation
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of Toxoplasma (Donald, et sl., 1996; Knoll and Boothroyd, 1998; Matrajt,: et el, 2002;
Striepen, et sl., 2002; Chaudhary, et el., 2005). The source of adenosine nucleotides for
T. gondii is more enigmatic. The parasites lack an uptake system for adenine
nucleotides themselves (Ngo, et el., 2000), but it was reported that tachyzoites are
capable of using adenine nucleotides as a purine source after degradation to adenosine
(Schwartzman and Pfefferkorn, 1982). A nucleoside triphosphate hydrolase (NTPase)
capable of hydrolysing ATP to AMP is released by the parasite into the parasitophorous
vacuole in which the parasite resides intracellularly (Asai, et sl., 1983; Asai, et sl.,
1995). However, tachyzoites appear to lack an ecto 5'-nucleotidase that could hydrolyse
the AMP to adenosine for subsequent uptake and so the route by which nucleotides are
used remains to be elucidated (Ngo, et sl., 2000).
Adenosine itself can be incorporated by T. gondii directly into AMP via adenosine
kinase and as this parasite enzyme is at a ten-fold higher activity than HXGPRT (Krug,
et el., 1989), it has been proposed that adenosine is the preferred source of purines for
the parasite (Krug, et sl., 1989). Consistent with this theory, an adenosine transporter
(TgAT1) was identified in the plasma membrane of T. gondii tachyzoites (Schwab, et
sl., 1995). However TgATl has only a low affinity for the nucleoside, which casts
doubt on it being the main entry mechanism for adenosine, which is thought to be
present only at sub-micromolar concentrations in the host cell cytoplasm and
parasitophorous vacuole. Moreover, mutants of T. gondiilacking HXGPRT (Donald, et
sl., 1996), the TgATl adenosine transporter (Chiang, et el., 1999), and adenosine kinase
(Darling, et al., 1999) have now all been created and, surprisingly, all are viable. Thus
there was a need to re-evaluate the mechanism of uptake, and importance as a source of
purine, of adenosine. There is very little known about the mechanism of purine uptake,
and as this represents the first step of the parasite's purine metabolism, this makes
purine nucleobase and nucleoside transporters an attractive target for chemotherapy.
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The work with Toxoplasmagondii has led to major new insights in nutrient salvage in
apicomplexan parasites, with the identification of novel high affinity nucleoside
(TgAT2) and nucleobase (TgNBT1) transporters. A detailed model of substrate binding
by TgAT2, explaining its unique high affinity for all physiological nucleosides, has been
created. This work was performed in collaboration with other research groups within
the Division of Infection and Immunity, and has, in part, been previously published as
De Koning et a1. (2003) Int J Parasitol. 33:821-31 (see Appendix Ill).
7.2 Results
7.2.1 Purine nucleobase is taken up by a high affinity hypoxanthine transporter
Figure 7.1A shows that uptake of [3H]hypoxanthine at 0.1 J..lM,1 J..lMand 10 J..lMby T.
gondiitachyzoites, was rapid and linear for up to 180 s, with rates of 1.0 ± 0.3 x 10-4, 4.3
± 0.2 x 10-4 and 1.75 ± 0.09 x 10-3 pmolfl O?parasitesj+s", respectively (calculated by
linear regression). [3H]Hypoxanthine transport at concentration of 0.3 J..lMmeasured at
120 s over a range of 0 - 1000 J..lMof unlabeled hypoxanthine was saturable and
complied with simple Michaelis-Menten kinetics, with a Km value of 0.91 ± 0.19 J..lM
and a Vmax value of 0.0045 ± 0.0014 pmol (107 parasites)-ls-l (n = 3) (Figure 7.1B and
inset).
The inhibitory effects of potential substrates for this hypoxanthine transporter,
designated TgNBT1, were tested by measuring initial uptake rates of 0.3 J..lM
[3H]hypoxanthine in the presence of varying concentrations of test compounds (Figure
7.2). The 6-keto nucleobases, guanine (6.9 J..lM) and xanthine (134 J..lM) inhibited
hypoxanthine transport by 50.2 ± 2.9 % (P < 0.005) and 61.4 ± 2.1 % (P < 0.005),
respectively, whereas the aminopurine adenine and the nucleosides, adenosine and
inosine, were less potent inhibitors (21.0 ± 3.8 %, 50.5 ± 2.0 % and 47.6 ± 5.7 %,
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respectively, at 1 mM). The hypoxanthine analogue allopurinol also weakly inhibited
hypoxanthine transport, by 29.7 ± 8.4 % at 1 mM (P < 0.05). Whereas, pyrimidines,
such as uracil, had almost no effect up to ImM on hypoxanthine transporter (Figure
7.2).
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FIGURE 7.1 Nucleobase uptake in T. gondii tachyzoites. A. Uptake of 100 nM (.), 1.0
J.lM(0) or 10 J.lM(A) [3H]hypoxanthine was linear for 180 s. B. Inhibition of 0.1 J.lM
[3H]hypoxanthine uptake by 0-1000 J.lMunlabeled hypoxanthine (Ieso = 0.59 ± 0.12
J.lM). Michaelis-Menten plot (inset) shows calculated Km and Vmax values for this
experiment of0.49 J.lMand 45 x 10-4pmolf lO?parasitesjls', respectively.
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FIGURE 7.2 Inhibition profile of the T. gondii nucleobase transporter, TgNBT1. Uptake
of [3H]hypoxanthine (0.3 J.lM)was measured in the presence of various inhibitors and
expressed as percentage of control, defined as [3H]hypoxanthine uptake in the absence
of inhibitor. Guanine (6.9 J.lM;P < 0.005), xanthine (133.5 J.lM;P < 0.005),
adenosine (1mM; P < 0.005) and inosine (1mM; P < 0.05) significantly reduced the
transport of hypoxanthine. Data shown are the average of three independent
experiments and S.E.
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Uptake of [3H]adenine at 0.1 JlM, 1 JlM and 10 JlM by extracellular T. gondii
tachyzoites was comparatively slow and linear for up to 180 s, with rates of 8.2 ± 2.0 x
10-6pmolt IO?parasitesj's', 6.8 ± 0.89 x 10-5pmol(107 parasitesr-s-' and 3.9 ± 0.7 x 10-4
pmolfl O?parasitesr-s', respectively. At 1 JlM [3H]adenine, uptake was not saturable by
unlabeled adenine concentrations up to 1mM (Figure 7.3).
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FIGURE 7.3 Uptake of 1 JlM [3H]adenine in T.gondiitachyzoites was determined at 120
s in the presence of unlabeled permeant (1-1000 JlM). No carrier-mediated transport of
adenine was observed, as indicated by the non-saturable linear uptake of adenine (5.3 ±
0.1 x 10-4pmolfl O?parasltesj+s'; r2 = 0.99).
7.2.2 Tachyzoites of Toxoplasma gondii possess two adenosine/inosine transporters
Uptake of (3H]adenosine at 1.25 JlM by T.gondiitachyzoites was linear for at least 90 s,
and saturable, with 2.5 mM unlabeled substrate greatly reducing uptake rates (Figure
7.4A). The residual rate in the presence of 2.5 mM unlabeled substrate was assumed to
be due to diffusion and in subsequent experiments uptake with 2.5 mM unlabeled
adenosine was subtracted from each data point to calculate the mediated uptake.
[3H]Adenosine transport (1.25 JlM) in the presence of unlabelled substrate (0 - 1000
JlM) conformed to simple Michaelis-Menten kinetics (Figure 7.4JJ.inset) with Km and
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Vrnax values of 105 ± 22 J..lM(n = 3) and 0.066 ± 0.002 pmolf IO? parasitesj+s' (n = 3),
respectively.
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FIGURE7.4 Transport of [3H]adenosine in extracellular tachyzoites. A. Uptake of 1.25
J..lM[3H]adenosine was measured over various intervals between 0 and 90 s in the
presence (0; rate = 1.1 ± 0.6 x 10-4 pmo1J107parasites/s) or absence (.; rate = 7.2 ± 1.0 x
10-4 pmol/Itl' parasites/s) of 2.5 mM unlabeled adenosine. B. Uptake of 1.25 J..lM
[3H]adenosine (measured over 45 s) in the presence of various concentrations of
unlabeled adenosine (ICso= 64 ± 17 J...lM).Inset shows the conversion to a Michaelis-
Menten plot, yielding calculated.Kmand Vmax values, for this experiment, of 55 ± 14 J...lM
and 0.069 ± 0.004 pmol(lQ7parasitesj!s', respectively.
Transport of [3H]inosine at 0.1 J...lM,1 J...lMand 10 J...lMwas linear for up to 180 s (Figure
7.5A). Uptake of [3H]inosine (1 J..lM),measured at 120 s, was saturable by unlabelled
inosine over the range 0 - 10 mM and exhibited Michaelis-Menten kinetics (Figure
7.5B and inset) . .Km and Vmax values for this transporter were calculated as 134 ± 36 J...lM
and 0.14 ± 0.03 pmo1J107parasites/s (n = 4).
To find out whether separate transporters are involved in the uptake of inosine and
adenosine, [3H]adenosine transport was measured in the presence of increasing
concentrations of unlabelled inosine and [3H]inosine transport was measured in the
presence of unlabelled adenosine.
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FIGURE7.5 Transport of [3H]inosine in extracellular tachyzoites. A. Uptake of 0.1 IlM
[3H]inosine (.; 1.6 ± 0.2 x 10-6 pmolt IO' parasitesjls'), 1 IlM [3H]inosine (0; 1.1 ± 0.1 x
10-4 pmolt lf)? parasitesrs') and 10 JlM [3H]inosine (.; 5.7 ± 0.3 x 10-4 pmolf IO?
parasitesl+s') measured over various intervals between 0 and 180 s. B. [3H]Inosine
uptake (Lp.M) was measured over 120 s in the presence of 0 - 10 mM unlabeled inosine
(ICso = 91.7 JlM). Inset shows conversion to Michaelis-Menten plot (Km = 100 JlM; Vmax
= 0.072 pmolf IO' parasitesr-s').
The results, depicted in Figure 7.6, show that inosine does inhibit adenosine transport,
and vice versa, but in a biphasic manner, revealing a high affinity transport capacity for
the two purine nucleosides. The presence of high affinity [3H]adenosine and
[3H]inosine transport was confirmed at label concentrations of 25 and 100 nM,
respectively (Figure 7.7A,B). Km and J(jvalues for the high and low affinity transporters
of [3H]adenosine and [3H]inosine are given in Table 7.1. The data are entirely
consistent with there being two transporters, both the previously described low affinity
nucleoside transporter TgATI (Schwab, et sl., 1995) and an additional high affinity
transporter, designated TgAT2. Both transport adenosine as well as inosine: the Km
values for [3H]adenosine transport are very similar (P> 0.05; unpaired T-test) to the /G-
values for adenosine using [3H]inosine as permeant, and this is also true for the reverse
experiment. It should be noted that the data in Figure 7.6 were obtained much later
than those in Figures 7.4 and 7.5. In the first set of experiments, we observed a rate
consistent with Figure 7.4, very consistently, leading to a Vmax estimate for adenosine of
0.066 ± 0.002 pmolf lff? cellsl+s' - note the small error over three experiments. In a
later series, using stabilates from the same strain, we consistently observed a much
higher rate of transport at low permeant concentrations and clear evidence for two
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transporter systems. Therefore, quantitative comparisons between the two sets of data
are inappropriate. Several explanations are possible for this apparent discrepancy, most
prominently the ability of Toxoplasma to express additional (high affinity) transporters
when needed. A subtle difference in culture conditions or host cells may have been
responsible for the change.
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FIGURE 7.6 Adenosine and inosine compete for the same transporters in T. gondii
tachyzoites. A. Inhibition of 1.25 jJM [3H]adenosine by up to 10 mM unlabelled inosine
was shown to be biphasic by non-linear regression (P=0.001l), with ICsovalues of 0.70
and 127 jJM. B. Transport of 1 jJM [3H]inosine was inhibited by adenosine in a biphasic
way (P=0.018), with ICsovalues of0.49 and 174 jJM, respectively. Inset shows the same
data on a different scale.
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FIGURE 7.7 High affinity transporters for adenosine and inosine. A. Uptake of 25 nM
[3H]adenosine (expressed as percentage of control- no inhibitor) was inhibited by up to
1 mM unlabeled adenosine (., ICso= 1.1 JlM) or inosine (0, ICso= 1.3 JlM). Inset shows
the conversion to Michaelis-Menten plot with Km = 0.61 JlM and Vmax = 0.30 pmolf lff
parasitesr+s'. B. Uptake of 100 nM [3H]inosine in the presence or absence of various
concentrations of unlabelled inosine (., ICso = 0.56 JlM) or adenosine (0, ICso = 0.76
JlM). Michaelis-Menten plot (inset) yielded Km (0.68 JlM) and Vmax (0.0026 pmolt lf)?
parasitesrs') values.
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TgATl TgAT2
Vmax
IG(adenosine)
IG(inosine)
[3H]adenosine [3H]inosine [3H]adenosine [3H]inosine
105±22 134±36 0.49±0.12 0.77±0.20
0.066 ± 0.002 0.14 ± 0.03 0.17 ± 0.04 0.0048 ± 0.0026
88 ± 35 0.40 ± 0.12
105 ± 19 0.28 ± 0.11
TABLE 7.1 Kinetic parameters for T. gondii nucleoside transporters using either
[3H]adenosine or [3H]inosine as permeant. Km (IlM) and Vma" (pmolfl O?cellsrts')
values were obtained by non-linear regression from Michaelis-Menten plots as
depicted in Figures 1 and 3. /G values for inhibition of [3H]permeant were calculated
from ICsovalues (IlM). All values are the average of 3-4 independent experiments.
7.2.3 TgAT2 is a broad specificity nucleoside transporter
Whereas the low affinity transporter is most likely the same adenosine transporter
described earlier by Schwab et al. (1995) and cloned by Chiang et al. (1999), a high
affinity nucleoside transport has not previously been described for T. gondii. We
therefore undertook a thorough analysis of the substrate selectivity of TgAT2, using 50
nM [3H]adenosine as a permeant (Table 7.2). The most striking characteristic of TgAT2
is that it displays very high affinity (/G < 2 IlM) for both purine and pyrimidine
nucleosides, with cytidine being the only natural nucleoside for which it has lower
affinity. However, nucleobases such as adenine, cytosine and uracil had no effect on
[3H]adenosine uptake at concentrations up to 1 mM (n = 3). This indicates that a
significant part of the high affinity binding is the result of interactions of the ribose
moiety with amino acid residues in the TgAT2 binding pocket. These interactions
appear to consist of hydrogen bonds to the 3' and 5' hydroxyl groups of the nucleosides,
as the /G values for 3'- and 5'-deoxythymidine were >200-fold higher than those for
thymidine. This translates into an apparent loss of Gibbs free energy for the interaction
of the substrate with the transporter of 12.9 and 16.8 kl/mol, respectively (Table 7.2).
It is highly unlikely that the 2' hydroxyl group contributes to substrate binding, as
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thymidine, which lacks a 2' hydroxyl group, displays the same affinity for TgAT2 as
does uridine, which does have a hydroxyl at this position. This observation also
suggests that the only other difference between uridine and thymidine, the methyl
group at position 5 of the pyrimidine ring, does not make an important contribution to
the binding energy of the nucleoside.
Compound Ki(IlM) AGO(kl/mol)
Purine nucleosides
Adenosine 0.49 ± 0.12 -36.0
Inosine 0.28 ± 0.11 -37.4
Guanosine 1.5 ± 0.3 -33.2
Xanthosine a 556 ±53 -18.8
3-Deazaadenosine a 400 ±45 -19.4
7-Deazaadenosine 0.24±0.04 -37.8
AraA 2.9 ± 0.8 -31.6
Pyrimidine nucleosides
Uridine 1.5±0.4 -33.2
Thymidine 1.3±0.5 -33.6
Cytidine 32± 10 -25.7
2-Thiouridine 0.68 ±0.06 -35.2
4-Thiouridine 0.40 ±0.03 -36.5
3-deazauridine a 360 ±78 -19.7
3'-deoxythymidine 280 ± 82 -20.3
5'-deoxythymidine 1040 ± 210 -17.0
Ribose a 22500 ± 7800 -9.4
TABLE7.2 TgAT2 inhibition constants (Ki) and Gibbs Free Energy (AGO)for various
nucleosides. IG or Km values were calculated form ICso values obtained from inhibition
curves featuring a minimum of 6 points over the relevant range, using equation 1.
[3H]Adenosine concentration was 50 nM throughout. Gibbs free energy was then
obtained using equation 2, as described in Chapter two. a Estimated from partial curve,
giving >50% inhibition. Hill slope was assumed to be -1, and eventual inhibition was
taken to be equal to that of 1mM adenosine.
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Even though the ribose moiety contributes very strongly to nucleoside binding by
TgAT2, ribose itself only weakly inhibited [3H]adenosine uptake. The estimated IV
value was around 22 mM. This is some 25 kl/mol less binding energy than with
adenosine or uridine and the difference must be attributed to binding of the purine or
pyrimidine base group. The keto groups at positions 2 and 4 of uridine were not
involved in interactions with the transporter, as IV values for 2-thiouridine and 4-
thiouridine were slightly lower than for uridine (Figure 7.8A). The slightly higher
affinity may be related to the protonation state of N3, as the thione group is less basic
than the keto group. As a result, protonated N3 is a slightly better H-bond donor in
either thiouridine. The importance of this is readily confirmed by the very low affinity
of TgAT2 for 3-deazauridine (Figure 7.8A). The o(~GO) of 13.5 kl/mol accounts for most
of the apparent bond energy of the pyrimidine ring. The remainder must, by default, be
the result of 1t-1t stacking with an aromatic amino acid residue, as the uracil moiety
contains no other functional groups capable of forming interactions of sufficient energy
with the TgAT2 binding pocket. The significantly lower affinity for cytidine than for
uridine or thymidine is explained by the greatly reduced level of protonation at N3,
which changes this residue from a hydrogen bond donor to an H-bond acceptor.
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FIGURE7.8 Substrate selectivity of TgAT2. Uptake of 50 nM [3H]adenosine by
extracellular tachyzoites was measured in the presences of various concentrations of
potential inhibitors and expressed as percentage of control, defined as [3H] adenosine
uptake in the absence of inhibitor. A. Pyrimidines: uridine (.), 2-thiouridine (0) and 3-
deazauridine (~). B. Purines and ribose: 7-deazaadenosine (a), 3-deazaadenosine (0)
and ribose ("). In the case of incomplete inhibition plots, the Hill slope was assumed
to be -1 and eventual inhibition 100%, being equal to inhibition by 1mM adenosine.
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Purines appear to be similarly bound by H-bonds to the 3' and S' hydroxyl groups, as
well as a single H-bond to a ring nitrogen residue and 7t-7t stacking. The unprotonated
N3 residue forms the main H-bond with the TgAT2 binding pocket, as evident from
the almost IOOO-foldhigher IV value for 3-deazaadenosine than for adenosine (Figure
7.8B). This constitutes an apparent loss of 16.6 kl/mol in Gibbs free energy. Assuming a
similar positioning of the purine and pyrimidine nucleosides in the transporter,
stabilised by the strong binding of the ribose moiety present in both, it is unsurprising
that both should be capable of interaction with the same aromatic residue for the
energetically favourable 7t-7t stacking (Figure 7.9). There was no evidence for further
interactions of TgAT2 with other parts of the purine ring. 7-Deazaadenosine
(tubercidin) displayed virtually the same binding energy as adenosine (Figure 7.89),
ruling out any contribution from N7. The lack of discrimination between aminopurines
and oxopurines (ie. adenosine and inosine) appears to rule out significant interactions
with either the amino or keto groups at position 6, or with NI (whether protonated as
in oxopurines or unprotonated as in aminopurines). However, the amino group at
position 2 appears energetically unfavourable, given the slightly lower affinity for
guanosine (Table 7.2). Neither is an H-bond acceptor more favourable at this position
given the o(~GO) of 18.8 kJ/mol of xanthosine, compared with inosine. This large loss of
interaction energy results mostly from the loss of N3 as an H-bond acceptor, since this
residue is protonated in xanthosine, but additionally from the same steric effects from
the substitution at position 2 that reduced affinity for guanosine. Substitution of the
ribose moiety for arabinoside reduces the Gibbs free energy of the interaction with
TgAT2, by 4.4 kj/mol, but adenine arabinoside (AraA) still displays high affinity for
this transporter.
The model for the interactions of TgAT2 with uridine and adenosine is shown in
Figure 7.9A. It seems reasonable to predict that the 7t-7t stacking occurs mostly with
the imidazole part of the purine ring, since the aromatic amino acid must be equally
well positioned for optimal energy gain with the pyrimidine ring.
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A TgAT2
B T. b. bruceiP 1
FIGURE7.9 Model for interactions between (A) the TgAT2 or (B)TbbPI binding pocket
and adenosine or uridine. Shaded areas depict areas of interaction with amino acid
residues (R) in the transporter binding pocket, most probably H-bonds. An aromatic
ring with rt-orbitals is schematically included to depict 1t-1t stacking with the purine or
pyrimidine ring. Apparent .1Go for the interactions is given in kl/mol, The model for
TbbPI was adapted from (De Koning and Jarvis, 1999).
The TgAT2 mechanism for binding of adenosine is very close to that used by the T. b.
brucei PI transporter (De Koning and Jarvis, 1999), depicted in Figure 7.9B for
comparison. The sole difference between the two binding pockets appears to be the
change of the aromatic residue of TgAT2 to a hydrogen bond donor in PI. Indeed, this
change, and the resultant absence of 1t-stacking to bind the pyrimidine ring, explains
the low affinity of PI for pyrimidine nucleosides (De Koning and Jarvis, 1999).
However, PI does bind uridine, with a Kivalue of830 ± 86jlM, but not 3-deazauridine,
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which does not inhibit PI-mediated pH]adenosine transport at concentrations up to 10
mM (De Koning and Jarvis, 1999). An estimation of a IVvalue for 3-deazauridine, and
O(dGO) relative to uridine, can not be given but it is clear that PI, like TgAT2, can form
a strong bond with N(3)H of a pyrimidine nucleoside (Figure 7.9).
7.3 Discussion
In a mammalian host, T. gondii develops within a host cell and is separated from the
host cytosol by the parasitophorous vacuole membrane (PVM). The precise nature of
the PVM is the subject of ongoing debate, but it is likely that it is freely permeable to
low-molecular weight molecules such as purines and pyrimidines and their nucleosides
(Schwab, et el., 1994). It follows that the free concentrations of adenosine and other
purine nucleosides and bases in the parasitophorous vacuole are similar to the
concentrations in the host cell cytosol, which is thought to be below 1 J.lM(Plagemann,
et el., 1988). This situation was not consistent with the previous literature which states
that adenosine is the main purine source for T. gondii (Krug, et sl., 1989) and that
tachyzoites express just a single, low affinity adenosine transporter, with a Km > 100 J.lM
(Schwab, et sl, 1995; Chiang, et el, 1999).This paradox seemed to be resolved with the
discovery of a NTPase that is secreted into the parasitophorous vacuole (PV) in large
amounts by the tachyzoites (Asai, et el., 1983; Sibley, et el., 1994;Asai, et sl, 1995) and
which was believed to produce large quantities of free adenosine within the PV by
degrading the ATP entering the PV from the host cell's cytosol (Schwab, et al., 1995).
However, it is now known that only a small proportion of the NTPase is in an active
form (Silverman, et sl., 1998) and it yields mono-phosphorylated nucleotides rather
than nucleosides (Asai, et el., 1995). AMP is a very poor purine source for tachyzoites
as it cannot be taken up without prior dephosphorylation (Schwartzman and
Pfefferkorn, 1982;Ngo, et el., 2000). Ngo, et al (2000) were not able to detect, either in
the PV itself or on the T. gondii plasma membrane, the ecto-5' -nucleotidase activity
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required to mediate this dephosphorylation. Moreover, activation of the NTPase leads
to rapid lysis of the host cell (Silverman, et sl, 1998). Thus the overall evidence
suggests that the enzyme does not play any significant role in purine salvage by the
intracellular tachyzoite.
Toxoplasma, like all protozoan parasites studied to date except for the opportunistic
Acanthamoeba (Hassan and Coombs, 1986), is a purine auxotroph (Perrotto, et el,
1971; Schwartzman and Pfefferkorn, 1982) and the absence of a credible source of
purines that could be salvaged by the low affinity transporter TgATI prompted us to
re-investigate purine transport in tachyzoites. Our finding that T.gondii expresses high
affinity transporters for purine nucleosides and for hypoxanthine/guanine explains how
the parasite is able to salvage efficiently the low levels of free purines that are thought
to be present in the PV.
The low affinity transport activity also described here is almost certainly the TgAT
transporter recently cloned by Chiang, et al (1999). This transporter displayed a Km of
114 J..lMand was sensitive to inosine. In 1995, Schwab and colleagues described a
similar inosine-sensitive adenosine transporter in T. gondii tachyzoites, with a Km of
120 J..lM,although it was unclear whether a second inosine transporter was also
expressed. These authors also reported that adenine and hypoxanthine inhibited
adenosine transport and suggested that this transporter mediated both nucleoside and
nucleobase uptake. However, inhibition by these bases did not exceed 50% at 1.6 mM
(Schwab, et el., 1995) and the identification of a high affinity hypoxanthine
transporter, which is reported here, suggests that the low affinity adenosine transporter
is unlikely to make any major contribution to nucleobase uptake in tachyzoites.
TgAT} was cloned by insertional mutagenesis that resulted in resistance to AraA
(Chiang, et sl., 1999). Chiang and colleagues reported that a single insertion event,
which resulted in a loss of TgATl activity, conferred AraA resistance. These findings
appear to differ from those of the current study, which demonstrate that tachyzoites
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are capable of expressing a second transporter that should be readily able to mediate
AraA uptake. There are several possible explanations for these apparently contradictory
findings. It is possible that TgAT2 does not in fact transport AraA, though it is
inhibited by it. However, this would not explain the apparent lack of (3H]adenosine
transport by the mutant line (Chiang, et el, 1999;Ngo, et sl., 2000). It is conceivable
that TgATI and TgAT2 are products of the same gene, produced by alternative splicing
or post-translational modifications. If this is the case, expression of active TgAT2 may
be controlled by environmental factors and may not have occurred under the culture
conditions and the type of host cells used in Chiang et al's study. A single amino acid
substitution between allelic isoforms of the candida albicans concentrative nucleoside
transporter CaCNT produced distinct high- and low-affinity nucleoside transporter
activities (Slugoski, et el, 2004). Moreover, it may be possible that a single insertion
event is capable of disrupting two adjacent genes and that such happened with the two
nucleoside transporters. Further studies on the regulation of the expression of these
transporters, and/or the cloning of TgAT2,will be required to resolve this issue.
The results of Schwab et el. (1995) and Chiang et sl. (1999) showed that TgATl
transports only purine nucleosides, as the transporter was insensitive to inhibition by
sub-mM concentrations of nucleobases or pyrimidine nucleosides. In contrast, TgAT2
displays high affinity for all natural pyrimidine and purine nucleosides. The
combination of very high affinity and broad specificity has not been described before
for a protozoan nucleoside transporter. On the basis of sequence homology, protozoan
nucleoside transporters characterised to date have been classified as belonging to the
ENT family, which includes the human equilibrative nucleoside transporters (Hyde, et
el, 2001). However, like the Leishmania donovani (Vasudevan, et el., 1998; Carter, et
sl., 2000b) and Trypanosoma brucei nucleoside transporters (Carter and Fairlamb,
1993; De Koning, et el., 1998; De Koning, and Jarvis, 1999), TgAT2 displays 2-3 orders
of magnitude higher affinity for its substrates than do any of the mammalian family
members. Functionally, TgAT2 most closely resembles the human sodium-dependent
nucleoside transporter hCNT3 in that this transporter also recognises all physiological
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nucleosides with similar affinity (apparent .Km values 15-52 J.lM)(Ritzel, et sl., 200tb;
Toan, et el., 2003).
The very broad substrate specificity, the high affinity and the high capacity of TgAT2
means that, like hCNT3 (Ritzel, et sl., 2001b; Smith, et sl., 2005), it could be an
efficient conduit for the uptake of various therapeutic nucleosides. We have therefore
further investigated the mechanisms that allow TgAT2 to bind oxopurines,
aminopurines and pyrimidines with sub-ulvl affinity, using the same techniques that
enabled the modelling of the transporter-substrate interactions of the T. brucei
nucleoside transporters (De Koning and Jarvis, 1999) and the human, trypanosome and
Leishmania major nucleobase transporters (Wallace, et sl., 2002; Papageorgiou, et sl.,
2005; Chapter three). The low affinities for 3'- and S'-deoxythymidine, relative to
thymidine, clearly demonstrate the importance of these hydroxyl groups for optimal
interactions with the transporter, even though it cannot be affirmed whether they
function as a hydrogen bond acceptor, donor, or both. In contrast, the 2' hydroxyl does
not contribute to transporter recognition, as thymidine has an equal affinity for TgAT2
as uridine. The high energy of the two ribose hydrogen bonds ensures that the ribose
moiety as a whole has a major contribution to the very high affinity of TgAT2 for
nucleoside substrates and is sufficient to explain the lack of interaction with any
nucleobases at concentrations below 1mM. It also helps to explain the broad specificity
for physiological nucleosides including 2'-deoxynucleotides. It shares this feature, as
well as a strong H-bond with N3 of the purine ring, with the T. b. bruceiPI transporter
(De Koning and Jarvis, 1999). However, whereas the latter transporter is purine-
specific, TgAT2 also efficiently transports pyrimidines. This major difference in
substrate specificity could be due to a single substitution of a H-bond donor in the
permeant binding pocket to an aromatic amino acid residue. Whereas Pl forms a H-
bond with an apparent energy of -13 kl/mol with N7 of adenosine, TgAT2 displayed
equal affinity for adenosine and 7-deazaadenosine (tubercidin). Neither is it likely that
TgAT2 forms H-bonds with Nl or with substitutions at position 6, as it does not
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discriminate between oxopurines (NI in lactam form) and aminopurines (pyrimidine-
like NI). The postulation of x-x stacking is therefore the result of exclusion of all other
possibilities and the necessity of accounting for -10 kl/mol in the Gibbs free energy
between 3-deazaadenosine and ribose. The situation is even clearer for the binding of
the pyrimidine nucleosides, as the pyrimidine ring of uridine is bound only through a
hydrogen bond at N(3)H: substitution of either keto group by thione failed to reduce
affinity for TgAT2. The difference in Gibbs free energy between binding uridine or
ribose was 23.8 kj/mol, and only 13.5 kj/mol could be attributed to the H-bond with
N(3)H. This leaves again -to kl/mol for n-stacking. The importance of a H-bond donor
at position 3 is also illustrated by the relatively low affinity for cytidine, the
predominant tautomeric form of which has an unprotonated N3. Similar x-stacking
energies have been reported for the T. b. brucei P2 aminopurine transporter (De
Koning and Jarvis, 1999) and the human FNTI nucleobase transporter (Wallace, et al,
2002).
T. gondii tachyzoites also express a high affinity transporter for hypoxanthine, which
may also transport guanine and xanthine, but not adenine, uracil or nucleosides. This
transporter, designated TgNBTI, is the first high affinity nucleobase transporter
described in an apicomplexan parasite. The only previous report on nucleobase
transport by an apicomplexan parasite was for the Plasmodium falciparum PfENTI
transporter, with JG values >300 ~M (Parker, et al, 2000). Carter et al (2000a)
described an almost identical nucleoside transporter (PfNT1), but reported that it was
not significantly inhibited by a lOO-fold excess of purine and pyrimidine bases.
However, high affinity hypoxanthine transporters have been detected in
trypanosomatid parasites, including T. brucei (De Koning and Jarvis, 1997a; De Koning
and Jarvis, 1997b; Burchmore, et al., 2003), Crithidia luciliae (Day and Gero, 1997), L.
major (Al-Salabi, et al., 2003), L. braziliensis panamensis (Hansen, et el., 1982), and L.
mexicana (Al-Salabi and De Koning, 2005) as well as in many other micro-organisms
and metazoans (De Koning and Diallinas, 2000). The narrow specificity of TgNBTI for
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just hypoxanthine and guanine is, however, unusual. Other eukaryotic nuc1eobase
transporters have predominantly been reported as broad-specificity purine transporters
or oxopurine/oxopyrimidine transporters (De Koning and Diallinas, 2000). The uptake
of hypoxanthine indeed appears to show that uptake rates are not saturating at the
expected concentration of -1 J.lM.In addition, there appears to be a second inhibitory
phase in the inhibition experiment, also indicative of a low affinity hypoxanthine
uptake system. The nature of this secondary, low affinity system was not investigated
in this study, but it is likely that it is mediated by one of the two broad specificity
nucleoside transporters, displaying low affinity for nucleobases and capable of
transporting them.
The absence of detectable adenine transport activity was surprising given the ability of
tachyzoites to incorporate [3H]adenine into nucleic acids (Krug, et el, 1989). However,
Krug et al (1989) postulated that adenine is first deaminated. Thus the use of adenine
may well also involve TgNBT1, although the required deaminase would need to be
located in the PV or at least on the T. gondii plasma membrane. Schwab et al (1995)
did report that (3H]adenine is taken up by tachyzoites, but did not investigate whether
this was saturable and so involved a transporter.
This study has demonstrated that TgAT2 binds nucleoside analogues, such as tubercidin
(7-deazaadenosine) and AraA, with high affinity, though formal proof that these
potential antimetabolites are indeed transported by TgAT2 will require studies with
radiolabelled compounds. The model presented here predicts that the same therapeutic
nuc1eosides efficiently transported by hCNT3 (Ritzel, et sl., 2001a; Ritzel, et sl., 2001b),
including gemcitabine, 5-fluoro-2'-deoxyuridine, fludarabine, cladrabine and, to a
slightly lesser extend, zebularine (Figure 7.10), will be excellent permeants for TgAT2.
While this makes TgAT2 a very promising conduit for therapeutic agents, it must be
remembered that in order to be effective against the growing parasites these agents
would need to be able cross the host cell membrane and so enter the PV. It was
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demonstrated that nitrobenzylthioinosine (NBMPR). an inhibitor of nucleoside
transport in mammalian cells. was transported by intracellular Toxoplasma gondii
grown in human foreskin fibroblast cells. However. under the same conditions.
uninfected fibroblast cells did not transport NBMPR (AI Safarjalani, et al. 2003). These
findings of purine nucleoside transport in T. gondii may aid in the identification of new
promising anti toxoplasmic drugs. Further studies on transport of potentially therapeutic
nucleosides by the various human nucleoside transporters should provide additional
insights as to whether such nucleoside antimetabolites could be effective agents against
toxoplasmosis and similar infections. although the possibility that infection by
Toxoplasma alters the permeability of the host cell. as is the case with infections with
Plasmodium (Kirk. 2001). should not be overlooked.
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FIGURE7.10 Structure of some therapeutic nucleosides, which can be excellent
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Chapter Eight
GENERAL DISCUSSION
CHAPTER VIIL General Discussion
The rationale behind this study of purine salvage in protozoa is that parasitic diseases
have been the cause of great suffering and death throughout recorded history. These
diseases. which include leishmaniasis and trypanosomiasis. are among the most
neglected in the world. affecting millions of the world's poorest people and attracting
little or no interest from pharmaceutical companies. Furthermore, other parasitic
diseases such as toxoplasmosis are considered as a major health problem for
immunocompromised individuals such as AIDS patients, and unborn children of
infected women.
Chemotherapy is currently the only option for the control and treatment of parasitic
infections as no vaccines are currently available to prevent or control the spread of
these diseases. Controlling the invertebrate vector of these parasites, such as the
mosquito, sandfly and tsetse fly. is very difficult due to insecticide resistance, concerns
regarding environmental damage and lack of adequate infrastructure and funds to
apply existing vector control methods on the required scale.
Treatment and control of parasitic diseases of both the human and the veterinary
condition is adversely affected by many different issues. Toxicity is one of the problems
associated with the current drugs. For example, Melarsoprol. an arsenical compound, is
the drug of choice for late-stage African trypanosomiasis, but often induces serious,
sometimes fatal side effects. Pentavalent antimonial compounds, either sodium
stibogluconate (Pentostam) or meglumine antimoniate (Glucantime) which are still the
first choice drugs in the treatment of all forms of leishmaniasis after many decades,
have many severe side effects (Wyler and Marsden. 1984; Navin. et al. 1992; Olliaro
and Bryceson, 1993; Hepburn, et sl., 1993; Gasser, et sl., 1994; McBride, et sl., 1995).
Pyrimethamine (Daraprim), an antimalarial drug, is used to treat toxoplasmosis, but
also has potential side effects. including bone marrow suppression, leukopenia, anemia.
thrombocytopenia and liver toxicity (Schwartzman, 2001).
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Resistance to common drugs is a severe and increasing problem in the treatment of
almost all parasitic diseases. The lack of response to pentavalent antimonials in visceral
leishmaniasis has been a problem for many years and is increasing worldwide
(Ouellette and Papadopoulou, 1993; Guerin, et al., 2002). The increasing incidence of
resistance to drugs used to treat African trypanosomiasis has become a real problem,
especially in the countries with highest transmission rates (Peregrine, 1994). For
example, treatment failure in melarsoprol-treated patients is on the increase.
particularly in Sudan, Angola, Democratic Republic of the Congo and Uganda (Legros.
et al., 1999). The development of resistance to isometamidium chloride has been
reported in both East and West Africa (Peregrine, 1994). Treatment failures have been
reported for toxoplasmosis when combinations of pyrimethamine-sulfadiazine and
pyrimethamine-clindamycin were used (Katlama, et el, 1996).
The high cost of some of the current drugs for parasitic diseases is also a major problem
because most of the people suffering from these infections are in poor counties.
Melarsoprol is very expensive as a complete course of treatment costs US$ 50.
However, at US$ 250 a patient. DFMO is just too expensive to use as treatment of late
stage sleeping sickness victims in Africa (Aksoy. 2003). and is used strictly as a last
resort for melarsoprol-refractory patients. In addition. the I.V. administration of
DFMO is extremely difficult under field conditions.
More effective and less costly therapeutic agents are therefore urgently needed as the
situation of parasitic diseases deteriorates and millions of people are at imminent risk.
The researchers' goal is to translate basic research discoveries into candidate drugs
ready for clinical trials. In theory. it should be possible after understanding the
physiology and biochemistry of these pathogens, to look for weak points that can be
exploited for chemotherapeutic intervention. The science of rational chemotherapy
began in earnest with the work of Paul Ehrlich who invented the term "chemotherapy"
and advanced the concept of the "magic bullet". an agent of low molecular weight that
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selectively attacks the foreign invading organisms curing the disease without causing
damage to the host (Bryant and Behm, 1989). One general approach to the
development and design of rational drugs is to identify fundamental biochemical
differences between parasite and host, such as the inability of protozoan parasites,
including Leishmania, Trypanosoma, and Toxoplasma, to synthesize purines de novo
(Berens, et sl., 1995).
The aim of this project. therefore, is to identify and characterize nucleobase and
nucleoside transporters involved in purine salvage. These carriers are of considerable
pharmacological interest since they are considered as promising targets for the
development of antiparasitic chemotherapy. Studying purine transporters in these
parasites is very useful to understand the biochemistry of these parasites as these
transporters play essential roles in their nutrition at the different stages of their life-
cycle. The identification and functional characterisation of these transporters can also
provide a target for chemotherapy by two approaches. First, by blocking the uptake of
essential nutrients like purines and developing inhibitors of these transporters.
However. using purine transporters as chemotherapeutic target in this way will be
almost impossible. Second, by the selective delivery of cytotoxic molecules (purines or
non-purines) to parasites using these transporters. Almost all current trypanocides act
selectively on the parasitic rather than the host cells because they are selectively
accumulated by the parasite as a result of differences in plasma membrane transporters
(De Koning. 200la; El Kouni, 2003). This approach. to rationally design new
trypanocides that are selectively accumulated through purine transporters, has already
been applied with considerable success in recent years (Barrett. et al, 2000; Rodenko
and De Koning, unpublished).
Analogues of purines, when used alone or in combination with other drugs, are being
evaluated as chemotherapeutic agents and are effective against almost any fast growing
cells (El Farrash, et al. 2003; Namazi, 2004). For example. allopurinol, a hypoxanthine
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analogue. has been evaluated in the treatment of Leishmania braziliensis infection and
Chagas disease (Cohn and Gottlieb. 1997). In addition. allopurinol has been used to
treat leishmaniasis alone (Pfaller and Marr, 1974; Marsden. et al. 1984) or combined
with other drugs (Martinez and Marr, 1992; Martinez. et al. 1997; Denerolle and
Bourdoiseau, 1999; Momeni, et al. 2002; Pasa, et al. 2005). Among many other
examples of apparently efficacious purine analogues. 9-deazainosine displayed
promising therapeutic indexes in L. donovani-infected hamsters (Berman. et al.• 1987).
We have extensively investigated purine nucleobase and nucleoside transporters in
Leishmania spp.. Trypanosoma spp.. and Toxoplasma gondii These organisms are
important as chemotherapeutic targets as they are responsible for the tragic
consequences of the diseases mentioned above and are also a good model for the study
of transporter function. These parasites are easily grown in suspension and to high
densities. their genomes have been sequenced and published. their genes do not have
introns and their biology and life cycle have been very well studied.
At the start of this project. there was nothing known about nucleobase transporters in
Leishmania species. We first identified a single transporter. designated LmajNBTl in
the promastigote forms of L. major (Chapter three). This transporter was the first
nucleobase transporter to be functionally characterised and was shown to possess a
high affinity for all physiological purine bases and moderately high affinity for
allopurinol. Studies with [3H]allopurinol confirmed that this transporter is its sole
route of entry into promastigotes. Despite numerous studies on allopurinol metabolism
in kinetoplastids (Marr, et al. 1978; Nelson. et sl., 1979a; Nelson, et al, 1979b; Marr,
1983; Marr and Berens. 1983), this study was the first to address the mechanism of
allopurinol uptake by the parasite. which is important in understanding the selectivity
of the drug as well as the potential for the development of resistance for allopurinol.
Indeed. there are indications that resistance to this analogue could be induced quite
easily (Cavaliere, et al, 1999;Kamau, et al. 2000).
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Earlier studies reported that L. donovani promastigotes also possess two purine
nucleoside transporters, designated LdNTI and LdNT2. The first transported adenosine
and its analogues, formycin A and tubercidin, as well as the pyrimidine nucleosides,
while the second carried inosine, guanosine, and their analogues including formycin B
(Iovannisci, et sl, 1984; Aronow, et sl., 1987). These findings were confirmed when
two closely linked genes, LdNTl.l and LdNTl.2, were identified. The LdNTl.l and
LdNT1.2 transporters mediated the uptake of adenosine and the pyrimidine nucleosides
with high affinity (Vasudevan, et sl., 1998). In addition, a single gene, LdNT2,
encoding the inosine-guanosine transporter function LdNT2, has been cloned (Carter,
et al., 2000b). It has also been suggested that the transport of adenosine, but not
inosine, seemed to have different activities in various strains of L. donovani
(Ogbunude, et sl., 1991) and L. major (Baer, et sl., 1992) promastigotes, which may be
related to the existence of the two gene copies for NTI. Two adenosine transporters, Tl
and T2, have also been reported in Leishmania donovani amastigotes (Ghosh and
Mukherjee, 2000). Tl is an adenosine/pyrimidine transporter and was very similar to
the LdNTl activity which was originally detected in promastigotes. T2, the second
adenosine transporter, is inhibitable by inosine and exclusively present in amastigotes.
It is thus evident that multiple purine transporters (isoforms) exist in all stages of
Leishmania, and that developing a single inhibitor to block them all will be exceedingly
difficult.
The next step in this study was to assess whether nucleobase transport activity is
different in various life cycle stages of Leishmania species. Therefore, a comparative
study was conducted of nucleobase transport in the amastigote forms of L. mexicana, as
L. major amastigotes cannot, as yet, be cultured in vitro. Our results confirmed that
hypoxanthine and allopurinol are taken up by a single plasma membrane transporter,
LmexNBTl, characterized its substrate profile in detail, and proved it to be extremely
similar to LmajNBTl. The finding that there is no significant difference in nucleobase
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salvage in amastigotes and promastigotes contrasts with the salvage of nucleosides in
these cells.
Nor is nucleobase transport identical in insect and mammalian stages of the related
kinetoplastid T. b. brucei It has been known for some time that bloodstream forms
express two nucleobase transporters, H2 and H3 (De Koning and Jarvis, 1997b),
whereas procyclic forms express only one, designated HI (De Koning and Jarvis,
1997a), while expressing a second, higher affinity transporter as a response to purine
starvation (De Koning, et sl., 2000b). We have now characterised this latter
transporter, H4, and identified it as the gene product of the ThNBTI gene (Chapter
five) that we recently cloned and expressed in yeast as well as in Xenopus oocytes
(Burchmore, et al, 2003). We thus not only cloned the first protozoan nucleobase
transporter, but also identified its physiological function in the parasite. Since the
publication of our findings, the cloning of two more, closely related, nucIeobase
transporters from T. b. brucei (Henriques, et el., 2003) and L. major (Sanchez, et sl.,
2004b) have been reported. These further studies confirmed that, in protozoa, purine
nucleobase transporters are encoded by ENT family genes (De Koning, et el, 2005).
However, it is as yet unclear whether pyrimidine transporters might be encoded by the
same family. Given that the genome sequences of most major protozoan pathogens
have now been published (Gardner, et al, 2002; Berriman, et al, 2005; Ivens, et al,
2005), that most ENT genes have now been cloned and characterised (Landfear, et al.
2004; De Koning, et al. 2005; This thesis) and that multiple pyrimidine transport
activities have been identified (De Koning and Jarvis, 1998; Papageourgiou, et al. 2005;
Gudin, et al. submitted). it must be postulated that these transporters are encoded by
an as yet unknown gene family.
Understanding the purine transporters and their unique substrate specificity might be
exploited to deliver cytotoxic purine analogues selectively into the parasite but not
human cells. The success of purine antimetabolites as therapeutic agents against some
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infectious diseases and malignancies relies on the efficient accumulation and selective
action on the target cell or organism. Therefore, a comprehensive study was conducted
in our group to compare the transport of purine nucleobase analogues by the H2
nuc1eobase transporter of bloodstream form Trypanosoma brucei brucei and the human
facilitative diffusion nucleobase transporter hFNTI (Wallace, et al. 2002; Wallace, et
el., 2004). This study was able to construct a model for the substrate recognition motif
of both carriers, and demonstrated that selective uptake of purine antimetabolites by
the TbH2, but not by hFNTI, is a viable option for the design of rational chemotherapy
(Wallace, et sl., 2002).
Our approach of establishing substrate recognition motifs for nutrient transporters has
recently been adopted for the study of human concentrative nucleoside transporters
(hCNTs) and human equilibrative nucleoside transporters (hENTs) (see Chapter one),
and the results seemed to confirm the possibility of selective accumulation by protozoa.
The differences in permeant selectivities among hCNTI, hCNT2, and hCNT3 are also
reflected in their different abilities to transport anticancer and antiviral nucleoside
drugs (Zhang, et sl., 2003). The group of Cass has been investigating the interactions of
uridine and its analogues, which are potential compounds in anticancer therapy. with
hCNTs expressed in a yeast strain that lacks NT activity. However, it has been found
that while hCNTI and hCNT3 were very similar, the differences in their ligand
recognition profiles were the result of differences in their permeant binding sites
(Zhang, et sl., 2003).Using an improved yeast expression system to test uridine binding
with hCNTI, hCNT2, and hCNT3, they identified the basis for differences in the ligand
recognition and permeant selectivities (Zhang. et el., 2005). Prior to that, a similar
study by the same group also compared the interaction of uridine, cytidine, and other
pyrimidine nucleoside analogues with the recombinant human equilibrative nucleoside
transporters hENTI and hENT2, which transports nucleobase, produced in yeast
(Vickers, et sl., 2002; Vickers, et sl., 2004).
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In our project, substrate specificities and affinities and recognition motifs were
determined using data profiles obtained from the standard kinetics parameters. This
allowed us to predict models of transporter-substrate interactions. which can help in
selection or development of drugs that will be efficiently accumulated by a target cell
or organelle. For example, a new class of tricyclic purine antimetabolites was tested for
toxicity in our laboratory and displayed a remarkable selectivity for the parasite's
transporter (up to 1000-fold higher affinity than for the corresponding human
transporter) and some of them showed greater trypanocidal activity than existing
hypoxanthine or guanine antimetabolites in vitro (Wallace, et aJ,2004).
Our results from the investigation of the transporters in the apicomplexan protozoan
Toxoplasma gondii, allowed us to predict a model of interaction with the pyrimidine
nucleosides, such as uridine, with TgAT2. We have demonstrated that this carrier
efficiently transports pyrimidine nucleosides but not nucleobases. The crucial
interactions that allow transport of pyrimidines in addition to purines appeared to
consist of strong hydrogen bonds to the 3' and 5' hydroxyl groups in the ribose ring,
and through a hydrogen bond at N(3)H in the base ring. Therefore, the binding
architecture of this transporter. with pyrimidine nucleosides, is very similar to
interactions between these substrates with the human concentrative nucleoside
transporters (hCNTs) and human equilibrative nucleoside transporters (hENTs)
(Vickers, et sl., 2002; Zhang, et el, 2003; Vickers, et al. 2004; Zhang, et el; 2005).
These models can predict that the same therapeutic nucleosides efficiently transported
by hCNT3 (Ritzel, et al. 2001a; Ritzel, et al.• 2001b), including gemcitabine, 5-fluoro-
2'-deoxyuridine, fludarabine, and cIadrabine will be excellent permeants for TgAT2.
This makes TgAT2 a very promising target for therapeutic agents. as these compounds
would need to cross the host cell membrane in order to get in to these parasites.
The current study also clearly shows that the substrate recognition models for the
nucleobase transporters of L. major (LmajNBTl). L. mexicana (LmexNBTl), and T.
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brucei (H2) are almost identical. For instance. these transporters appear to make similar
hydrogen bonds with hypoxanthine. through N(1)H, N3. N7 and N(9)H. but this
common motif is very different from that of the human facilitative diffusion nucleobase
transporter hFNT1 (Wallace. et al.• 2002; Chapter three). This suggests that these
related kinetoplastids would accumulate similar purine antimetabolites, which could be
designed to be excluded from human cells. Therefore. any ideal compound that should
be synthesised has to be compatible with the models proposed. Looking at the binding
sites of the transporter pocket. amino acid side chains can form a variety of hydrogen
bonds. and in fact. eleven of the 21 amino acids can form hydrogen bonds through
their side chains. Free amino group can serve as H-bond donors and free carboxyl
groups can serve as hydrogen bond acceptors. Figure 8.1 shows. for example, a
predicted model of interaction between the purine analogue 6-mercaptopurine and
binding sites of the protozoan nuc1eobase transporter and the human nuc1eobase
transporter hFNTl. 6-Mercaptopurine is a successful agent for treatment of cancer
(Galmarini, et al. 2002). The cytotoxicity of this class of purines is thought to depend
mainly on the incorporation of their phosphorylated derivates into DNA, which
interferes with the function of DNA polymerases, ligases, and endonuc1eases.
Moreover. thiopurines may also cause toxic effects by inhibiting other enzymes such as
S-phosphoribosyl-I-pyrophosphate amidotransferase, IMP dehydrogenase, or
ribonucleotide reductase, which are all involved in de novo purine synthesis enzymes.
This might explain the failure of this compound against protozoan parasites, as these
parasites cannot synthesis purines de novo.
Preliminary toxicity studies on human cell lines, with selected purine analogues that
show sub-micromolar in vitro antiprotozoal activities, are currently in progress in our
group. Some of these purine analogues have been rationally designed for selective
uptake by the parasite, and measurements of the affinities for human and parasite
transporters have indeed shown higher affinity for the protozoan transporters
(Rodenko and De Koning, unpublished). With our understanding of purine uptake by
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some of the major protozoan parasites now virtually complete, the outlook for
development of selective purine-based drugs appears highly promising.
After understanding the first step of purine salvage in these parasites, the conversion of
any promising compound by the parasite's metabolism to a form harmful to the
organism is crucial. Selective toxicity therefore needs to be the result of either selective
uptake or differences in the metabolic enzymes for pathways. Therapeutic action will
then depend on such enzymes as the phosphoribosyltransferases, among others, that
convert the analogues into nucleotides, though some purines, including kinase
inhibitors, may not need any metabolic conversion for their mode of action.
Combining our knowledge of the purine transporters with a good understanding of the
metabolism of different purine analogues, would ensure selective and efficient salvage
of such designer drugs.
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FIGURE8.1 Model for the interactions between the TbH2 (A) and hFNTl (B)
transporters and purine analogue 6-mercaptopurine. Estimated Gibbs free energy for
proposed bonds are indicated as - kj/mol. This model was adapted from Wallace et al.
(2002).
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APPENDICES
ApPENDIX 1MEDIA, BUFFERS, AND SOLUTIONS
Appendix I: Media, Buffers, Solutions
HOMEM MEDIUM
Components Quantity per litre
HEPES
MEMAmino acids (SOX)
MEM Non-essential Amino acids (100X) (Gibco)
Ig
2g
0.3 g
0.11 g
1mg
0.1 mg
S.96g
10ml
10ml
S-MEM (Gibco)
Glucose
Sodium bicarbonate
Sodium pyruvate
p-aminobenzoic acid
Biotin
Make up to pH 7.5-7.6 as the pH will, after filter sterilising, drop to 7.0-7.2. Filter
sterilise using 0.22 11mMillipore filter into sterile bottles. Complete medium (for L.
major) contains 10% Fetal Calf Serum (FCS) and 90% HOMEM. Store at 4 QCto use
within 12weeks and medium appears to be stable at -20 QCfor at least 6 months.
HMI-9 MEDIUM
Components Quantity per litre
Iscoves MEM
Hypoxanthine (or adenosine for purine nucleobase-free)
Kanamycine
Penicillin
Streptomycin
Bathocuprione disulphonic acid
Thymidine
Pyruvate
730 m!
2mM
30Ilg/ml
50 u/ml
50 lJg/ml
50 11M
160 IJM
ImM
B
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~-mercaptoethanol
L-cysteine
NaHC03
2mM
ImM
3.02 g
Adjust to final pH 7.5 and filter sterilise. Add 20% of Fetal Calf Serum (FCS) or dialysed
FCS for purine nucleobase-free.
SCHNEIDER'S DROSOPHILA MEDIUM
Components Quantity per litre
Calcium Chloride (anhydrous
Magnesium Sulfate
Potassium Chloride
Potassium Phosphate Monobasic
Sodium Bicarbonate
Sodium Chloride
Sodium Phosphate Dibasic
B- alanine
L-arginine
Lvaspartic acid
L-cystine.2HCl
L-cysteine
L-glutamic acid
L-glutamine
Glycine
L-histidine
L-isoleucine
L-leucine
L-lysine
L-methionine
L-proline
L-serine
L-threonine
L-tryptophan
L-tyrosine.2Na.2H20
L-valine
Fumaric acid
Glucose
a-ketoglutaric acid
Malic acid
Succinic acid
0.6 g
1.8 g
1.6 g
0.45 g
0.4 g
2.1 g
0.7 g
0.5 g
0.6 g
0.4 g
0.02 g
0.06g
0.8 g
1.8 g
0.25 g
0.4 g
0.15 g
0.15 g
1.65 g
0.15 g
1.7 g
0.25 g
0.35 g
0.1 g
0.72 g
0.3 g
0.06 g
2g
0.35 g
0.6 g
0.06g
c
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Trehalose
Yeast extract
2g
2g
The pH of the medium was adjusted to 5.5 with 1.0 M HC!. Filter sterilise and add 0.3%
gentamicin. The medium was supplemented with 20% of Fetal Calf Serum (FCS).
SDM-79 MEDIUM
Components Quantity per litre
S-MEM F14 powder
Medium 199 TC4S powder
MEM amino acids (SOX)
MEM Non-essential Amino acids (100X)
Glucose
HEPES
MOPS
NaHC03
Sodium pyruvate
L-alanine
L-arginine
L-glutamine
L-methionine
L-phenylalanine
L-proline
L-serine
L-taurine
L-threonine
L-tyrosine
Adenosine
Guanosine
Glucosamine HCI
Folic acid
p-aminobenzoic acid
Biotin
7g
2g
8ml
6ml
Ig
8g
Sg
2g
100mg
200mg
100mg
300mg
70mg
80mg
600mg
60mg
160mg
359mg
lOOmg
lOmg
lOmg
SOmg
4mg
2mg
O.2mg
Adjust to final pH 7.3 and filter sterilise. Add 10% of Fetal Calf Serum (FCS). Store at 4
DC to use within 12 weeks
PURINE-FREETRYPANOSOMEMEDIUM(PFTM)
D
ApPENDIX I MEDIA, BUFFERS, AND SOLUTIONS
Components Quantity per litre
RPM! 1640 medium
S-MEM powder
MEM (SOX)amino acids
MEM Non-essential Amino acids (lDDX)
CaCb.2H20
Glucose
HEPES
MOPS
NaHC03
Sodium pyruvate
L-alanine
L-arginine
L-glutamine
L-methionine
L-phenylalanine
L-proline
L-serine
L-threonine
L-tyrosine
L-taurine
Glucosamine HCI
Folic acid
p-aminobenzoic acid
Biotin
Sodium acetate
130 ml
7g
8mI
6ml
39 mg
19
8g
Sg
2g
D.2 g
0.2 g
D.1 g
D.3 g
7D mg
80 mg
0.6 g
6D mg
0.35 g
D.1 g
D.3 g
SOmg
5 mg
20mg
D.2 mg
6.5 mg
Adjust to final pH 7.3 and filter sterilise. Supplement with 7.5 mg/l bovine hemin, 5%
dialysed Fetal Calf Serum (FCS) and D.2 mM final of inosine.
YPAD (YEAST EXTRACf-PEPTONE-DEXTROSE AND ADENINE MEDIUM)
Components Quantities
Yeast extract
Peptone
Glucose
Adenine hemisulphate
6g
12 g
12 g
60 mg
E
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Bacto-agar (if solid medium required)
dH20
10 g
600ml
Adjust to final pH 6.0, autoclave at 121 QCfor 15 minutes and store at 4 QC.
SC-URA (SYNTHETIC COMPLETE MEDIUM MINUS URACIL)
Components Quantities
Difco Yeast Nitrogen Base without amino acids
Glucose
Synthetic complete drop out mix:
Adenine hemisulphate
Arginine HCI
Histidine HCL
Isoleucine
Leucine
Lysine HCI
Methionine
Phenylalanine
Homoserine
Tryptophan
Tyrosine
Valine
Bacto-agar (if solid medium required)
dH20
4g
12 g
0.5 g
2g
2g
2g
2g
4g
2g
2g
3g
6g
3g
2g
9g
10 g
600ml
Add all ingredients (except agar) to water and adjust pH to 5.6 with 10 M NaOH.
NOTE- this step is important for highest efficiency transformation. Autoclave at 121 QC
for 15 minutes.
CBSS BUFFER (CARTER'S BALANCED SALT SOLUTION)
Components Quantity per litre
MES
NaCl
KCl
CaCl2
6.4 g
5.7 g
342.9 mg
44.1 mg
F
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MgS04
NaH2P04
MgCl2
Glucose
17.2 mg
904.8 mg
60.9mg
2.7 g
Adjust to final pH 6.0 and store at 4QC.
ASSAY BUFFER
Components Quantity per litre
Glucose
HEPES
MOPS
NaHC03
KCL
MgC1.6H20
NaCl
NaH2P04.2H20
CaCh.2H20
MgS04.7H20
2.53 g
8.0 g
5.0 g
2.0 g
347.5 mg
62.5 mg
S.7 g
913.5 mg
40.7 mg
19.9 mg
Adjust to final pH 7.3 and store at 4°C. Note- for uptake assays using yeast, assay buffer
without the addition of glucose is used for the final wash and re-suspension (all other
quantities remain the same).
OIL MIXTURE
Components Quantities
Mineral oil (Sigma)
di-n-butyl phthalate
SOml
350ml
2%SDS
Components Quantities
Sodium dodecly sulphate
dH20
109
500 ml
G
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PSG (PHOSPHATE-BUFFERED SAUNE PLUS GLUCOSE)
Components Quantity per litre
Na2HP04 (anhydrous)
NaH2P04.2H20
NaCl
13.48 g
0.78g
4.25 g
Make to one litre with dH20 (PS buffer). Dissolve 10 g of glucose in approximately 200
ml of dH20 (Glucose solution). Add six volumes of PS to four volume of glucose
solution (PSGbuffer). Adjust to pH 8.0 exactly and store at 4°C.
DNA EXTRACTION BUFFER
Components Quantities
(1.0 M) Tris (pH 8)
(0.5 M) EDTA
(5.0 M) NaCI
dH20
10 rnl
2 rnl
4 rnl
to 200 ml
NAD DIAPHORASE ASSAY REACTION BUFFER
Components Quantities
NADH-disodiurn salt
0.1 M Phosphate buffer pH 7.3
dH20
4 rna
0.8 rnl
1.2 rnl
TBE RUNNING BUFFER
Components Quantities
Tris (pH 8)
Boric acid
EDTA
dHzO
53.9 a
27.5 g
2.3 g
to 5 litres
LBMEDIUM
H
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Components Quantity per litre
Trvptone
Yeast extract
NaCl
10 a
S,g
10
Adjust to final pH 7.0, autoclave at 121°C for 15minutes and store at 4°C.
I
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Appendix II: Supplementary Data
A. Structure of some purine nucleobases and nucleosides and their analogues used to
construct the models for the interactions between the transporters binding sites and the
permeants.
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B. Structure of some pyrimidine nucleobases and nucleosides and their analogues used
to construct the models for the interactions between the transporters binding sites and
the permeants.
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c. Multiple alignment of human and protozoan ENT genes. Alignment was generated
using the program dialign (Morgenstern, B. (1999) DIALIGN 2: improvement of the
segment-to-segment approach to multiple sequence alignment. Bioinformatics 15,211-
218) using the blosum62 matrix. Reproduced from De koning et al. (2005).
Key aliphatic, aromaticlhydrophobic, blue; positive, red; negative, magenta;
hydrophilic, green; praline, yellow; glycine, orange.
hENTI
hENTl
LdNTl.l
hENT3
ThAT ...
ThNTS.I
hENT~
ToNTI
ThAT B
Th_U-O
Th.U-E
ThAT-F
ThAII
ThAI GC~"TI
C~"T2
ThAT 1
PiNT!
LdNTl
ThNTl
ThNT3
ThNT4
ThNT5
ThNT6
lm.'.T3
ThNT;
lm.'."T4
ThNBTI
bENT I
bENT2
LdNTl.l
bENT}
ThAT A
ThNTS.l
bENT~
IgNTI
ThAI B
ThAI-O
ThAI-E
ThAT-F
ThAII
ThAI G
Cc\"TI
Ct:'<TI
ThAI I
PiNT!
LdNT2
ThNT2
ThNT3
ThNT4
ThNT5
ThNT6
lm.'."T3
ThNTI
lm.'\"T~
ThNBTl
10
I
20
I
so
I
30
I
40
I
TIS H - - - - - - - - - - - - - - - - - - - - - - - - -
A- - - - - - - • - - - - - - - - - - - - - - - - - - - - - - - -
MOIAPDHREPQEQ ESRKWY--------- -------
... VVSEDDFQHSSNSIYRTISSSLR ... DQEALLEKLLDR
- - Q-
L Q R-
SQRLEEPSVA I-- VVMSFTFD
60
I
70
I
- E - - -
SHQLEE ...... EA ... Q Q LRAR
I EERAVAAQQMSKA--
- D- - -
- K- - -
- KD- -
- R- - -
K
ApPENDIX 11 SUPPLEMENTARY DATA
110 120 I~O
bEl\'Tl
bENT2
LdNTl.l
hENT3
ThAT A
ThNTil
hENT4
TgNTl
ThAT B
ThAT-D
ThAT=E
ThAT F
Th.UI
Th.U G
CC\.[
C!)l'2
ThAT 1
PiNT!
LdNT2
ThNT2
ThNT3
ThNT4
ThNT5
ThNT6
l.l:ru"'3
ThNT7
Lm."'4
ThNBTl
160 170 190 lOO
bENT I
hENT2
LdNTU
bENT3
ThAT A
ThNTS.l
bENT4
TgNTl
ThAT_B
ThAT D
ThAT-E
ThAT-F
ThATI
ThAT G
CC·"I
Cc\'T2
ThAT 1
PiNT!
LdNT2
ThNT2
ThNT3
TbNT4
ThNT)
TbNT6
Lm..... 3
TbNT7
Lm..... 4
TbNBTl
210 220 130 ~.I0 250
bENTl
bENT2
LdNTU
bENT3
ThAT A
ThNTil
hENT~
TgNTl
ThAT B
ThAT-D
TbAT-E
ThAT-F
Tb.UI
ThAT G
Ct:'>'[
Cc\.2
ThAT]
PiNT!
LdNT2
TbNT2
ThNT3
TbNT~
IbNT)
TbNT6
Lm."'3
TbNT;
Lm."H
TbNBTl
L
ApPENDIX II SUPPLEMENTARY DATA
260 170 1S0 290 300
I I
bENT 1 E -
bENTl T -
LdNTl.l E -
bENT3 N-
ThA.T A KRTEDRVA
ThNrS.l E -
bENT4
TgNTl
ThAT B E -
Th_U-O S -
Th.U-E E -
ThAT-F E -
ThATI
H-
ThAT G
KRTEDRVA
CrSTI E -
CD-12 H-
ThAT 1 E -
PiNT! VNK-
LdNT2 Q-
ThNTl E -
ThNr3 E -
ThNr4 E -
ThNr5 E -
ThNr6 T -
Lm.'-n -.-ThNT7 K-
Lm.'i~
S -
ThNBTl E -
310
bENT 1
hENT2
LdNTl.l
bENT3
ThAT A
ThNrS.1
bENT4
TgNTl
ThAT B
ThAT-D
ThAT-E
ThAT-F
ThATI
ThAT G
C£,<il
C£'<12
ThAT 1
PiNT!
LdNT2
ThNrl
ThNr3
ThNr4
ThNT5
ThNr6
Lm.'n3
ThNr7
Lm.'i4
ThNBTl
bENT 1
bENTl
LdNTl.l
bENT3
ThAT A
ThNrS.1
bENT4
TgNTl
ThAT B
ThAT-D
ThAT-E
ThAT-F
Th.UI
ThAT G
CD-il
CD-12
ThAT 1
PiNT!
LdNTl
ThNTl
ThNr3
ThNr4
ThNr5
ThNr6
Lm."i3
ThNri
Lm.xi~
ThNBTl
410
I
410 430
I I
K L.L I S KG E E -
_KAELLQSDEN
~.I0 450
I I
RQPFSTNPVAQ
E -
SEIYGDLI
-IE- E
: IS E
- E
- E
- E
QD
E -
M
ApPENDIX II SUPPLEMENTARY DATA
bENTI
bENT2
ldNTUbENT3
ThAT AThNT81
bENT4
T!NTIThAT BThAT-D
ThAfE
ThAfF
ThAT!
ThAT G
Cf:'I.l
C~'T2ThAT 1
PINT!
LdNT2ThNT2
ThNT3
ThNT4ThNT5
ThNT6
1=".3ThNT7
lm."'~ThNBTI
bENTl
bENT2
LdNTU
bENT>ThAT AThNT8.1
bENT4TgNTlThAT BThAT-DThAT-E
ThAT-F
Th.U!
ThAT GC~.r
C~'2ThAT 1
PINT!
LdNTl
ThNTl
ThNT>
ThNT4
ThNT5ThNT6
L='\'T3ThNT7
lm.""~ThNBTI
bENT I
bENT2
LdNTU
bENT>
ThAT A
ThNTS.1
bENT4
TgNTlThAT BThAT-D
ThAT-E
ThAr-F
ThAI!ThAT G
C~.l
Cf:'I'2ThAT 1
PINT!
LdNT2
ThNT2
ThNT3ThNT4
ThNT5ThNT6
lm."'3ThNI7
lm."'~ThNBTI
460
I
470
I
~so
I
490
I
soo
I
EPESEP-
S KEV~-
KA· .. D·
RE· . AQ-EGERVE.
ECEREA·
VA· ID·
H
KA· D·
D-
D·
N·
D·
L·
D·
R· KVAAS NRACHHlSLLYDDRFFT
510
I
520
I
530
I
540
I
550
I
I Q
I A
VA
RERlEAE TQEFAlE SHD AAVNATQT ACDCAHSQMTS EVSKEVVT
560 S70 580
I I IRA K· DEP·
Al· E·
c x . A
YE· QQ.K S . T S .
DE· R S .
NN· IT·
590
I
600
I
VQTAAAKSE AV
.......................
KSNVMISIVD!P::IITM
DD· ID·
C K· A
EKNAEAHKDDPLAERELSEEES DSRAVEAADL ATVDDK·· ·-ERALNEEE DEVRAVTSEEFHVKR
Kl\J
TM
TM
TMTM
EAPKAGEKEVTLDAMEEADE· DE·
DE·
DE·DE.
DE·DE·
DE·
VRAV
K E·
K E·
K E·
KE-
KE-
V R·
K E·
SDAFVAKSGAVLQATGDA RM
NKNVlNADID[ KM
NKNVLNADIDP KM
NKNVlNADI DP OM
NKNVlNADIDP KM
NKNVLNADIDP DMAV RQA DTCS SN
N K N V L N A D I D~ KM
QKTAELERDNNDl AAA·
N
ApPENDIX II SUPPLEMENTARY DATA
610 630 6-10 650
I
hENT! EESGV. S VS N·
hENT2 .
LdNTl.!
bENT3
ThAT A
ThNTS_l
bENT~
TgNIl
Th_U B
lbAT-D
Th_U=E
lbAT F
ThATI KIMD.
lbAT G R T D·
Cf:\,l
Cf:\T2 V.L D·
ThAT J
PiNT!
LdNT2 IDlbNT2 K T D·lbNT3 K T D·lbNT4 R T D·ThNT) K T D·
ThNT6 R T D·
Lm.'H3 S D··
lbNT7 K T D·
Lm."~ D·
lbNBTI
680 700
I
bENT!
hENT2
LdNTU
bENT3
lbAT A
lbNTS.I
hENT4
TgNT!
ThAT B V.
ThAT-D T DV·
ThAT-E T DV·
lbAT-F I DR·
ThATI ADT.
ThAT G L
CfNTI
Cf:\TI T·
lbAT J
PiNT!
LdNTl
lbNT2
lbNT3
ThNT4
ThNT)
lbNT6
Lm.YD
ThNT7
Lm.'<"T4
lbNBTl
hENT!
hENT2
LdNTU
bENT3
ThAT A
ThNTS!
hENT4
TgNT!
ThAT B
lbAT-O
lbAT-E
ThAT-F
ThATI
ThAT G
Cf:\,l
C~,2
ThAT J
PiNT!
LdNT2
lbNT2
ThNT3
lbNT4
ThNT)
ThNT6
Lm.'<T3
ThNT7
Lm.'<'~
ThNBTl
o
ApPENDIX II SUPPLEMENTARY DATA
bENT I
bENT2
LdNTU
bENT3
re....T ...
ThNTil
bENT4
TgNTl
Th....T B
ThAT-O
Th.U-E
ThAT-F
ThATI
ThAT G
C~.l
Cf:'<'2
ThAT 1
PiNT!
LdNT2
ThNT2
ThNT)
ThNT4
ThNT;
ThNT6
laL."\iTI
ThNT7
laL."\i.4
ThNBTI
bENT I
bENT2
tdNTl.I
hENT)
ThAT A
ThNTil
hENT4
TgNTl
ThAT B
ThAT-O
ThAT-E
ThAT-F
ThATI
ThAT G
Cfl>.1
CNT2
ThAT 1
PINT!
LdNT2
ThNT2
ThNT)
ThNT4
ThNT;
ThNT6
1=',,3
ThNT7
laL."'~
ThNBTI
bENT I
bENT2
LdNTU
bENT3
ThAT A
ThNTS.1
bENT4
TgNrl
ThAT B
ThAT-O
ThAT-E
ThAT-F
ThATI
ThAT 0
Cfl>.l
C£>.12
ThAT 1
PiNT!
tdNT2
ThNT2
ThNT3
ThNT4
ThNT;
ThNT6
laL.xr 3
ThNT7
laL."\i'~
ThNBTI
760 780 790 soo
p.
p -
L -
p -
p -
1 -
I .
I
850
I
YN
860
I
ASTAN SILAGL·
LFNI v t. K OtPPIOVTQ
p
ApPENDIX II SUPPLEMENTARY DATA
D. Details of oligonucleotide primers used for amplification of AT-B, AT-D and
controls (TbATl and TbNBTl) fragments from T. brucei genomic DNA and eDNA, and
their sequences and annealing temperature.
Primer Sequence Annealing temp
AT-D F2 5'-GAT GCT CGG TIT TIA TIC AG-3' 52°C
AT-D F3 5'-GCA AGT AAG GTC GAT GCT CGG-3' "
AT-D R2 5'-ATG TCA CAC TGT TAT TIC AGC-3' "
AT-D R4 5'-CAG CTG TAA TIA ATG CGG AAG AG-3' "
AT-B F1 5'-CGC TIC ACC ATC TAG CTG AG-3' 56°C
AT-B Rl 5'-TIA CCT CCT CTI AGG GAC AG-3' "
P2 (ThATl) F 5'-GAC TGT CGA CAT GCT CGG GTI TGA CTC AGC C-3' 55°C
P2 (ThAT1) R 5'-GAC TCT GCA GTA GTG CTA CTI GGG AAG CCC-3' "
NTBl F 5'-GAC TAA GCT TIG GAG TGT CCC TIC TAA TGC C-3' 55°C
NTBl R 5'-GAC TGG ATC CCC TIG TIC TIG TAG TIT GAG C-3' "
Q
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